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Summary  
 
During central nervous system (CNS) development, extensive reciprocal interactions 
exist between different cell types, including neural progenitors, neurons, endothelial 
cells, microglia and other glial cells that are crucial in driving proper development. 
Moreover, neurons and vessels share striking anatomical and molecular features and 
are presumably orchestrated by an overlapping repertoire of signaling systems. 
Here, we identify an important neuron/vessel/glia-interaction essential for the correct 
formation of the neurovascular system in the CNS that involves the CD95 receptor 
and ligand system. Deletion of CD95 receptor in neurons, as shown before, and in 
endothelial cells result in aberrant branching and growth of both cell types in the 
postnatal CNS. Furthermore, we identify microglia as the main source of CD95L and 
microglial-specific deletion thereof impairs proper neurovascular development. CD95 
promotes endothelial cell branching and proliferation by acting as a receptor tyrosine 
kinase that upon activation leads to recruitment of SFK and p85 which further elicit 
Akt and Erk signaling, two effectors that are crucial in regulating endothelial cell 
growth. These data highlight a coordinated neurovascular development instructed by 
microglial-derived CD95L and impact the importance of microglia for the 
establishment of the neurovascular network during CNS development.  
In tumorigenesis, angiogenesis is reactivated and takes place extensively to support 
tumor cell growth. Glioblastoma multiforme (GBM), the most aggressive and deadly 
type of tumor in the brain, is characterized by a high level of angiogenesis. The CD95 
receptor and ligand system also fosters tumor angiogenesis. However, this does not 
occur by direct activation of CD95 on endothelial cells, but rather results from CD95 
activation on GBM cells. Activation of CD95 on GBM cells by CD95L leads to an 
increase in the release of pro-angiogenic factors that promote vessel growth in the 
tumor. 
Together, our data demonstrate a novel role of CD95 in angiogenesis both during 
development and tumorigenesis and show a potential to target CD95 in neurovascular 
diseases or tumor angiogenesis.  
 
 
 
 
Zusammenfassung  
 
Im Laufe der Entwicklung des zentralen Nervensystems (ZNS) finden umfangreiche 
wechselseitige Interaktionen zwischen verschiedenen Zelltypen, wie zum Beispiel 
neuralen Progenitorzellen, Neuronen, Endothelzellen, Mikroglia und andere gliale 
Zellen, statt, welche äußerst wichtig zur Entwicklung beitragen.  Darüber hinaus 
teilen Neuronen und Blutgefäße auffällig ähnliche anatomische und molekulare 
Eigenschaften und werden vermutlich von einem überlappenden Repertoire an 
Signalsystemen orchestriert.  
Hier identifizieren wir eine wichtige Neuron-Blutgefäß-Glia-Interaktion, die 
entscheidend zur korrekten Formation des neurovaskulären Systems in ZNS beiträgt 
und in der das CD95 Rezeptor und Ligand System wesentlich involviert ist. Deletion 
des CD95 Rezeptors in Neuronen, wie bereits gezeigt, und in Endothelzellen führt 
zur anomalen Verzweigung und Wachstum beider Zelltypen im post-natalen ZNS. 
Des Weiteren identifizieren wir Mikroglia als die zentrale Quelle von CD95L und 
Mikroglia-spezifische Deletion von CD95L beeinträchtigt die richtige Entwicklung 
des neurovaskulären Systems. CD95 fördert die Verzweigung und Proliferation von 
Endothelzellen durch seine Funktion als Rezeptortyrosinkinase, welche nach 
Aktivierung zur Rekrutierung von SFK und p85 führt, die Akt und Erk Signale 
auslösen, zwei Effektoren, die entscheidend in der Regulation von 
Endothelzellwachstum sind. Diese Daten heben eine koordinierte neurovaskuläre 
Entwicklung hervor, welche durch Mikroglia-abgeleiteten CD95L instruiert wird, 
und verdeutlichen die Wichtigkeit von Mikroglia in der Etablierung des 
neurovaskulären Netzwerks in der ZNS Entwicklung.  
In der Tumorentwicklung wird Angiogenese reaktiviert und findet umfangreich statt, 
um Tumorzellwachstum zu unterstützen. Glioblastoma multiforme (GBM), der 
aggressivste und tödlichste Tumor im Gehirn, ist durch einen hohen Grad an 
Angiogenese charakterisiert. Das CD95 Rezeptor und Ligand System fördert auch 
die Tumorangiogenese. Allerdings erfolgt dies nicht durch direkte Aktivierung von 
CD95 auf Endothelzellen, sondern resultiert vielmehr von der CD95 Aktivierung auf 
GBM Zellen. Die Aktivierung von CD95 auf GBM Zellen durch CD95L führt zum 
Anstieg von pro-angiogenen Faktoren, welche das Blutgefäßwachstum im Tumor 
vorantreiben. 
Zusammenfassend legen unsere Daten eine neue Rolle von CD95 in der Angiogenese 
sowohl während der Entwicklung als auch der Tumorigenese dar und zeigen das 
Potential CD95 in neurovaskulären Krankheiten oder in der Tumorangiogenese zu 
targeten.  
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1. INTRODUCTION 
1.1 The cellular diversity of the central nervous system  
The human brain is a profoundly complex organ with immense capabilities, some of 
which we utilize – as in this thesis - to understand its structure and function. Within 
the brain, 86 billions neurons of thousands of different subtypes can fire via 100-500 
trillion synaptic connections to enable the cognitive capabilities of thought, speech, 
emotion etc. – often all at the same time (Azevedo et al., 2009; Drachman, 2005).  
Many different cell types in the brain support its functionality and have co-evolved 
with neurons to create a balanced system. Cells of neural origin such as neurons, glial 
cells, ependymal cells as well as non-neural origin as endothelial cells, pericytes and 
microglia arise concurrently during development and support each other during and 
beyond developmental stages. Neurons are often regarded as the central, working cell 
type of the brain. However, without the other cell types the brain is not capable of 
functioning. In fact, it is estimated that a similar number of supporting cells and 
neurons exists in the human brain (Azevedo et al., 2009).  
The study of the brain’s structure and function requires manipulations that can 
obviously only be conducted in animal models. Here, we utilize the mouse, the most 
commonly used mammalian model, to elucidate the cellular interactions during CNS 
development. 
The mouse brain differs from that of humans in several aspects, although many 
cellular and molecular processes are highly conserved. The most obvious difference is 
the lyssencephalic nature of the mouse brain that lacks cortical folding. This also 
results in a smaller number of neurons that amounts to 71 million in the mouse brain. 
Interestingly, mice also have more neurons than glial cells (Azevedo et al., 2009).  
In the next chapters, the development of the mouse central nervous system will be 
introduced, specifically focusing on the generation of neurons, vessels and microglia – 
the central cell types relevant for this thesis work.  
  
1.2 Developmental neurogenesis in the mammalian brain  
The development of neurons undergoes several stages and is a prolonged process that 
starts at mid-embryonic age and lasts until approx. four weeks after birth. First, neural 
stem cells are generated and give rise to neurons that through migration reach their 
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final destination in the brain. Second, neurons extend axons and dendrites in shapes 
characteristic for each neuronal type that serve as senders and receivers of information, 
respectively. And lastly, synapses are formed between neurons to build the complex 
neural circuitry, a process that is driven by neuronal activity to establish a mature 
pattern of connectivity (McAllister, 2000). The generation of neurons in the cortex 
follows a stereotypic process that has been analysed in detail and is thus often used as 
a model to study neurogenesis. In the following, the two first steps of neuron 
development relevant for this thesis will be further elucidated.  
 
1.2.1 Generation of cortical neurons from radial glia 
During early embryonic development, the CNS arises from the ectoderm at 
gestational day 7.5 to 9.5 (E7.5 to E9.5) with the formation of the neural plate and 
subsequently the neural tube. Neuroepithelial cells within the neural tube proliferate 
through symmetric division to generate a large pool of cells from which the neural 
cells arise later on (Stiles and Jernigan, 2010) (Figure 1.1). 
The generation of neurons – neurogenesis - begins at E9.5-E10.5 with the transition 
of neuroepithelial cells to radial glial cells (RG) that establish the ventricular zone 
(VZ). These cells with astroglial characteristics in terms of marker expression (e.g. 
Glast, BLBP, nestin) are multipotent embryonic neural stem cells that give rise to 
neurons, astrocytes and oligodendrocytes (Götz and Barde, 2005; Kriegstein and 
Alvarez-Buylla, 2009). Newborn neurons subsequently migrate along the radial 
process of RG towards the cortical plate where they find their final position 
(Kriegstein and Alvarez-Buylla, 2009) (Figure 1.1). Where this final position is and 
which type of neurons they become is controlled by a combination of spatial and 
temporal cues.  
Spatial control of neuronal diversity is imposed in the manner that different domains 
of the developing forebrain contain different combinations of diffusible morphogens 
to which radial glia respond with the activation of a specific genetic program, 
resulting in the production of specific types of neurons. This patterning is already 
established early in development starting at E9.5 with the secretion of FGFs, SHH, 
WNTs and BMPs at specific signaling centers of the neural tube. Patterning by these 
factors results in regional-specific expression of a combination of homeodomain and 
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basic helix-loop-helix (bHLH) transcription factors, such as Pax6, Emx1, Gsx1/2, 
Fezf2, Mash1, Nkx2.1 etc., the levels of which define a specification towards a certain 
neuronal subtype (Iwata and Hevner, 2009; Paridaen and Huttner, 2014). 
 
 
Figure 1.1: Radial glia cells give rise to cortical neurons and glial cells. During early 
development neuroepithelial cells give rise to radial glial cells that either directly differentiate 
into neurons or through intermediate progenitor cells (nIPCs).  Close to birth, radial glial 
cells also differentiate into oligodendrocytes through an intermediate stage (oIPCs)  or detach 
from the ventricle to become astrocytes. IPC, intermediate progenitor cell; MA, mantle; MZ, 
marginal zone; NE, neuroepithelium; nIPC, neurogenic progenitor cell; oIPC, 
oligodendrocytic progenitor cell; RG, radial glia; SVZ, subventricular zone; VZ, ventricular 
zone. (adapted from (Kriegstein and Alvarez-Buylla, 2009)). 
 
The cortex is organized in six layers (layer I-VI) and the different layers are generated 
in a temporal sequence where the early-born neurons populate the deep cortical layers, 
while late-born neurons migrate through already established layers to be sequentially 
added to more superficial layers in an inside-out fashion (Greig et al., 2013). The 
timing also determines the neuronal type being generated. The first neurons being 
born form the preplate and differentiate to Caja-Retzius and subplate neurons. The 
next wave of neurons are born E11.5 and mainly become layer VI corticothalamic 
projection neurons. This is followed by layer V subcerebral projection neurons born at 
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around E13.5 and layer IV granule neurons born one day later. Moreover, callosal 
projection neurons populate the cortex with the ones born at E12.5 localizing to deep 
layers while those that are born between E14.5 and E16.5 migrate to the superficial 
cortical layers II/III (Greig et al., 2013; Kriegstein and Alvarez-Buylla, 2009).    
At E16.5, when neurogenesis is mostly finished, RG cells switch from a neurogenic to 
a gliogenic fate. First, astrocytes are being generated, peaking at E18.5-19.5, followed 
by oligodendrocytes, the majority of which are born postnatally (Greig et al., 2013; 
Kriegstein and Alvarez-Buylla, 2009) (Figure 1.1).  
 
1.2.2 Axon and dendrite formation  
Directly after birth, post-mitotic neurons assume a bipolar morphology and undergo 
axo-dendritic polarization to eventually develop into polarized cells with a single long 
axon and many short highly branched dendrites (Cheng and Poo, 2012). In cortical 
principal neurons and cerebellar granule cells, the leading process of the migrating 
neuron becomes the dendrite, while the trailing process develops into the axon 
(Cheng and Poo, 2012; Hatanaka and Murakami, 2002). Axons and dendrites differ 
in their function, structure and morphology. Axons act as the information output 
compartment whereas dendrites represent the information input compartment of 
neurons. Whereas dendrites have specialized structures of main excitatory synaptic 
sites including spines, axons do not. Moreover, while axons have unidirectional plus-
end-distal microtubules, dendrites possess both plus- and minus-end-distal 
microtubules that influence the transport of organelles and molecules. Axons and 
dendrites serve the core functions of neurons of signal transduction and synaptic 
transmission, thus their correct formation and targeting is highly important.  
The establishment of neuronal polarity is regulated by several signaling pathways, 
including the PI3K-mediated activation of AKT/Gsk3β and Cdc42/Par3/6 signaling 
as well as cAMP-induced PKA/LKB1/Sad kinase signaling (Kim et al., 2011). 
Interestingly, global inhibition of Gsk3β results in multiple axon formation, while 
overexpression of the phosphorylation dead form Gsk3β-Ser9Ala inhibits axon 
formation (Jiang et al., 2005; Yoshimura et al., 2005). 
After specification of the axon/dendrite identity, dendrites further undergo five 
critical stages of morphogenesis: 1) guidance; 2) branching; 3) dendritic tiling and 
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self-avoidance; 4) differentiation and 5) pruning (Puram and Bonni, 2013) (Figure 
1.2). During the guidance stage, dendrites follow guidance cues to move away from 
the soma and toward their target field while growing and increasing in length and 
diameter. In order to cover their complete target field, dendrites need to branch and 
they do so several times, forming extensive secondary and tertiary branching. This 
occurs mainly by interstitial branching, with new branches extending from the side of 
existing dendrite shafts as filopodia before becoming stable branches. The extent of 
dendritic branching is controlled by dendritic tiling mechanisms whereby non-
redundant coverage by dendrites of the same neuronal type is ensured through growth 
inhibition upon contact with neighboring cells of the same type. Moreover, self-
avoidance mechanisms limit dendrite growth and secure that dendritic branches of the 
same neuron do not crossover each other, but rather spread out evenly within distinct 
territories. Once neurons have formed dendrites, these differentiate and develop 
specialized structures called spines that are the site of synapses. Dendrite maturation 
further involves pruning whereby branches are retracted and eliminated to ensure that 
only the correctly innervated ones remain (Puram and Bonni, 2013).  
         
Figure 1.2: Process of dendritic development. Neuron branching of dendrites starts with 
initiation, followed by outgrowth and guidance through guidance molecules and continues 
with branching, spine formation and growth stop. (adapted from (Scott and Luo, 2001)) 
 
On a molecular level, these processes are regulated by numerous cell-intrinsic and 
cell-extrinsic cues. Cell-intrinsic cues comprise of transcription factor activity, 
cytoskeletal molecules, motor proteins and microtubule regulators as well as cell cycle-
regulated ubiquitin ligases. These factors allow a cell-specific interpretation of 
environmental cues that can be different depending on neuronal cell type, thus 
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generating diversity in dendrite morphology. Transcription factors can be expressed in 
different types of neurons to execute different functions in a cell-type specific fashion. 
Cux1 and Cux2 for example specifically promote dendrite branching in layer II-III 
pyramidal neurons by suppressing p27Kip1 (Cubelos et al., 2010; Li et al., 2010). Of 
the cytoskeleton regulators the Rho family GTPases are crucial for dendrite dynamics 
through cell structural changes. The GTPase RhoA reduces dendrite length by 
regulating myosin light chain and actomyosin contractility (Nakayama et al., 2000; 
Winter et al., 2001). In contrast, Rac1 and Cdc42 of the same family promote 
dendrite arborization (Scott et al., 2010). Another imported regulator of dendritic 
growth is the cell cycle-regulated ubiquitin ligase Cdc20-APC that triggers 
polyubiquitylation and degradation of the transcriptional regulator Id1, resulting in 
increased dendrite growth and elaboration (Kim et al., 2009; Puram and Bonni, 
2013).  
Cell-extrinsic cues that regulate dendrite morphogenesis include many secreted 
molecules, contact-mediated regulators and neuronal activity. Several secreted 
molecules act as guidance for dendritic targeting, such as Slits, Ephrin A7 and Wnt5 
that repel dendrite branches, whereas netrins and semaphorins attract branching. 
Neurotrophins such as NGF, BDNF, NT-3/4 are another class of secreted molecules 
that promote dendrite growth and arborization, partially through activity-dependent 
pathways via inactivating phosphorylation Gsk3β at Ser9 (Rui et al., 1AD). 
Contact-mediated regulators are especially important for dendrite tiling and self-
avoidance. The cell adhesion molecule DSCAM is expressed in thousands of different 
isoforms on different dendrites of a neuron and has been shown to induce self-
avoidance in Drosophila neurons through isoform specific homophilic binding to 
individual dendrites (Wojtowicz et al., 2004).  
Neuronal activity is another key factor in regulating dendrite development. It induces 
calcium transients within the cell that activates CaMKs which can positively or 
negatively affect dendrite complexity depending on context (Valnegri et al., 2015). 
Calcium signals induced by voltage-gated calcium channels (VGCC) for example can 
activate the protease calpain that promotes dendrite pruning (Kanamori et al., 2013). 
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Axons and dendrites share many mechanisms of growth. Secreted guidance molecules 
both steer axons and dendrites toward the correct direction. However, how dendrite 
and axon growth are differentially regulated is generally not well studied. Two 
principles of regulation have been proposed with one involving mechanisms that 
regulate either axon-specific or dendrite-specific growth, termed “dedicated 
mechanisms”, and the other involving mechanisms that direct dendritic and axonal 
development in opposite manners, termed “bimodal mechanisms” (Wang et al., 
2014). The bHLH transcription factor NeuroD is one example of a dendrite-
dedicated regulator. It promotes specifically dendritic growth and arborization, but 
not axonal morphogenesis (Gaudillière et al., 2004). Conversely, the small GTPase 
Rac1 inhibits axonal outgrowth and elongation, but does not affect dendrite 
branching (Luo et al., 1996). The secreted molecule Sema3A of the semaphorin 
family act as bimodal regulator with opposite effects on axons and dendrites. Sema3A 
promotes dendrite initiation, targeting and growth but suppresses axonal formation by 
inhibiting cAMP activity that is important for axon initiation and enhancing cGMP 
activity that supports dendritic growth. Similarly, Sema3A also serves as a 
chemoattractant for cortical dendrites while acting as a chemorepellent for cortical 
axons (Polleux et al., 2000; Shelly et al., 2011a; 2011b). 
 
1.3 Vascular development in the CNS  
The vertebrate CNS is made up of the brain, spinal cord and retina and its 
vascularization during development is crucial to supply newly born neurons with 
oxygen and nutrients, long before they form axons and dendrites to build a neuronal 
network (Ruhrberg and Bautch, 2013). In spite of the brain only representing 2% of 
the body mass, it utilizes almost 25% of the entire body’s energy, thus making it 
highly dependent on metabolic supply from blood vessels (Lacoste et al., 2014). It is 
estimated that the human brain encompasses up to 100 billion vessels, which would 
mean that each neuron is supplied by a vessel (Quaegebeur et al., 2011). 
In contrast to non-CNS vessels, the CNS endothelium is equipped with a tightly 
regulated neurovascular unit (NVU) that is composed of endothelial cells lining the 
blood vessels, perivascular cells (i.e. pericytes and vascular smooth muscle cells) and 
vascular astrocytes interacting with each other to form the blood-brain barrier (BBB). 
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The CNS vasculature is also distinct to other tissues in that the endothelial cells are 
thinner, the pericyte coverage is higher and the communication with the surrounding 
parenchymal cells is more pronounced (Quaegebeur et al., 2011).  
Vascularization of the early CNS, similar to all other embryonic tissues, is established 
by the process of vasculogenesis – the de novo generation of new blood vessels through 
differentiation of mesoderm-derived angioblasts. The definitive CNS, however, is 
vascularized exclusively through angiogenesis – the sprouting of new blood vessels 
from pre-existing ones (Flamme et al., 1997). In the following the cellular and 
molecular mechanisms regarding CNS vascularization will be introduced.  
 
1.3.1 Vascularization of the mouse brain  
Early in CNS development at E7.5-8.5 when the neural tube is established, 
angioblasts are recruited by the neuroepithelium to form a perineural vascular plexus 
(PNVP) in the hindbrain via vasculogenesis (Hogan, 2004). From this first vascular 
plexus, new capillaries sprout via angiogenesis from E9.5 on in a caudal to cranial 
direction, attracted by pro-angiogenic factors, to form the intraneural vessel plexus 
(INVP) (Vallon et al., 2014). Both the establishment of the PNVP and the INVP 
depend heavily on Vegf-A expression from the neuroepithelium (Breier et al., 1992). 
Neuroectodermal deletion of VEGF-A using the Nestin-cre VEGF-Afl/fl mice results 
in complete failure of the forebrain to be vascularized due to migratory arrest of 
endothelial cells at the periphery of the early CNS and ultimately leads to 
developmental retardation and neural tissue death (Raab et al., 2004). The 
periventricular areas are especially high in VEGF-A expression, attracting extensive 
branching and arborization of capillary sprouts from the pial surface to form a 
temporary periventricular vascular plexus around the ventricular spaces and spinal 
cords central canal (Arnold and Betsholtz, 2013; Breier et al., 1992; Greenberg and 
Jin, 2005; Vasudevan and Bhide, 2014).  
The first cortical vessels are formed this way beginning form E12.5 when endothelial 
cells migrate from the pial surface towards the ventricle to establish the first loop-
structured dense plexus. This is followed by a second plexus beneath the developing 
cortical plate at E14.5 which is interconnected to the first plexus via a few penetrating 
branches. At E15.5 tangential vessels to the pial surface develop in the intermediate 
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zone. At E18.5 the ventricular plexus looses much of its definition and a complex 
vascular network forms (Stubbs et al., 2009) (Figure 1.3).  
After birth, angiogenesis decreases, however, it has been shown using two-photon 
time-lapse microscopy in living mice that during the early postnatal period extensive 
microvascular remodeling takes place. Endothelial cell proliferation as well as vessel 
branching continue and peak at around P10, dropping thereafter and stabilizing by 
P25. Unlike in earlier developmental stages, endothelial sprouts in postnatal brain 
often contain only one tip cell and span rather short distances between nearby 
microvessels (Harb et al., 2012).  
 
Figure 1.3: Development of vessels in 
the somatosensory cortex. Staining of 
vessels by Isolectin B4 from 
development stage E12 to adulthood 
and schematic drawings thereof. Vessels 
start entering the cortex at E12 and form 
two plexi at E14 that further branch to 
cover the majority of the cortex. MZ: 
marginal zone, CP: cortical plate, SP: 
subplate, IZ: intermediate zone, SVZ: 
subventricular zone, VZ: ventricular 
zone, I-VI represent cortical layers in the 
adult. Scale: 100 µm (adapted from 
(Stubbs et al., 2009)) 
 
 
 
 
 
 
 
 
During adulthood, endothelial cells are mostly quiescent during homeostasis with 
little microvascular formation and elimination being maintained (Harb et al., 2012). 
Interestingly, however, the brain is capable of increasing its microvascular density in 
response to neuronal activity and hypoxia (Black et al., 1990; Harik et al., 1996). 
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1.3.2 Vascularization of the mouse retina  
The retina and the optic nerve are extensions of the brain and develop as 
exvaginations of the forebrain neuroectoderm (Fruttiger, 2007; Mancuso et al., 2008). 
In contrast to the vasculature of the cortex, the vasculature within the mouse retina 
develops completely postnatally. Before birth, the retina is avascular, only supplied by 
two extra-retinal vasculatures, the choroidal vessels around the optic cup that nurture 
the outer retina, and the hyaloid vessels in the vitreous humor that supply the inner 
retina and lens (Mancuso et al., 2008; Ruhrberg and Bautch, 2013).  
    
Figure 1.4: Development of blood vessels in the retina. Blood vessels in the retina develop 
postnatally starting at the optic nerve in the central retina. The first superficial layer of vessels 
(1) cover the retina completely by P8 after which the deep layer is formed through vertical 
sprouting from P8-P10 (2). Lastly, an intermediate layer of vessels is formed between the 
superficial and deep layer until P15 (3). (adapted from (Milde et al., 2013)) 
 
In the first eight days after birth, the hyaloid vessels regress and new vessels extend 
radially from the central retina to the periphery through endothelial cell proliferation, 
sprouting and migration, ultimately leading to the formation of the primary vascular 
plexus in the retina (Gerhardt et al., 2003; Pitulescu et al., 2010). The endothelial 
cells are mainly guided by astrocytes and Mueller glia that release large amounts of 
VEGF-A (Gerhardt et al., 2003). Beginning from P7, the primary superficial plexus 
sprouts vertically into deeper layers of the retina, first generating the deep vascular 
plexus in the outer plexiform retinal layer (OPL) from P8-P10 and subsequently the 
intermediate vascular plexus at P10-15 (Arnold and Betsholtz, 2013; Milde et al., 
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2013). Following this, vascular remodeling and differentiation into arteries and veins 
takes place until a mature vascular network is formed at six weeks after birth (Arnold 
and Betsholtz, 2013) (Figure 1.4). 
Due to the stereotypical vessel growth, the retina represents an ideal system to study 
angiogenesis in vivo and has been utilized to characterize many mechanisms of 
angiogenesis.  
 
1.3.3 Cellular and Molecular determinants of CNS vascularization  
The process of angiogenesis is governed by sprouting tip cells that spearhead new 
vessel formation and by proliferating stalk cells that extend sprouts and form the 
vessel lumen. Sprouting tip cells subsequently anastomose with neighboring tip cells 
to form vascular loops, followed by blood perfusion and vessel maturation (Herbert 
and Stainier, 2011; Potente et al., 2011). The process of sprouting, extension, 
branching and anastomosis repeats until a full vascular network is established (Figure 
1.5).  
The initiation of angiogenesis occurs upon pro-angiogenic factor stimulation and 
liberation of endothelial cells from the basement membrane (Potente et al., 2011). 
Tip cells are enriched in matrix metalloproteases (MMPs) such as MT-MMP1 that 
break down basement membrane and free endothelial cells, allowing them to extend 
plasma membrane protrusions called filopodia toward guidance cues (Arroyo and 
Iruela-Arispe, 2010; Eble and Niland, 2009; Wang et al., 2014). 
The tip/stalk cell identity is mainly established by DLL4/Notch and VEGF-A 
signaling that acts as a branching pattern generator (Potente et al., 2011). During this 
process, the guidance cue VEGF-A induces Notch ligand DLL4 expression in tip 
cells that results in Notch activation in neighboring cells. These cells establish a stalk 
cell phenotype through Notch-induced downregulation of VEGF receptor (including 
VEGFR2, VEGFR3 and NRP1) and parallel upregulation of anti-angiogenic factors 
such as sFlt1 and Jagged1 (Eilken and Adams, 2010; Moya et al., 2012; Phng and 
Gerhardt, 2009; Potente et al., 2011). Notch thus acts as a suppressor of the tip cell 
phenotype and promoter of stalk cell specification.  
Once tip and stalk cell identities are established, tip cells must be guided correctly for 
proper vascular patterning. To this end, tip cell filopodia function as sensors for 
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attractive and repulsive cues. Similar to axonal growth cones of neurons, tip cells 
express guidance receptors such as ROBO, UNC5B, NRP, Plexin-D1 and Ephrin 
receptors that can respond to the guidance cues Slit, Semaphorin and Ephrin ligands 
(Carmeliet and Tessier-Lavigne, 2005; Potente et al., 2011). The molecular 
mechanisms that regulate tip cell filopodia are just beginning to be unraveled. VEGF-
A for instance activates VEGFR2 in tip cells to induces PI3K, followed by Rac/Rho 
and Grb2 that result in Cdc42 activation, leading to stimulation of actin 
reorganization, filopodia formation and cell migration (De Smet et al., 2009; 
Matsumoto and Mugishima, 2006). Moreover, it has been shown in the mouse retina 
that VEGFR2-expressing neurons regulate directionality of angiogenesis by titrating 
VEGF-A (Okabe et al., 2014). 
 
Figure 1.5: Cellular and molecular mechanisms of angiogenesis. a) In homeostasis during 
adulthood, endothelial cells are normally quiescent. b) Upon angiogenic stimulation through 
growth factors such as VEGF that is secreted by the neuroepithelium during development, 
extracellular matrix (ECM) degradation becomes activated and loss of pericytes is induced. 
Furthermore, tip cells (TC) are selected through VEGFR2 and neighboring cells are 
inhibited in TC fate through lateral inhibition by DLL4-Notch signaling. c) TC sprouting is 
guided by different growth factors and are followed by stalk cells (SC) which form the vessel 
lumen. When TC contact other TCs, the process of anastomosis is initiated which is 
supported by associated myeloid cells. d) After new vessels are established vessels become 
perfused and are stabilized by pericytes that are recruited through PDGF-B and ECM 
deposition. (adapted from (Herbert and Stainier, 2011)) 
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While tip cells are finding the orientation, stalk cells proliferate via VEGF-A induced 
MAP kinase activation and start to form a lumen by coalescence of intracellular 
vacuoles and joining of vacuoles from adjacent stalk cells in a process called cell 
hollowing (Potente et al., 2011; Strilic et al., 2009; Zeeb et al., 2010). 
The next step in the angiogenic process is anastomosis where tip cells fuse with 
adjacent tip cells to form new vessel circuits. Microglia have shown to facilitate this 
process by bridging between tip cell filopodia (Fantin et al., 2013). The new vessel 
connection is then strengthened by the adherens junction molecules VE-cadherin and 
N-cadherin, the buildup of extracellular matrix into the basement membrane and the 
recruitment of supporting vascular smooth muscle cells (pericytes or mural cells 
depending on context) through endothelial cell-derived PDGFB (Cavallaro and 
Dejana, 2011; Lindahl et al., 1997; Potente et al., 2011). With this, new vessels enter 
the maturation state, where the hierarchically branched network is remodeled and 
adapted to tissue needs (Jain, 2003). Also the start of blood perfusion contributes to 
this by decreasing VEGF expression, thus shifting endothelial cells towards 
quiescence, and by determining arterio-venous differentiation (Potente et al., 2011).  
VEGF-A signaling through its receptor VEGFR2 and NRP-1 is the major pathway 
regulating vasculogenesis and angiogenesis in the CNS, however, many other factors 
have been identified to induce angiogenesis in endothelial cell-autonomous or -non-
autonomous ways. Endothelial cell-specific deletion of the VEGFR2 and its co-
receptor NRP1/2, TGFBR1/2 (Robson et al., 2010; Sridurongrit et al., 2008), β–
catenin (Stenman et al., 2008) or the orphan G-protein coupled receptor GPR124 
(Kuhnert et al., 2010) all lead to defects in proper CNS angiogenesis and embryonic 
lethality (Vallon et al., 2014).  Similarly, neuroepithelium-specific deletion of genes 
such as VEGF-A, WNT7a/b (Daneman et al., 2009; Stenman et al., 2008), ID1/3 
and the integrins αv and β8 (McCarty, 2004; Proctor, 2005) result in angiogenic failure 
and CNS hemorrhage (Vallon et al., 2014).  
 
1.3.4 Concurrent development of vessels and neurons – the neurovascular link  
The Belgian anatomist Andreas Versalius aleady noticed five centuries ago that nerves 
and vessels run parallely and form highly branched and complex networks through 
sterotypical patterning during development (Adams and Eichmann, 2010; Lacoste et 
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al., 2014). Particularly in the periphery,  blood vessels and nerves spread to all edges of 
the body and are often aligned (Eichmann and Thomas, 2013).  The morphogenesis 
of neurons and vessels shares striking anatomical, cellular and molecular features and 
is orchestrated by an overlapping repertoire of extracellular signals (Segura et al., 
2009).  
Developing neurons use growth cones at axonal terminals for guidance during 
neuronal network formation (Tessier-Lavigne and Goodman, 1996) and similarly, 
blood vessels use endothelial tip cells for guidance during sprouting angiogenesis 
(Gerhardt et al., 2003). Both systems are governed by the a gradient of guidance 
molecules that has initially been discovered as axon guidance cues but have been 
recently coined “angioneurins” due to their acitivty in vessels as well as in neurons 
(Zacchigna et al., 2007). Four main families of guidanance cues have been identified: 
ephrins, semaphorins, netrins and slits. These ligands bind to their respective 
receptors: Eph family receptor, NRP/Plexin-D1, UNC5B and ROBO4 and act as 
attractive or repulsive cues (Adams and Eichmann, 2010).  
Beside the classical guidance cues, the blood vessel growth factor VEGF-A has also 
been shown to influence nervous system development in that it promotes axonal 
growth (Silverman et al., 1999; Sondell et al., 1999) as well as axon guidance in the 
visual system (Erskine et al., 2011) and at the floor plate of the spinal cord (Ruiz de 
Almodovar et al., 2010). 
In addition, neurons and vessels influence each other extensively during development. 
Starting from E10.5, the neuroepithelium drives the initial ingression and the 
stabilization and pruning of blood vessels (Daneman et al., 2009; Hogan, 2004). Later 
in the embryonic cortex, radial glia neural progenitors stabilize the vascular network 
via modulation of Wnt signaling (Ma et al., 2012). In turn, vessels are positioned in 
the neural progenitor niche and promote neurogenesis, neuronal migration and 
neurite outgrowth (Shen et al., 2004; Stubbs et al., 2009). In the peripheral nervous 
system, sympathetic axons follow neurotrophic factors released by arteries to reach 
their destination (Damon et al., 2007; Makita et al., 2008).  
The neural and vascular system thus not only utilizes the same molecules to grow but 
also support each other’s development.  
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1.4 Glioblastoma and tumor vascularization  
Brain tumors are a rare tumor entity with less than 2% of all tumors diagnosed each 
year (Jemal et al., 2009). However, the most common type in the adulat that accounts 
for nearly 40% of all primary brain tumors – glioblastoma multiforme (GBM) – is one 
of the most deadly tumors with a 5-year survival rate of only 5% and a median survival 
of only 15 months, despite of multimodal therapy (Behin et al., 2003; Furnari et al., 
2007; Stupp et al., 2005). One hallmark of GBM is extensive microvascular 
proliferation (Brem et al., 1972; Louis et al., 2016) and in fact, GBM is one of the 
most vascularized tumors. Tumor cells need vessels for nutrients and oxygen, and 
similar to neural progenitors during development, glioma stem cells seek proximity of 
vessels as they support their growth and proliferation (Calabrese et al., 2007). 
Tumor growth depends heavily on blood vessels, as Judah Folkman postulated in the 
early 70’s: “Solid tumors can grow to visibility only if they can vascularize themselves.” 
(Folkman, 1971; 1972). Studies have in fact shown that tumors need to turn on the 
“angiogenic switch”, upon which the balance of pro- and angiogenic activity in 
homeostasis is tipped towards pro-angiogenic factor release, in order to grow beyond 
1-2 mm in diameter (Fidler et al., 2002; Vallon et al., 2014). 
Vascularization within a tumor follows similar mechanisms as during development 
with the tumor hijacking molecular determinants of normal angiogenic processes. In 
GBM, sprouting angiogenesis is initiated by angiopoietin-mediated disruption of pre-
existing vessels, followed by ECM breakdown and acquisition of tip/stalk cell identity 
(Hardee and Zagzag, 2012).  
VEGF-A, the master regulator of angiogenesis, also plays a crucial role in tumor 
angiogenesis. Tumor cells strongly upregulate expression of VEGF-A, promoted by 
hypoxia, acidosis and oncogenes (Ras, Src) (Carmeliet and Jain, 2000; Fukumura et 
al., 2001). Moreover, chemokines including IL-8 and CXCL12 (Li and Ransohoff, 
2009; Salmaggi et al., 2003; Schmidt et al., 1999) and growth factors such as PDGF 
and FGF (Carmeliet and Jain, 2011) drive angiogenesis in GBM. 
Due to the constant exposure to VEGF-A and other pro-angiogenic molecules 
released by tumor cells and the tumor niche (e.g. myeloid cells) (Brandenburg et al., 
2015; Osterberg et al., 2016), tumor vessels can not mature properly and are highly 
abnormal, characterized by high permeability and leakiness, disorganization, 
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tortuosity and low pericyte coverage (Guo et al., 2010; Winkler et al., 2004). 
Moreover, in the brain, the BBB is impaired and vessels exhibit pores as large as 550 
nm in diameter (Hobbs et al., 1998). The consequence of this is a high interstitial 
fluid pressure and edema, which can cause severe complications in the patient.  
Due to the high impact of angiogenesis in brain tumor progression, angiogenesis 
inhibitors have been developed as a treatment option for GBM. The most prominent 
one is the VEGF-A neutralizing antibody bevacizumab. The major benefit from 
bevacizumab is vessel normalization that is associated with reduced vascular 
permeability and edema (Vredenburgh et al., 2007). However, the success of 
bevacizumab is dampened by the fact that it only increases progression-free survival 
by 3-4 months in combination with radiotherapy and temozolomide chemotherapy, 
but not overall survival (Chinot et al., 2014; Gilbert et al., 2014). Patient relapse 
represents a big problem, moreover, VEGF-A inhibition has been shown to increase 
the invasive phenotype of GBM (Paez-Ribes et al., 2009). 
Beside angiogenesis, other mechanisms of neovascularization in GBM include 
vasculogenesis, vascular co-option, vascular mimicry and GBM to endothelial cell 
transdifferentation (Hardee and Zagzag, 2012). Vascular co-option is an early 
mechanism that involves tumor cells attaching to pre-existing vessels (Holash et al., 
1999; Zagzag et al., 2000). Later, tumor cells can establish functional vessel-like 
networks, also incorporating into endothelial networks, in a process called vascular 
mimicry (Yue, 2005). Although still controversial, it has also been shown that GBM 
cells can transdifferentiate into endothelial cells that integrate into functional vessesl 
(Ricci-Vitiani et al., 2010; Soda et al., 2013; Wang et al., 2010).  
 
1.5 Microglia during the development of the central nervous system  
Microglia were discovered in the brain by a student of Ramon y Cajal – Pio del Rio 
Hortega in 1932 (Kettenmann et al., 2011). Initially described as the resident immune 
cells of the brain, it is now recognized that microglia have manifold functions beyond 
immune modulation such as regulation of development, maintenance of neural 
homeostasis and response to injury followed by regulation of repair (Nayak et al., 
2014). Microglia in a resting state have a highly ramified morphology that enables 
dynamic monitoring of their environment and direct communication with neurons, 
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astrocytes and blood vessels (Davalos et al., 2005; Nimmerjahn et al., 2005; Stence et 
al., 2001; Wake et al., 2009). In response to a pathological insult, microglia respond 
by transforming into an activated amoeboid phenotype to orchestrate an innate 
immune response (Casano and Peri, 2015). 
Microglia make up 5-15% of all glial cells in the human brain (Lyck et al., 2009; 
Pelvig et al., 2008) and their ontogeny is highly conserved amongst vertebrates (Pont-
Lezica et al., 2011), making them likely to play an important role in maintaining 
CNS health. Furthermore, they secrete a plethora of neuroactive molecules (Lucin 
and Wyss-Coray, 2009) and express receptors for all known neurotransmitters 
(Kettenmann et al., 2011) which theoretically enables them to sense and react to 
neuronal activity. Indeed, a lack of microglia, for instance in Hoxb8 mice, can lead to 
compromised brain function, learning skills and individual behavior as seen by 
excessive compulsive grooming (Chen et al., 2010b). 
In the following, the origin and development of microglia will be highlighted and the 
function of microglia during development will be described, specifically focusing on 
its role in neuronal and vessel development of the CNS.  
 
1.5.1 The origin and development of microglia  
The lineage and origin of microglia had been a long-standing debate. Initially, it was 
thought that microglia, like other macrophages, are of hematopoietic origin and 
exclusively derive from circulating monocytes due to similar marker expression (Nayak 
et al., 2014).  
A recent series of publications however refuted this model and proved that microglia 
are distinct from bone marrow-derived monocytes/macrophages and instead derive 
from the embryonic yolk sac during primitive hematopoiesis.  
First indications of this were found in the avian system, where chimeras between 
chick embryos and quail yolk sacs showed establishment of primitive myeloid cells 
invading the brain rudiment independently of blood supply (Cuadros et al., 1993). 
Moreover, in non-irradiated parabiotic mice, microglia were maintained by self-
renewal without the need of bone marrow progenitors (Ajami et al., 2007). More 
convincing evidence was presented by Ginhoux et al. in a fate mapping study in which 
Runx1+ progenitors of the yolk sac were shown to give rise to primitive macrophages 
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that populate the brain (Ginhoux et al., 2010). This was further confirmed by Schulz 
et al. who showed that deletion of Myb, a transcription factor essential for 
hematopoiesis, led to deficiency in hematopoietically derived monocytes/macrophages 
but did not affect numbers of microglia in the CNS (Schulz et al., 2012). Additional 
FACS approaches in the last few years have identified that microglia derive from 
CD45-cKit+ and Tie2+ erythromyeloid progenitors (EMP) that convert to 
CD45+cKit-Cx3cr1+ microglia (Kierdorf et al., 2013; Perdiguero et al., 2015).  
These cells invade the brain rudiment at E8.5, surround the neuroepithelium at E9.5 
and start to colonize the CNS parenchyma at E10.5 after entering the 
neuroepithelium (Ginhoux et al., 2010). Once in the neuroepithelium, microglia 
proliferate rapidly and populate the brain from dorsal to ventral and rostral to caudal 
(Arnold and Betsholtz, 2013). The number of microglia rises steadily from E8.5 
onwards, with 58% of microglia being PCNA+ at E16.5 and the majority (95%) of all 
microglia actually being generated within the first two weeks after birth (Alliot et al., 
1999). During this period, microglia differentiate from cells of an amoeboid to a more 
branched morphology and become completely ramified throughout the brain by P28 
(Herbomel et al., 2001; Orłowski et al., 2003; Sorokin et al., 1992). Also during 
adulthood, microglia are normally maintained through local self-renewal. Only under 
certain pathological conditions such as inflammation (Ajami et al., 2007) or 
irradiation (Kierdorf et al., 2013; Mildner et al., 2007) does infiltration of blood-
derived monocytes and bone marrow-derived cells into the CNS occur. 
Which route microglia take to enter the brain is still controversial. It has been shown 
that microglia colonization of the brain occurs with embryonic vascularization (Ajami 
et al., 2007). Moreover, Ncx-/- mice that have a defective sodium calcium exchanger 
and therefore lack functioning blood circulation do not have microglia in the brain at 
E10.5 (Ginhoux et al., 2010). However, despite the vascular system being the primary 
route for transport, microglia also appear in regions of the developing CNS devoid of 
blood vessels and in the embryonic retina, microglia arrive well before post-natal 
retinal angiogenesis occurs (Ginhoux et al., 2010; Koushik et al., 2001; Rigato et al., 
2011). It is thus likely that ventricles or para-meninges also serve as routes of entry 
(Cuadros and Navascués, 1998). In avian studies for instance, microglia have been 
shown to cross the pial membranes and the roof plate independently of blood vessels 
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(Cuadros et al., 1993; Kurz and Christ, 1998). Neuronal cell death-induced 
nucleotide release has further shown to guide microglia into the brain and mediate 
their distribution (Casano et al., 2016). 
 
1.5.2 Function of microglia during CNS development  
Although microglia are distributed throughout the brain during homeostasis, there 
are certain locations where they are found more frequently. These include areas of cell 
death, close to developing blood vessels, areas containing developing axon fascicles 
and near radial glial cells (Pont-Lezica et al., 2011). The proximity of microglia to 
these locations correlates with functions that they perform during development. In 
fact, interaction of microglia with other cell types in the brain is indispensible for 
normal development (Figure 1.6). 
 
             
Figure 1.6: The role of microglia during CNS development. Microglia support different 
processes during CNS development, including the take up of apoptotic neurons, support of 
neurogenesis and axonal growth, refinement of synapses as well as patterning of vessels. 
Theses processes are regulated by various signaling pathways. (modified from (Casano and 
Peri, 2015)) 
 
1.5.2.1 Role of microglia in neuronal development  
1.5.2.1.1 Neuronal death  
Traditionally, microglia have been mainly attributed the role of phagocyting apoptotic 
neurons (Bessis et al., 2007; Desbarats et al., 2003; Kuida et al., 1998; la Rosa and de 
Pablo, 2000; Oppenheim, 1991; Schlegelmilch et al., 2011; Zuliani et al., 2006). 
Approximately half of all immature neurons that are generated during development 
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undergo apoptosis (Kuida et al., 1998; la Rosa and de Pablo, 2000; Oppenheim, 
1991). These dead cells have to be removed and microglia play a central role in this 
clearing process (Ashwell, 1990; Calderó et al., 2009; Sierra et al., 2010). 
Interestingly, the arrival of microglia in the brain parenchyma correlates with the 
presence of apoptotic cells (Cuadros et al., 1993; Dalmau et al., 1997; Rigato et al., 
2011; Wakselman et al., 2008). In vivo imaging of zebrafish embryos has shown that 
microglia engulf apoptotic neurons by extending their processes and encapsuling them 
(Peri and Nüsslein-Volhard, 2008). Microglia sense and are recruited to dying 
neurons through factors released by them such as chemotactic signals including ATP 
(Davalos et al., 2005) or the ligand fractalkine (Cx3cl1) that activates MFG-E8 in 
microglia to bind phosphatidilserine exposed to the cell surface of apoptotic neurons 
(Hanayama et al., 2002). The phagocytic functions of microglia do not only keep the 
brain clear of dying cells during development but also contributes during adulthood to 
maintain healthy neural networks (Nayak et al., 2014).  
 
1.5.2.1.2 Neuronal survival and neurite formation  
The generation of neurons and microglia occur concomitantly in the developing brain, 
thus it is not far-fetched to assume that they interact to affect each other’s 
development.  In fact, microglia secrete a plethora of trophic factors such as bFgf, 
Egf, Pdgf, Ngf, Bdnf (Araujo and Cotman, 1992; Nakajima et al., 2001; Yamagata et 
al., 1995)  that can potentially support neuronal function. Conditioned medium from 
low-density cultures of microglia has for instance been shown to promote neuronal 
survival as well as increase neurite outgrowth in vitro (Chamak et al., 1994; Morgan et 
al., 2004; Nagata et al., 1993; Zhang and Fedoroff, 1996). Moreover, Csf1, an 
important factor for microglia proliferation and development, can also act as a 
neurotrophic factor to enhance neurite outgrowth (Michaelson et al., 1996).   
One recent study by Ueno et al. further confirmed a crucial role of microglia in 
regulating neuronal survival in vivo. Ablation of microglia during postnatal 
development was shown to critically reduce survival of layer V cortical neurons. This 
neuro-supportive effect acted through fractaline (Cx3cl1) and IGF-1 release, as 
downregulation or deletion of Cx3cr1 or Igf1 led to layer V neuron death (Ueno et al., 
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2013). Notably, microglia seem to only affect neuronal survival in a specific cortical 
layer, the reason of which is so far unknown.   
 
1.5.2.1.3 Synaptogenesis  
Beside its association with dying neurons, microglia are also often found being lined 
up along developing axon fibers throughout development in different species 
(Cuadros et al., 1993; Herbomel et al., 2001; Innocenti et al., 1983; Ueno et al., 2013; 
Verney et al., 2010). This specific localization allows them to regulate neurons in yet 
another way, namely through synaptic pruning. In mice, synaptic pruning takes place 
during postnatal stages for remodeling of synapses and is crucial for the establishment 
of a functional, mature neuronal network (Arnold and Betsholtz, 2013). Microglia 
establish transient connections with neuronal synapses (Wake et al., 2009) and during 
synaptic maturation pre- and postsynaptic proteins have been found within phagocytic 
compartments of microglia, especially in the cerebral cortex, hippocampus and 
thalamus of postnatal mice (Paolicelli et al., 2011; Schafer et al., 2012; Tremblay et 
al., 2010). The engulfment of synapses by microglia is partially regulated by 
fractalkine signaling, with mice deficient in Cx3cr1 that have a transient decrease of 
microglia during early postnatal days exhibiting reduced synaptic pruning and less 
mature synapses 2-3 days after birth. This also results in deficiency in functional brain 
connectivity on an electrophysiological and behavioral level, apparent through reduced 
social interaction and increased repetitive behaviors (Paolicelli et al., 2011; Zhan et 
al., 2014). Moreover, the complement system is involved in microglial synaptic 
pruning. The complement factor C1q on neurons can activate C3 receptors (CR3) on 
microglia, leading to synaptic complement activation and subsequent phagocytosis 
and synaptic elimination (Lui et al., 2016; Stevens et al., 2007). 
Through synaptic remodeling, microglia are directly involved in neuronal plasticity 
and can also affect synaptic structure in response external stimuli. In the juvenile 
mouse visual cortex, light deprivation has shown to result in increased association of 
microglia to dendritic spines and axon terminals, accompanied by the generation of 
phagocytic structures (Tremblay et al., 2010). 
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Beyond synaptic elimination, microglia also affect synaptic strength by releasing 
TNFα (Zhong et al., 2010) and by enhancing AMPA-type glutamate receptors on 
hippocampal neurons (Beattie et al., 2002).  
 
1.5.2.2 Role of microglia in neurogenesis  
Microglia are located closely to radial glia in different regions of the CNS, such as the 
hippocampus (Dalmau et al., 1997), retina (Santos et al., 2008; Sánchez-López et al., 
2004) and the spinal cord where more than half of microglia are in contact with radial 
glia (Rigato et al., 2011). In vitro, microglia have been shown to direct migration and 
differentiation of embryonic cortical neural precursor cells (Aarum et al., 2003), 
regulate the size of the neural precursor pool (Cunningham et al., 2013) and facilitate 
differentiation of basal forebrain progenitors into cholinergic neurons (Jonakait et al., 
2000). Moreover, in vivo, microglia can enhance neurogenesis and oligodendrogenesis 
in the early postnatal subventricular zone via the release of cytokines (Shigemoto-
Mogami 2014). In the adult brain, microglia have shown to regulate adult 
hippocampal neurogenesis through apoptosis-coupled phagocytosis of new-born 
neurons (Sierra et al., 2010). 
 
1.5.2.3 Role of microglia in CNS angiogenesis  
Microglia arrive in the brain at around the same time as the first endothelial cells and 
in the retina well before vascularization occurs in the first postnatal days. With their 
location in close proximity to the vasculature during CNS development (Checchin et 
al., 2006; Cuadros et al., 1993; 1992; Dalmau et al., 1997; Fantin et al., 2010; 
Herbomel et al., 2001; Monier et al., 2007; Rigato et al., 2011), microglia are in a 
prime position to interact with vessels and influence their development.   
In fact, some parenchymal microglia have end-feet that are in direct contact with the 
basal lamina of microvessels (Lassmann et al., 1991) – termed juxtavascular microglia 
– and it has been shown that upon traumatic injury they migrate along the surface of 
blood vessels (Grossmann et al., 2002). In the retina, microglia are already present 
during postnatal angiogenesis, and are distributed as single cells with a regular density 
in front of the growing vascular plexus (Rymo et al., 2011).  
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Several laboratories have studied the function of microglia in vessel development after 
their depletion using either genetic models such as the Csf1op/op (homozygous 
inactivating mutation of Csf-1 gene) or Pu.1-/- mice that both lack microglia, or 
chemical/pharmacological ablation with clodronate liposomes or Csf1-antagonists. 
These experiments consistently showed an abnormally sparser vascular network 
accompanied by a reduction of vessel branches both in the developing brain and retina 
in absence of microglia (Checchin et al., 2006; Fantin et al., 2010; Kubota et al., 
2009; Rymo et al., 2011). Microglia deletion did not, however, affect the number of 
tip cells, filopodia or the ingression of vessels (Fantin et al., 2010; Kubota et al., 
2009).  
Interestingly, in the hindbrain and retina, microglia processes associate closely with 
endothelial tip cells, especially between neighboring tip cells, and actively bridge 
vascular sprouts. This has been shown to promote endothelial tip cell fusion and 
anastomosis (Checchin et al., 2006; Fantin et al., 2010; Rymo et al., 2011). Also the 
time of microglia association with vessels in early development correlates with vessel 
growth. When the SVP is formed between E10.5 and E11.5 with the major phase of 
vascular networking, the number of microglia also peaks (Fantin et al., 2010). 
Consistent with this observation, hindbrain microglia numbers correlates with the 
number of vessel branch points (Fantin et al., 2010).  
A model of aortic ring culture showed oriented migration of microglia towards the 
ring followed by an increased vessel branching. This effect was also achieved using 
microglia conditioned medium, indicating that soluble factors secreted by microglia 
can promote vessel sprouting (Rymo et al., 2011). Which factors microglia release and 
which mechanisms come into play to promote vessel growth, however, remains to be 
discovered. Due to phenotypic differences of vessel defects in mice lacking Vegf-A, it 
can be excluded that this is the factor regulating microglia-mediated angiogenesis 
(Fantin et al., 2010)  
  
1.6 The CD95/CD95L signaling system  
CD95 (also called Fas or Apo-1) is a type I transmembrane receptor of the tumor 
necrosis factor receptor (TNFR) superfamily. Receptors of this family sense the 
extracellular environment and communicate changes thereof through a variety of 
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intracellular effectors. Structurally, they are characterized by up to six well-conserved 
cysteine-rich domains (CRDs) at the N-terminal extracellular side that are 
responsible for specific receptor-ligand interaction (Locksley et al., 2001). 
CD95 further belongs to the death receptor subfamily, which is defined by an 80 
amino acid death domain (DD) in the cytoplasmic part (Bodmer et al., 2002). As the 
name of this subfamily indicates, CD95 was initially discovered to induce apoptotic 
cell death upon activation. However, an increasing amount of reports suggest that 
CD95 also has non-apoptotic and, paradoxically, even reverse roles in eliciting 
migration, invasion, inflammation and proliferation (Brint et al., 2013) (Figure 1.7). 
The functional details and the differential outcomes of CD95/CD95L signaling will 
be described in the following sections.   
 
 
Figure 1.7: The CD95 signaling system. A) CD95 can activate apoptosis through FADD 
binding to its death domain, followed by recruitment of procaspase-8 and its autoproteolytic 
cleavage to caspase-8. Necroptosis can also be induced through inhibition of RIPK. B) CD95 
can activate multiple non-apoptotic pathways through recruitment of SFKs and other SH2 
adaptors such as p85 of PI3K to its phosphorylated death domain. This induces several 
downstream pathways including NFkB, JNK, Erk and Akt that ultimately lead to cell 
survival, migration or proliferation. Crosstalk between the apoptotic and non-apoptotic 
pathways exist, e.g. pro-caspase 8 can lead to activation of Erk. (adapted from (Martin-
Villalba et al., 2013)) 
 
The CD95 receptor is activated through binding of its cognate ligand CD95L (or 
FasL). CD95L is a type II transmembrane protein of the TNF superfamily of 
cytokines. Similar to other family members, the ligand trimerizes through well-
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conserved internal residues and exposes a less-conserved external surface that allows 
receptor-specific binding (Locksley et al., 2001). Binding of trimerized CD95L 
induces trimerization of the CD95 receptor and triggers downstream signaling. 
CD95L is normally membrane-bound, but can be cleaved by metalloproteases to 
generate a soluble form (Kayagaki et al., 1995; Tanaka et al., 1998).  
 
1.6.1 Apoptotic function of CD95  
CD95 was the first death receptor identified and was discovered as a cell surface 
molecule expressed on human lymphocytes that triggers apoptosis upon stimulation 
with agonistic antibodies (Trauth et al., 1989; Yonehara et al., 1989). Extensive 
studies of the signaling pathway elicited by CD95 activation has led to a detailed 
picture of how CD95 mediates apoptosis.  
The first step is the binding of trimerized CD95L to CD95 which leads to clustering 
of the receptor on the cell membrane and the stabilization of an open confirmation of 
its intracellular DD. This allows the recruitment of the DD-containing protein 
FADD (Fas associated protein with death domain) which binds to CD95’s DD 
through homotypic interactions via its own DD (Scott et al., 2009). FADD possess a 
death effector domain (DED) to which procaspase-8 is recruited. Once the number 
of procaspase-8 exceeds the number of FADD at the receptor, the caspase-activating 
chain can cluster and together with the regulator c-FLIP the death-inducing-
singaling complex (DISC) is formed (Dickens et al., 2012; Peter and Krammer, 2003; 
Schleich et al., 2012). Subsequently, caspase-8 is activated through self-cleavage and 
triggers caspase-3 either directly or indirectly via the mitochondrial apoptotic 
pathway, eventually resulting in apoptotic cell death (Kischkel et al., 1995) (Figure 
1.7).  
CD95-mediated cell death has been implicated in many processes both during 
homeostasis and disease. Particular the immune system depends on CD95/CD95L 
signaling for proper functioning. For instance, CD95L has been shown to be 
responsible for the perforin-independent cytotoxic activity of killer T cells (Berke, 
1995; Lowin et al., 1994). Moreover, immunological tolerance in immune privileged 
sites has been suggested to be induced through CD95L-induced cell death of 
inflammatory cells (Griffith et al., 1996; Nagata, 1997). In mice with reduced 
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expression of CD95 (lpr ~ lymphoproliferation) or non-functional CD95L (gld ~ 
generalized lymphoproliferative disease), which have been extensively used as animal 
models for CD95/CD95L, lymphadenopathy and a systemic lupus erythematosus like 
autoimmune disease develops. This is caused by the lack of activation-induced cell 
death in T-cells and the resulting accumulation of aberrant T-cells (Alderson et al., 
1995; Brunner et al., 1995; Takahashi et al., 1994; Watanabe-Fukunaga et al., 1992). 
In cancer, CD95L on cytotoxic T-cells and NK cells have shown to kill cancer cells 
expressing CD95. However, CD95L expression on tumor cells has also suggested  to 
be the mechanism for tumor immune evasion by inducing death of CD95+ infiltrating 
cytotoxic immune cells, known as the “tumor strikes back” effect (Peter et al., 2015). 
 
1.6.2 Non-apoptotic functions of CD95  
In the recent past, it became slowly clear that in a context-dependent manner, CD95 
can also transmit non-apoptotic cellular functions, such as cell proliferation, migration 
and inflammation.  
First indications of a apoptosis-independent function of CD95 already appeared as 
early as 1993, where proliferation was found to be stimulated in CD3-activated T-
cells (Alderson et al., 1993; Desbarats et al., 1999) and fibroblasts (Freiberg et al., 
1997).  
Further evidence for the non-apoptotic role of CD95 came from the cancer field 
where realization dawned that many different types of cancer cells are resistant to 
CD95-induced apoptosis. Stimulation of cancer cells with CD95 - once thought to be 
a good therapeutic approach to treat tumors through inducing apoptosis - led to the 
activation of signaling pathways such as Erk1/2, NfκB that increased motility and 
invasiveness of the tumor cells (Barnhart et al., 2004). Moreover, CD95 has shown to 
support tumor growth in various cancers via JNK and Jun pathways (Chen et al., 
2010a) (Figure 1.7). 
Outside of the cancer field, CD95 has also exhibited non-apoptotic functions. 
Although highly liver toxic under homeostatic conditions (Ogasawara et al., 1993), 
CD95 can accelerate liver regeneration after partial hepatectomy (Desbarats and 
Newell, 2000), possibly due to activation of EGFR and Erk in quiescent hepatic 
stellate cells (Reinehr et al., 2008). 
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The non-apoptotic functions of CD95 seem to be also mediated via the DD. Within 
CD95’s DD lies a modified immunoreceptor tyrosine-based activatory/inhibitory-like 
motif (ITAM/ITIM) consisting of the amino acid sequence YXXL that has been 
suggested to recruit alternative players. The tyrosine-residue (Y) within the motif is 
susceptible to phosphorylation through members of the Src-family kinase (SFK) 
thereby providing a platform for binding of SH2 domain containing proteins and 
leading to activation of various non-apoptotic pathways (Sancho-Martinez and 
Martin-Villalba, 2009; Schlottmann et al., 1996). 
 
1.6.3 Regulation of the pro- and anti-death decision via CD95 
With CD95 seemingly signaling for opposite functions it is obvious to ask how the 
switch between life and death is regulated. The mechanisms of this molecular switch 
are not fully elucidated and seem to be highly context-dependent. The most likely 
scenario is a concomitant activation of both apoptotic and non-apoptotic signaling 
components upon CD95 activation, where the balance of apoptosis-inhibiting factors 
and the availability of cell-growth-promoting kinases eventually determine the 
ultimate outcome.  
Three main levels of regulation can be found for the molecular switch CD95: 1) 
extracellular level, 2) DISC level and 3) mitochondria level (Yurchenko et al., 2012).  
On the extracellular level, it has been suggested that the membrane-bound form of 
CD95L is responsible for apoptosis while soluble CD95L drives other cellular 
functions (O' Reilly et al., 2009), although this theory is still controversial. Moreover, 
low concentrations of CD95L could result in survival signaling (Lavrik et al., 2007). 
At the level of the DISC, reduced expression of FADD or caspase-8 can lead to 
decreased apoptotic induction (Tourneur L, Oncogene, 2003 Fulda S, Oncogene 
2001). Furthermore, the protein cFLIP (cellular FLICE inhibitory protein) can 
inhibit the interaction of caspase-8 with the DISC, thus preventing execution of 
apoptosis (Irmler et al., 1997; Lavrik and Krammer, 2011). In apoptosis-resistant 
glioma cell lines, it has further been shown that FADD association with CD95 can be 
inhibited by the adaptor protein TRIP6 that directly binds to the intracellular domain 
of CD95. TRIP6 leads to activation of NfκB or phosphorylation by src family kinases 
(SFK) to induce migration (Lai et al., 2010). 
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At the mitochondria, deregulation of anti-apoptotic proteins such as the Bcl2 family 
proteins or XIAPs can tip the balance between life and death as well (Igney and 
Krammer, 2002). 
 
1.6.4 CD95 in the central nervous system  
The relevance of the CD95/CD95L signaling system in the nervous system has 
received little attention for many years due to the more obvious immune system-
related defects of the lpr and gld mutant mice. In the late 90s however, first studies 
showed wide expression of CD95 in the developing brain of rodents. CD95 was 
mainly found in cells of the ventricular/subventricular zone (VZ/SVZ), hippocampus, 
cerebellum and cortex. Expression begins at E14.5-E15.5, peaks at early postnatal 
stages and declines thereafter (Cheema et al., 1999; Park et al., 1998). After the 
completion of neural development, CD95 expression is reduced to an almost 
undetectable level, except for the neurogenic regions of the SVZ and dentate gyrus 
(DG), where CD95 activation has been suggested to increase neural stem cell survival 
and differentiation through c-src/PI3K/Akt (Corsini et al., 2009).  
CD95L seemed to follow a similar expression pattern as CD95 during development 
(French et al., 1996; Shin et al., 2002; Zuliani et al., 2006), however, ligand 
expression has been shown to be primarily present in neuroglial cells, including 
microglia, within white matter regions (Shin et al., 2002).  
Early studies related CD95 expression to the apoptosis of immature neurons (Cheema 
et al., 1999; Le-Niculescu et al., 1999) – however, these studies were conducted in 
vitro and might not reflect the actual situation in the brain. In fact, CD95 has been 
shown to promote neuronal growth in several studies. First, adult lpr mice with the 
Murphy Roths Large (MRL) background – called MRL have also been shown to 
have abnormal neuronal morphology with reduction of dendrites and atrophy of 
dendritic spines in pyramidal neurons of the parietal cortex and hippocampus (Sakić 
et al., 1998). Second, activation of CD95 in developing or regenerating neurons after 
sciatic nerve injury enhances neurite outgrowth through Erk activation and 
subsequent expression of p35, a neuron-specific activator of Cdk5 (Desbarats et al., 
2003). Thirdly, lpr or gld mice display abnormal branching of hippocampal neurons 
with less complex dendritic trees than wildtype mice. The CD95-induced neuronal 
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branching seemed to be caspase-independent and required dephosphorylation of Tau 
that promotes assembly and stabilization of microtubules (Ruan et al., 2008; Zuliani 
et al., 2006). Lastly, the cytoplasmic membrane proximal domain of CD95 was found 
to recruit the adaptor protein ezrin, which in turn activates the small GTPase Rac1 to 
induce neurite growth in cortical neurons (Ruan et al., 2008). 
 
1.6.5 CD95 in brain tumors  
Many types of tumors in the brain such as gliomas, oligodendrogliomas and 
ependymomas express CD95, and in gliomas, expression positively correlates with the 
degree of malignancy (Frankel et al., 1999; Gratas et al., 1997; Kleber et al., 2008; 
Riffkin et al., 2001; Tachibana et al., 1996). CD95L is also expressed in gliomas, 
preferentially at the tumor/host interface and close to vessels within the tumor (Kleber 
et al., 2008). Interestingly CD95L has shown to be highly epxressed in microglia of 
brain with glioma transplants (Badie et al., 2001).  
Similar to other tumor cells, glioma cells are resistant to apoptosis-induction by 
CD95 (Barnhart et al., 2004; Kleber et al., 2008; Weller et al., 1994). Instead, CD95 
acts as a key driver of basal invasion by recruiting the src-family kinase (SFK) Yes and 
activating PI3K and Akt to induce the expression of matrix-metalloproteases MMP-2 
and MMP-9 (Kleber et al., 2008). Moreover, a new form of cell death called “death 
induced by CD95 or CD95L elimination” has been described for the requirement of 
CD95/CD95L for cancer cell survival, including glioma cells. Elimination of either 
receptor or ligand leads to death that resembles a necrotic form of mitotic catastrophe 
(Hadji et al., 2014). CD95 activation on glioma cells can also result in the induction 
of the chemokines MCP-1, IL-8 and IL-6 through the Erk pathway that together 
form a tumor-promoting inflammatory environment (Choi et al., 2001; 2002). 
Another study conducted by our lab has shown that CD95 expression further 
associates with glioblastoma stemness and epithelial to mesenchymal transition 
(EMT), features required for tumor maintenance (Drachsler et al., 2016). 
The tumor growth-promoting effect of CD95 has led to the development of a 
therapeutic approach to treat grade IV glioblastoma. A fusion protein consisting of 
the extracellular domain of the CD95 receptor and the Fc domain of IgG, called 
APG101, has been designed as a decoy to block CD95L. Phase II clinical trial has so 
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far shown promising results with an increased percentage of patients reaching six 
months of progression free survival using APG101 in combination with radiotherapy 
(Bendszus et al., 2012). 
 
1.6.6 CD95 in angiogenesis  
Endothelial cells widely express CD95, and similar to other systems, both pro-
apoptotic as well as non-apoptotic functions have been described for CD95 in 
endothelial cells, either resulting in inhibition or promotion of angiogenic processes.  
Generally, endothelial cells are resistant to CD95L-induced apoptosis (Aoudjit and 
Vuori, 2001; Richardson et al., 1994; Sata and Walsh, 1998; Sata et al., 2000; Suhara 
et al., 2001; Takemura et al., 2004). This resistance has been explained by PI3K/Akt 
activation upon CD95L stimulation that promotes survival and concomitant 
upregulation of the regulator c-FLIP which blocks caspase-8 activity and thus 
apoptosis-induction (Aoudjit and Vuori, 2001; Suhara et al., 2001; Takemura et al., 
2004). Consistently, it has been shown that CD95L-induced Akt phosphorylation 
mediates endothelial nitric oxide synthase (eNOS) expression that regulates vascular 
tone and proliferation. In absence of CD95, lpr mice exhibit hypertension with 
endothelial dysfunction (Takemura et al., 2004).  
Further, CD95 can also actively promote angiogenesis. Local stimulation of CD95 in 
vivo using an agonistic CD95 antibody triggers inflammation and pronounced 
neoangiogeenesis independent of apoptosis (Biancone et al., 1997). This might be 
elicited indirectly through CD95-induced inflammation, however, evidence of direct 
stimulation of angiogenesis comes from a study that shows increased secretion of 
VEGF by human umbilical vein endothelial cells (HUVECs) after exposure to 
CD95L (Marx et al., 1999). 
Under certain conditions, CD95 has been reported to activate apoptosis in endothelial 
cells, for instance under hypoxia, after detachment and after stimulation with TNFα 
or VEGF (Aoudjit and Vuori, 2001; Cardier et al., 1999; Sata and Walsh, 1998).  
Furthermore, a number of studies following the traditional path of thought of CD95, 
implicates it in apoptosis during angiogenic processes in vivo, especially in different 
models of retinopathy. The main problem in retinopathies is the overgrowth of vessels 
that can eventually lead to blindness. In lpr and gld mice, exacerbated vessel growth 
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was observed in models of age-related macular degeneration (AMD) and retinopathy 
of prematurity, supposedly owing to a lack of apoptosis in endothelial cells (Barreiro 
et al., 2003; Davies et al., 2003; Kaplan et al., 1999). In AMD, CD95L expressed on 
retinal pigment epithelial cells was shown to be responsible for apoptosis activation in 
CD95-expressing endothelial cells beneath the retina (Kaplan et al., 1999). 
During development, CD95 on endothelial cells has been reported to be responsible 
for pruning of the vasculature by CD95L expressing T-leukocytes that induce 
endothelial-cell apoptosis (Ishida et al., 2003). Moreover, it has been suggested that 
endogenous angiogenesis inhibitors like thrombospondin 1 (TSP1) and pigment 
epithelium-derived factor (PEDF) act through upregulation of CD95L on 
endothelial cells to induce their apoptosis (Volpert et al., 2002). 
Unlike the receptor, CD95L is only expressed at low levels or is completely absent in 
endothelial cells in vivo (Cardier et al., 1999; Motz et al., 2014), although expression 
in cultured HUVECs has also been shown (Sata and Walsh, 1998; Sata et al., 2000). 
In the vasculature of various tumors however, CD95L seems to be upregulated on 
endothelial cells by factors released by tumor cells, and contributes to tumor immune 
evasion through apoptosis-induction of cytotoxic T-cells (Motz et al., 2014). 
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1.7 Aims of the study  
In this dissertation the role of CD95 in developmental regulation of the neurovascular 
system as well as in brain tumor angiogenesis is examined.  
CD95 has been reported to be expressed by endothelial cells and neurons in the CNS. 
However, functional studies thereof in the two systems have been often contradicting. 
Previous studies in our laboratory have uncovered that CD95 promotes neuronal 
branching during CNS development in a neuron-specific manner. As the vascular and 
nervous system are highly dependent on each other and are often co-regulated by the 
same set of molecules, we hypothesized that CD95 may act as an angioneurin to 
promote both endothelial cell as well as neuronal complexity during development.  
As a first aim, we studied the effect of endothelial-specific deletion of CD95 on vessel 
growth. As we discovered that the ligand for the CD95 receptor – CD95L – is mainly 
expressed by microglia, we further analysed the phenotype of mice containing a 
deletion of CD95L in microglia.  
A second aim of the study was to identify the molecular mechanisms governing 
CD95’s function in vessel development. Interaction partners and potential 
downstream effectors of CD95 were examined to decipher how CD95 may promote 
vessel growth.  
Developmental mechanisms of growth are often exploited by cancers and we further 
hypothesized that CD95 may also play a role during tumor angiogenesis in the brain. 
Thus, we studied the effect of CD95 stimulation as well as deletion on angiogenesis 
in glioblastoma, one of the most vascularized tumors.  
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2. MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Chemicals and Reagents  
 
Table 2.1: List of chemicals, reagents and kits 
Chemical/Reagent/Kit Manufacturer  
β-mercaptoethanol Sigma 
Accutase Sigma  
Agarose Sigma 
Agilent high-sensitivity DNA kit  Agilent  
Amerham Hyperfilm ECL GE Healthcare 
B27 supplement Invitrogen 
BCA kit Thermo Fisher Scientific 
BD PharmLyse Lysing buffer BD Biosciences 
bFGF Relia tech 
Bovine serum albumin (BSA) Sigma 
Brain tissue dissociation kit (P) Miltenyi Biotec 
Calcein AM Life technologies 
CD95L-T4 Apogenix GmbH 
Collagenase/Dispase Roche  
ColorPlus Prestained Protein Ladder Broad Range NEB 
cOmplete protease inhibitor cocktail tablets Roche 
C tubes Miltenyi Biotec 
DeadEnd Fluorometric TUNEL System Promega 
dNTP mix (10 mM)  Fermentas 
Dulbecco’s Modified Eagles Medium (DMEM)  Invitrogen  
Dithiothreitol (DTT) Thermo Fisher Scientific 
Dynabeads M-280 Streptavidin Thermo Fisher Scientific 
Enhanced chemoluminescence substrate (ECL) Perkin Elmer 
EGF Promocell 
EGM-2 Bullet kit   Lonza 
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Chemical/Reagent/Kit Manufacturer  
ERCC Spike-In mix  Ambion  
Ethanol Riedel de Haen  
Eukitt Mounting Medium  Sgima 
FASER kit – APC Miltenyi Biotec  
FD Rapid GolgiStain Kit  FD Neurotechnologies  
Fetal calf serum (FCS) Biochrom 
Fluoromount-G Southern Biotech 
2% gelatin Sigma 
GoTaq Flexi Green DNA polymerase Promega 
Glutamine Life Technologies 
Glycerol Sigma 
Glycine Sigma 
Hank’s Balanced Salt Solution (HBSS) Invitrogen 
Heparin Cell Culture Grade Sigma  
Hoechst 33342 Biotrend 
Human Angiogenesis Antibody Array R&D Systems 
Hydrochloric acid (HCl) VWR 
Isoflurane Baxter 
Ketavet (100mg/ml) Pfizer 
4x Laemlli Buffer Bio-Rad 
Lipofectamin 2000 Invitrogen  
L-Glutamine (100x) Invitrogen  
LY294002  Cell Signaling 
MangoTaq DNA polymerase Bioline 
Matrigel  BD Biosciences 
Matrigel (growth-factor reduced) BD Biosciences 
mirVana miRNA Extraction kit Ambion 
Mix-n-Stain CF488A Antibody Labelling kit  Biotium 
Nitrocelulose transfer membrane  Bio-Rad 
Neural Tissue Dissociation kit Miltenyi Biotec 
Neurobasal A Medium Invitrogen  
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Chemical/Reagent/Kit Manufacturer  
NEB-Next Library Preparation kit NEB  
PD98095 Cell Signaling 
Oligonucleotide primers MWG 
ON-TARGET plus Non-targeting pool Dharmacon  
On-TARGET plus Human FAS SMARTpool Dharmacon 
Opti-Mem Gibco 
4% Paraformaldehyde (PFA) in phosphate buffer Roth 
1 x PBS (without Mg2+ and Ca2+) PAA 
PCR H2O Braun 
Penicillin/Streptomycin Invitrogen 
Pierce Co-Immunoprecipitation Kit Thermo Fisher Scientific 
Pierce IP Lysis Buffer Thermo Fisher Scientific 
PhosSTOP Roche 
Potassium chloride (KCl) AppliChem 
Potassium phosphate monobasic (KH2PO4) Gerbu 
QuantiTect Primer Assay, Fas, mouse Qiagen 
Qubit dsDNA high-sensitivity (HS) kit Life Technologies  
RNAlater Ambion 
Rnase-free Dnase set Qiagen 
Rnase-free H2O Ambion 
RNaseZAP Sigma 
Rompun (2%) Bayer 
Skim milk powder Roth 
SMARTer Ultra Low RNA Kit for Illumina 
Sequencing – HA 
Clontech 
Sodium azide (NaN3) Merck 
Sodium citrate tribasic dehydrate Sigma 
Sodium chloride (NaCl) Sigma 
Sodium choloride 0.9% sterile (NaCl) Braun 
Sodium dihydrogen phosphate (NaH2PO4) Sigma 
Sodium dodecyl sulphate (SDS) Sigma 
45 
Chemical/Reagent/Kit Manufacturer  
Sodium hydrogen phosphate (Na2HPO4) Sigma 
Sodium hydroxide (NaOH) Sigma 
Sunflower Oil Sigma 
SuperFrost slides Roth 
Sucrose Sigma 
SYBR Green Master Mix Life technologies  
Tamoxifen Sigma 
TGX Gels (Mini-Protean or Criterion, 4-20%, 10%, 
12%) 
Bio-Rad 
Tools for mouse surgery Fine Science Tools  
Trans-Blot Turbo Transfer Buffer  Bio-Rad 
Tris base Sigma 
Triton X-100 Sigma 
Trypsin-EDTA (0.05%) Invitrogen 
Tween-20 Sigma 
Western Bloting Filter Paper Bio-Rad  
Xylene Sigma 
 
2.1.2  Solutions and Media  
 
Table 2.2: List of solutions and media 
Solutions Composition 
Histology and Immunofluorescence 
Blocking buffer for IHC  Triton X-100, 0.3% 
FCS 5% 
Dissolve in PBS 
FACS staining buffer PBS 1x 
FCS 5% 
PBS (20x) 160 g/L NaCl  
23 g/L Na2HPO4 
4 g/L KCl  
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4 g/L KH2PO4 
Fill up to 1L with H2O and adjust pH to 7.4  
Solutions Composition 
Perfusion solution  5.71 mg/ml Ketavet 
2.8 mg/ml Rompun  
in NaCl 0.9% 
0.1 M Phosphate buffer 69 ml 0.2 M Monobasic Stock (NaH2PO4, 13.9 
g/500ml) 
231 ml 0.2M dibasic stock solution (Na2HPO4, 
7H2O, 53.65 g/L) 
Fill up to 600 ml (pH7.3)  
30% sucrose buffer 30g sucrose in 100ml Millipore H2O 
Citric acid buffer for 
antigen retrieval 
10 mM sodium citrate tribasic dehydrate 
0.05% Tween-20 
Dissolve in VE-H2O and ajust to pH 6.0 
Tamoxifen (TAM) Tamoxifen 10 mg/ml 
In a 9:1 mixture of sunflower oil and EtOH  
  
Cell culture  
Endothelial cell medium EBM2 
Neurobasal A medium 500 ml Neurobasal A medium  
10 ml B27 Supplement (50x) 
5ml L-Glutamine (200mM) 
5ml Penicillin/Streptomycin (10 000 units/ml and 10 
000 µg/ml) 
2 µg/ml Heparin  
20 ng/ml bFGF 
20 ng/ml EGF  
  
Western blot  
PBS-Tween  Tween-20 0.1% 
47 
Dissolve in PBS 
Running buffer 10 g/l Tris Base  
30.28 g/l glycine 
150 g/l SDS 
 
2.1.3 Antibodies 
 
Table 2.3: List of antibodies 
Antibodies for flow cytometry 
Antibody Clone Isotype Conjugate Dilution Manufacturer 
CD11b M1/70 Rat IgG2b FITC 1:200 eBioscience 
CD31 390 Rag igG2a PE/FITC 1:100 eBioscience  
CD45 30-F11 Rag IgG2b APC-Cy7 1:200 BD 
CD95 Jo2 Hamster 
IgG2, λ2 
PE-Cy7 1:100 BD  
CD95L MFL3 Hamster IgG APC 1:100 BD  
Prom1 
(CD133) 
13A4 Rat IgG1 PerCP-
eFluor710 
1:75 eBioscience 
PSD95 7E3-1B8 Mouse IgG1 Alexa 488 
(conjugated 
with Mix-
n-Stain kit) 
1:100 Life 
technologies 
O4 O4 Mouse IgM PE 1:25 Miltenyi 
Biotec 
Glast  ACSA-1 Mouse 
IgG2a 
PE 1:30 Miltenyi 
Biotec 
      
Primary antibodies for immunohistochemistry  
Antibody Clone Isotype Conjugate Dilution Manufacturer 
CD31 Poly-
clonal 
Rabbit IgG - 1:100 Abcam 
(a28364) 
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Antibody Clone Isotype Conjugate Dilution Manufacturer 
Collagen IV  Poly-
clonal 
Rabbit - 1:100 Novotec 
Iba1 Poly-
clonal 
Rabbit IgG - 1:100 Wako  
Iba1 Poly-
clonal 
Goat IgG - 1:100 Abcam 
(ab107159)  
IsolectinB4 - - Alexa647/ 
Alexa568 
1:100 Life 
technologies  
pH3 3H10 Mouse IgG1 - 1:1000 Millipore  
pH3 Poly-
clonal 
Rabbit  - 1:100 Cell Signaling 
Ki67 SP6 Rabbit   1:100 Novus 
Biologicals 
      
Secondary antibodies for immunohistochemistry  
Antibody Clone Isotype Conjugate Dilution Manufacturer 
Mouse Poly-
clonal 
Goat IgG1/ 
Donkey IgG 
Alexa488 1:400 Life 
technologies  
Rabbit Poly-
clonal 
Goat IgG1/ 
Donkey IgG 
Alexa555 1:400 Life 
technologies 
Goat Poly-
clonal 
Donkey IgG Alexa488 1:400 Life 
technologies 
 
 
     
Primary antibodies for immunoprecipitation and Western blot  
Antibody Clone Isotype Conjugate Dilution Manufacturer 
Akt  Poly-
clonal 
Rabbit - 1:1000 Cell signaling 
(#9272) 
Apo1  Rabbit - 10 ug  Apogenix 
CD95  7C10 Rat IgG2a - 1:500 Acris 
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Antibody Clone Isotype Conjugate Dilution Manufacturer 
Erk(1/2) Poly-
clonal 
Rabbit - 1:1000 Cell signaling 
(#9102) 
Gapdh Fl-335 Rabbit IgG - 1:2000 Santa Cruz 
IRS1 Poly-
clonal 
Rabbit - 1:1000 Santa Cruz 
p85 Poly-
clonal 
Rabbit IgG - 1:1000 Millipore (06-
195) 
Phospho-
Erk(1/2) 
Poly-
clonal 
Rabbit - 1:1000 Cell signaling 
(#9101) 
phospho-Akt 
(Ser473) 
Poly-
clonal 
Rabbit - 1:1000 Cell signaling 
(#9271) 
SFK Poly-
clonal 
Rabbit - 1:1000 Cell Signaling 
(#2108) 
      
Secondary antibodies for Western blot  
Antibody Clone Isotype Conjugate Dilution Manufacturer 
Rabbit Poly-
clonal 
IgG HRP 1:5000 Jackson 
Immuno-
Research 
Rat Poly-
clonal 
IgG HRP 1:5000  Jackson 
Immuno-
Research 
 
2.1.4 Peptides 
 
Table 2.4: List of peptides 
Species Name Amino acid sequence 
Human Scrambled control 
(hScr) 
SS-Biotin-SGSG-LKDKHTE(p)YKAGKILD 
Alanine mutant  SS-Biotin-SGSG-HGKKEAADTLIKDLK 
50 
(hA) 
Wildtpe CD95 
(hY) 
SS-Biotin-SGSG-HGKKEAYDTLIKDLK 
Phosphorylated 
CD95 (hpY)  
SS-Biotin-SGSG-HGKKEA(p)YDTLIKDLK 
(with hydrolytically stable phosphotyrosine 
analogue F(CF2PO3)) 
Mouse  Scrambled control 
(mScr) 
SS-Biotin-SGSG-KA(p)YHKDDSKLGLGQI   
Alanine mutant 
(mA) 
SS-Biotin-SGSG-HGKSDAAQDLIKGLK 
Wildtpe CD95 
(mY) 
SS-Biotin-SGSG-HGKSDAYQDLIKGLK 
Phosphorylated 
CD95 (mpY)  
SS-Biotin-SGSG-HGKSDA(p)YQDLIKGLK 
(with hydrolytically stable phosphotyrosine 
analogue F(CF2PO3)) 
The peptides were synthesized by PSL GmbH, Heidelberg 
 
2.1.5 Primers 
 
Table 2.5: List of primers for genotyping 
Name Nucleotide sequence (5’ – 3’) 
CD95 forward GGCTTTGGAAAGGAATTTCCTCCTAAGAAG 
CD95 reverse TGCAGTTGCTGAGATGAACCATTTTCTCTG 
CD95L forward GAA CAC AGA CCT ACA CAG AAG TCA CAT C 
CD95L reverse TGCAGTTGCTGAGATGAACCATTTTCTCTG 
LysM Cre forward  CCCAGAAATGCCAGATTACG 
LysM Cre reverse CTTGGGCTGCCAGAATTTCTC 
Cdh5-CreERT2 
forward  
GCC TGC ATT ACC GGT CGA TGC AAC GA 
 
Cdh5-CreERT2 
Reverse 
GTG GCA GAT GGC GCG GCA ACA CCA TT 
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2.2 Methods  
2.2.1 Animal Experiments  
2.2.1.1 Animals 
Experimental mice were housed in the animal facilities of the German Cancer 
Research Center (DKFZ, Heidelberg, Germany) at a twelve-hour dark/light cycle 
under standard conditions and had ad libitum access to food and water.  
All animal experiments were performed in accordance with institutional guidelines of 
the German Cancer Research Center and were approved by the Regierungspräsidium 
Karlsruhe, Germany (G309/14). 
C57BL/6J mice were purchased from Charles River or bred in house at the DKFZ 
Center for Preclinical Research core facility.  
CD95fl/fl mice (carrying a loxP-flanked CD95 gene) were a kind gift from K. 
Rajewsky. Cdh5-(PAC)-CreERT2 mice were a kind gift from R. Adams (Sorensen et 
al., 2009). CD95Lfl/fl mice were a kind gift from M. Lévi-Strauss (Karray et al., 2004). 
LysM-Cre mice were purchased from Jackson Laboratories (Bar Harbor, Maine).  
CD95fl/fl mice were crossed with the Cdh5-(PAC)-CreERT2 line to generate 
CD95fl/fl;Cdh5-(PAC)-CreERT2 mice. Newborn CD95fl/fl;Cdh5-(PAC)-CreERT2 
pups were intragastrically injected with 50 µg of tamoxifen in 50 µl sunflower oil/10% 
ethanol at postnatal days P1, P2, P3 and P5. Tamoxifen-induced cre negative 
littermates were used as controls. For tumor implantation, adult mice (8-10 weeks) 
were injected with 250mg/kg tamoxifen in 100 µl sunflower oil/10% ethanol once per 
day for 5 days.  
CD95Lfl/fl mice were crossed with the LysM-Cre line to generate CD95Lfl/fl;LysM-
Cre mice. Cre negative littermates were used as controls. 
Fox Chase SCID® Beige mice for transplantation experiments were purchased from 
Charles River.  
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Table 6: List of experimental mice 
Short name Full name Description Reference 
C57BL/6J  Wildtype mice  
Cdh5-(PAC)-
CreERT2  
B6-Tg(Cdh5-
cre/ERT2)1Rha 
Fastm1Cgn 
 
Tamoxifen-inducible Cre 
recombinase under the 
control of endothelial-
cell specific promoter 
Cdh5 
Sorensen et al., 2009 
CD95fl/fl B6-Fastm1Cgn 
 
Mice harboring loxP-
flanked exon IX of CD95 
that codes for its death 
domain  
Hao et al., 2004 
CD95Lfl/fl B6-Fasltm1Lest 
 
Mice harboring loxP-
flanked CD95L gene 
Karray et al., 2004 
Fox Chase 
SCID Beige  
CB17.Cg-
Prkdcscid Lyst bg 
/Crl 
 
Immune-deficient mice 
lacking T- and B-cells 
and with defective 
natural killer cells  
 
LysM-Cre 
 
 
B6.129P2-
Lyz2tm1(cre)Ifo/J 
Cre recombinase under 
the control of 
macrophage-specific 
promoter LysM 
Clausen et al., 1999 
 
2.2.1.2 Orthotopic injection of SMA560 cells 
10,000 SMA560 cells in 2 µl were injected into the striatum of CD95fl/fl or 
CD95fl/fl;Cdh5-CreERT2 mice at the coordinates x=0, y=2, z=3 from the bregma using 
a stereotact. 
 
2.2.1.3 Xenografting and treatment with CD95L beads  
SCID beige mice (8 -10 weeks old, female) were subcutaneously transplanted with 
10,000 GBM cells in 100 µl matrigel. Tumor size was measured every week with a 
caliper and after establishment of tumors, mice were intravenously injected with 2x106 
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CD95L-coated beads through the tail vein. Two weeks later animals were sacrificed 
and tumors were retrieved after transcardial perfusion.  
 
2.2.1.4 Perfusion  
Mice were anesthetized by intraperitoneal injection of 800 µl perfusion solution. After 
the thoracic cavity was opened, the heart was exposed and transcardial perfusion was 
performed with 10 ml of HBSS. For immunohistochemistry, the mice were 
additionally perfused with 10 ml of 4% PFA.  
 
2.2.2 Cell and Tissue Biology  
2.2.2.1 Culture of human umbilical vein endothelial cells (HUVECs) and bEnd.3cells 
HUVECs (Lonza) were maintained in endothelial basal medium-2 (EBM-2, Lonza) 
supplemented with EGM-2 SingleQuot Kit Supplements and Growth Factors 
(Lonza) on 0.1% gelatin-coated flasks. bEnd.3 cells were are gift of Carmen Ruiz de 
Almodovars lab and were maintained in DMEM supplemented with 1x glutamine 
and 1x penicillin/streptomycin. Cells were kept in 5% CO2 at 37°C and HUVECs 
were used up to passage 6 for experiments.  
For CD95L stimulation, HUVECs were starved on endothelial basal medium-2 with 
0.1% FCS and bEnd.3 cells in DMEM with 0.1% FCS for 12 hours and subsequently 
treated with 40 ng/ml CD95L-T4 (Kleber et al., 2008) for 5, 10, 15, 20 or 30 min.  
For treatment with LY294002 (Cell Signaling) and PD98095 (Cell Signaling), cells 
were pretreated with different concentrations of the inhibitors for 1 hour, after which 
inhibitors were removed and replace by medium with CD95L-T4.   
 
2.2.2.2 Endothelial tube formation assay  
The endothelial tube formation assay was performed according to Arnaoutova et al. 
(Arnaoutova et al., 2009). 80 µl of growth factor reduced matrigel was plated in each 
well of a 96-well plate and allowed to gel at 37°C for 30 min. 15000 HUVECS in 
EBM-2 supplemented with 35 ng/ul bFGF were seeded per well and the formation 
of endeothelial tubes was assessed after 12 hours. For visualization, tubes were stained 
with the live cell dye Calcein AM (8 µg/ml) before imaging. Experiments were 
performed in triplicates.   
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For CD95L stimulation, HUVECs were stimulated for 4 hours on control- or 
CD95L (CD95L-T4) coated lipid membranes prior to plating on matrigel. For 
siRNA experiments, knockdown was allowed to occur for 48 hrs and cells were then 
plated on matrigel.  
 
2.2.2.3 siRNA-mediated knockdown in HUVECs  
For siRNA-mediated knockdown of endothelial cells, 100 000 HUVECs were plated 
in one well of a 6-well-plate. On the next day, 50 nM siRNA targeted against CD95 
(On-TARGET plus Human FAS SMARTpool, Dharmacon, 
GAACAUGGAAUCAUCAAGG, UGGAAGGCCUGCAUCAUGA, 
UGAGGAAGACUGUUACUAC, GCGUAUGACACAUUGAUUA) was 
transfected using Lipofectamine 2000 according to manufacturer’s protocol. Briefly, 
150 µl Optimem and 9 µl Lipofectamin 2000 were mixed and added to a mixture of 
150 µl Optimem and 4 µl siRNA, which was then put dropwise onto one well of 
HUVECs. Non-targeting scrambled siRNA (ON-TARGET plus Non-targeting 
pool, Dharmacon) was used as a control. siRNA knockdown was performed for 48 
hours before the experiment.  
 
2.2.2.4 CD95L supported membrane and beads preparation (conducted by Gülce Sila 
Gülcüler) 
The model of membrane bounded CD95 ligand was prepared by the deposition of 
planar lipid membranes on solid substrates as previously described (Kaindl et al., 
2012). The desired bilayers were made from stock solutions of DOPC (Avanti) 
containing 0.8 mol% of biotin-DOPE (Avanti) resulting in 8.7nm lateral distance 
(<d>) of CD95L molecules (<d> = (AreaLipids /(Molar fractionbiotin-DOPE)1/2) and only 
DOPC as control bilayers. The lipids were mixed in a chloroform solution, first dried 
under a stream of nitrogen, and then kept in a vacuum chamber at 25°C for 12 hrs. 
Afterwards, they are hydrated in distilled water to a final concentration of ~1mg/ml. 
This resulted in multilamellar vesicles that were rendered unilamellar (SUVs) by 
pulsed sonication with a tip sonicator (Misonix, New York, USA) for 30 min at 1.0 
W. The debris from the sonication tip and SUVs were separated by 
ultracentrifugation for 10 min and then stored at 4°C. The glass slides from Menzel 
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(Braunschweig, Germany) were cleaned by RCA protocol (Kern and Puotinen, 1970). 
Afterwards, they were intensively rinsed with water, dried at 70 °C, and stored in a 
vacuum chamber. The bottomless plastic fluidic channels (µ-slide I) (Ibidi) were 
bonded with glass slides by using Polydimethylsiloxane (Sylgard184, Dow Corning 
Co., USA). Supported membranes were prepared by deposition of SUV suspensions 
onto the cleaned bonded chambers. After 1 h incubation, the chambers were 
intensively rinsed with de-ionized water to remove the remaining vesicles. 
Subsequently, the supported membranes were incubated with 1 µg/ml neutravidin 
(Invitrogen) for 15 min and thoroughly washed with de-ionized water. In the next 
step, the membranes were incubated with aqueous CD95L-T4-biotin (20 nM) 
(Apogenix) solution for 1hr at room temperature. Finally, the samples were carefully 
washed with PBS and it was replaced by pre-warmed cell culture medium. The 
supported membranes were kept at 37°C prior to the cell experiments.  
The prepared lipid vesicles as above were also used to form supported lipid monolayer 
on porous silica microspheres NUCLEOSIL® standard C18 phases, nonpolar 
(Macherey-Nagel). The lipid vesicles were incubated with silica beads at 60°C for 
2hrs by rotation. The coated beads were centrifuged down and washed with PBS. 
CD95L functionalization on lipids was performed as described above by additional 
rotation for beads incubation.  
 
2.2.2.5 Culture of SMA560 cells  
SMA560 cells were were maintained in DMEM supplemented with 1x glutamine 
and 1x penicillin/streptomycin. Cells were kept in 5% CO2 at 37°C. 
 
2.2.2.6 Culture of patient-derived glioblastoma (GBM) cells  
Collection of patient samples was approved by the Ehtics committee of the Charite 
University Medicine, Campus Virchow-Klinikum, Berlin (EA3/023/06). The 
specimen was examined by a neuropathologist to confirm that the tumor met WHO 
critera for glioblastoma. The sample was dissociated using the Brain Tumor 
Dissociation Kit (P) and subsequently expanded in culture in Neurobasal medium 
supplemented with B27,heparin (2 µg/ml) and the growth factors EGF (20 
ng/ml)and bFGF (20 ng/ml) at 5% CO2 and 37°C. 
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2.2.2.7 Collection of conditioned medium from GBM cells  
For collection of conditioned medium 10 000 GBM cells were incubated on control- 
or CD95L-membranes for 4 hours in NBM without supplements and subsequently 
allowed to rest on one well of a 6 well plate for 24 hours in medium with 50% NBM 
with and 50% without supplements. 2 ml of conditioned medium was then collected 
and filtered through a 0.22 µm sterile filter. The conditioned medium was stored at -
80°C before usage for experiments. 
 
2.2.2.8 Flow cytometry  
For flow cytometry analysis of embryonic and postnatal brain, whole E14.5, P1 and 
P6 brains were retrieved and single cell suspensions were generated using the Neural 
Tissue Dissociation Kit  (P). Subsequently, cells were washed in PBS with 10% FBS 
and stained with the following antibodies: PE-Cy7 conjugated anti-CD95 and APC-
conjugated anti-CD95L with PercP-eFluor 710-conjugated CD133 and Alexa488-
conjugated anti-PSD95 or with APC-Cy7-conjugated CD45, FITC-conjugated 
CD11b and PE-conjugated anti-CD31. For anti-Glast PE staining the Neural 
Dissosciation Kit (T) was utilized due to Glast sensitivity to papain. Anti-O4 PE 
staining was conducted in separate experiment. Both anti-O4 and anti-Glast staining 
were combined with anti-CD45 APC-Cy7 to exclude immune cells, anti CD95-PE-
Cy7 and anti-CD95L APC. For CD95L staining, an amplification step was 
introduced (due to weak signal) using the FASER kit – APC. FACS was performed 
at a BD FACS Canto II machine. Unstained and fluorescence minus one controls 
were used for gating and compensation. At least 50000 single cells were recorded. 
Data were analysed using the FlowJo software. Median fluorescence intensity values 
were compared and normalized to unstained control.  
For FACS analysis of cultured HUVECs, cells were detached from cell culture flasks 
with trypsin and washed twice with PBS. Blocking was performed with 10% FBS in 
PBS for 30min. Subsequently, HUVECs were stained with APC-conjugated anti-
CD95 (Apogenix, 1 µg) and FITC-conjugated CD31 antibody for 1 hour. Unstained 
and single stained cells were used as controls. After washing three times with the 
blocking solution, cells were analysed on a BD FACS Canto II machine. Data were 
analysed with FlowJo.  
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2.2.2.9 TUNEL staining 
For TUNEL staining, HUVECs on control- or CD95L-coated membranes were 
fixed for 15 min using 1% PFA, washed twice 5 min with PBS and stained using the 
DeadEndTM Fluorometric TUNEL system kit (Promega) according to manufacturer’s 
protocol. Cells were counterstained with Hoechst33342 (1:3000) and imaged on a 
Zeiss Cell Observer with a 63x objective.  
 
2.2.2.10 Immunohistochemistry of the brain 
For immunohistochemistry of the brain, pups were sacrificed, their brains extracted 
and fixed in 4% PFA overnight. 100 µm coronal sections were prepared using a 
vibratome. Sections were stored in PBS with 0.05% sodium azide until staining. For 
stainings, sections were incubated in PBS with 0.3% Triton X-100 and 5% fetal calf 
serum for one hour to block unspecific binding sites.  For different analyses, sections 
were stained with anti-Iba1 antibody and anti-pH3 antibody diluted in blocking 
solution over night at 4°C with shaking. After washing the sections 3 times 5 min 
with PBS, secondary antibody staining was performed using the appropriate Alexa-
fluorophore antibodies diluted in blocking buffer for 2 hour at room temperature. 
Furthermore, Alexa-647 conjugated IsoB4 was added to the secondary antibodies, as 
well as Hoechst33342 to stain for nuclei. Sections were then washed three times 5 
min with PBS again, and in a last step with PB buffer. After mounting with 
Fluoromount-G, the sections were allowed to dry at room temperature for 30min and 
were stored in the dark at 4°C until imaging. 
 
2.2.2.11 Immunohistochemistry of the retina (performed by Rosario Yerbes Cadenas 
and Nathalie Tisch) 
Mice were sacrificed at P6, eyeballs were isolated and fixed in 4% PFA on ice for 2 
hours. Retinas were isolated and blocked with 0.3% Triton X-100/1% bovine serum 
albumin in PBS for 2h at room temperature (RT). The retina vasculature was stained 
with Alexa568-conjugated Isolectin B4, anti-collagen IV antibody and anti-pH3 
antibody diluted in blocking solution, overnight at 4°C and subsequently incubated 
with appropriate Alexa-labeled secondary antibodies for 2h at RT. Afterwards retinas 
were flat mounted and imaged.  
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2.2.2.12 Golgi staining of the brain  
Mice were sacrificed at P3, brains were taken out and rinsed shortly with Millipore 
water. Subsequently, the brains were directly processed using the FD Rapid 
GolgiStain kit according to manufacturer’s instructions with some modifications. 
Brains were first incubated in a 1:1 mixture of Solution A and B for 3 days at 37°C. 
Subsequently, brains were transferred to 30% sucrose and incubated for 1 day at room 
temperature. The next day, brains were cut to 200 µm sections in 6% sucrose using a 
vibratome. After washing two times with Millipore H2O, the sections were developed 
in a 2:1:1 mixture of Millipore H2O, Solution C and D for 10 min. This was followed 
by 2 times 4 min washing of the sections with Millipore H2O.  Sections were then 
mounted with Fluoromount-G.  
 
2.2.2.13 Immunohistochemistry and vessel analysis of xenograft tumors 
Xenograft tumors were fixed overnight in 4% PFA and were subsequently paraffin 
embedded and cut into 5 µm sections on a microtome. Paraffin sections were cleared 
using xylene and dehydrated using 100%, 95%, 70% and 50% EtOH. Antigen-
retrieval was performed in citric acid buffer for 20 min at 95°C. After cooling down 
for 30 min, blocking was performed using PBS with 0.3% Triton X-100 and 5% FBS 
for 1 hour at room temperature. Sections were stained with primary antibody for anti-
CD31 antibody at 4°C over night and appropriate Alexa secondary antibody diluted 
in blocking buffer for 2 hours at room temperature. Dehydration was then performed 
using 50%, 70%, 95% and 100% ethanol. After clearing with Xylene, the sections 
were mounted using Eukitt.  
 
2.2.3 Microscopy analyses  
2.2.3.1 Imaging and analysis of endothelial tubes  
Microscopy was performed on a Zeiss Cell Observer (Observer.Z1) with 4x objective. 
Images were subsequently cut into same sizes to remove the rim of the 96-well on the 
picture. Tubes were analyzed with the ImageJ plugin Angiogenesis Analyzer 
(http://image.bio.methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-ImageJ) using 
the Batch fluorescent mode. Data are expressed as mean±SD. Statistics were 
performed using unpaired two-tailed t-test. 
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2.2.3.2 Imaging and analysis of vessels in the cortex 
Images of cortex vessels were obtained on a Leica SP5 confocal microscope at the 
DKFZ light microscopy core facility. Vessels were imaged in a blind manner with a 
20x objective, and optical stacks (12 slices, 5 µm thick) of the same cortical region 
(somatosensory/motor cortex) of control and KO brains were acquired. At least 5 
images of different sections per brain were taken. Vessel area and branching were 
analysed using the Fiji (ImageJ) software with a custom written macro (Appendix 5.1 
I./II.). Briefly, background was first subtracted using the rollerball function and 
Gaussian blur was applied to smoothen the image. Next, vessels were segmented 
using the color threshold function. To measure the area of the image covered by 
vessels, the analyse particles function was used, with an exclusion size of 400 px. For 
branch analyses, thresholded images were used as input for the skeletonize and analyse 
skeleton 2D/3D functions that automatically detect branches and measure their 
length and branching points.  
Cell proliferation analysis was conducted by counting pH3 and IsoB4 double positive 
cells, whereby excluding IsoB4+ microglia either by morphology or additional Iba1 
staining.  
Data are expressed as mean± SD. Statistics were performed using unpaired two-tailed 
t-test. 
 
2.2.3.3 Imaging and analysis of vessels in the retina (performed by Rosario Yerbes 
Cadenas and Nathalie Tisch) 
Pictures were taken using a Zeiss LSM 510 confocal microscope (BZH, Heidelberg) 
and image analysis was accomplished manually with Fiji (ImageJ). The endothelial 
cell coverage (vessel area) was calculated as IsoB4+ area per retina area. Branching and 
branching points were counted and normalized to total vessel area per retina. For the 
analysis of endothelial cell proliferation, pH3+/IsoB4+ endothelial cells were counted 
and normalized to vessel area. Vessel regression analysis was accomplished by 
counting ColIV+IsoB4- structures (empty sleeves) and correlating them to retina vessel 
area. Data are expressed as mean± SD. Statistics were performed using unpaired two-
tailed t-test. 
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2.2.3.4 Imaging and analysis of Golgi-stained neurons 
Neurons were imaged in a blind fashion with a 40x objective on a Zeiss Cell Observer 
(DKFZ light microscopy core facility) using a color camera in brightfield mode. 
Stacks (1 µm) were imaged to cover whole single neurons. To assess neuron 
branching, branches were traced manually using ROIs in Fiji (ImageJ). At least 10 
neurons per brain were traced. Data are expressed as mean± SD. Statistics were 
performed using unpaired two-tailed t-test. 
 
2.2.3.5 Imaging and analysis of tumor vessels 
Images were acquired at a Leica SP5 confocal microscope (DKFZ) with a 20x 
objective. At least two 2x2 tile scans per tumor were used for analysis. Vessel area was 
quantified using Fiji (ImageJ) with a macro (Appendix 5.1 I.) and normalized to the 
tissue area imaged. Data are expressed as mean± SD. Statistics were performed using 
unpaired two-tailed t-test. 
 
2.2.3.6 Imaging and analysis of tumor volume 
To assess intracranial glioblastoma tumor size, we utilized a stereological method. 
Tile scans of tumors were taken for every tenth section of the tumor stained with 
DAPI and imaged using the Zeiss Cell Observer with a 4x objective. The area 
covered by tumor cells was measured using Fiji (ImageJ). The measured area values 
were used to interpolate a function for the whole tumor and mathematical integration 
of the function resulted in the interpolated tumor volume. The calculations were 
conducted using a R script written by Frederik Ziebell (Appendix 5.2.1).  
 
2.2.4 Biochemical analyses 
2.2.4.1 Protein extraction and concentration determination  
Cells were harvested, washed with chilled PBS and lysed in Pierce IP lysis buffer with 
cOmplete protease inhibitor cocktail and phosphate inhibitor cocktail for 20 min on 
ice. For protein isolation from tissue, the tissue was subsequently homogenized using 
the Minilys machine (Precellys). After centrifugation at 16000 x g for 10 min at 4°C, 
the supernatant was taken and protein concentration was determined using the BCA 
61 
kit. Standardized concentrations of bovine serum albumin (BSA) was used for 
calibration.  
 
2.2.4.2 SDS-PAGE and Western blot 
Equal amount of protein from cel lysates were boiled for 5 min in Laemmli buffer 
with β-mercaptoethanol. Proteins were resolved by SDS–PAGE followed by Western 
blotting to nitrocellulose membranes using the Trans-Blot Turbo Transfer System 
(Bio-Rad). Membranes were blocked with 5% Skim Powder Milk in PBS-Tween for 
1 h and then probed over night at 4°C with the following antibodies dissolved either 
in 5% Milk or 5% BSA according to manufacturer’s instructions: anti-CD95, anti-
ERK 1/2, anti-phospho-ERK 1/2, anti-Akt, anti-phospho-Akt (Ser473), anti-p85 
and anti-GAPDH (for concentrations see Table 3). Immunoreactive proteins were 
visualised with horse raddish peroxidase (HRP)-conjugated anti-rabbit or anti-rat 
antibodies by incubation for 1h at room temperature. The HRP signal was detected 
using ECL and membranes were developed using the ChemicDoc Touch imager 
(Bio-Rad). Quantification of Western blots were conducted in Fiji (ImageJ).  
 
2.2.4.3 Immunoprecipitation  
For immunoprecipitation, the Pierce co-immunoprecipitation kit was used according 
to manufacturer’s instructions. First, 10 µg IgG and 10 µg anti-CD95 antibody (Apo-
1) were each immobilized to one Pierce Spin Column. Next, HUVEC cells were 
lysed (see 2.2.4.1) and 1 mg of whole cell lysate was used as input. The lysate was 
then pre-cleared in a control agarose resin spin column. Afterwards, 500 µl of lysate 
was added to the IgG- and the antibody-bound columns and allowed to incubate 
under rotation overnight at 4°C. After incubation, the columns were washed 5 times 
with IP lysis buffer. Finally, elution was performed using 60 µl elution buffer and 
eluates were subjected to SDS-PAGE and Western blot to analyse proteins bound to 
IgG and CD95. All stepes were performed at 4°C 
 
2.2.4.4.Peptide pulldown assay 
The peptide pulldown assay was performed with DTT-cleavable, biotinylated 
peptides containing the YXXL motif present in the human or mouse CD95 death 
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domain as previously described with modifications (Letellier et al., 2010) (see peptide 
sequences in Table 4). A scrambled negative control was generated and subjected to 
Blast to confirm non-target in the human/mouse genome. Another negative control 
containing a mutant version of the YXXL motif with an non-phosphorylatable 
alanine instead of Y was also generated. A wildtype peptide with a non-modified 
Y291 (human) or Y283 (mouse) was used as bait. Furthermore, a phosphorylated 
CD95 peptide that contains a more stable phosho-mimic CD95-tyrosine 291 
(human) or 283 (mouse) by using F2Pmp group instead of phosho-tyrosine (Meyer 
and Köhn, 2011) was also generated a bait. Cleavage site was introduced to the 
peptides with 15-mers bearing an N-terminal biotin on the tetrapeptide linker 
SGSG. Biotinylation was done using sulfo-NHS-SS-biotin (Pierce) that allows 
reductive cleavage of the 15-mer from the biotin group.  
500 µg lysate of HUVEC cells or mouse brain tissue were incubated overnight at 4°C 
under rotation with 50 µM of either of the four biotinylated and DTT-cleavable 
peptide, human and mouse, respectively. 
After incubation of the bait peptides with the lysate, 40 µl Dynabeads M-280 
streptavidin were added and incubated for 1.5 h at 4°C under rotation. Beads were 
washed 5 times with lysis buffer in a magnetic rack and resuspended in 30 µl 4x 
Laemmli buffer. The first supernatant was taken as a flowthrough control. In order to 
cleave the bait peptides with bound proteins from the magnetic beads to reduce 
background binding, 50 mM DTT was added for 20 min at room temperature and 
supernatant was taken for SDS-PAGE and Western blotting as described with anti-
p85 and anti-SFK.  
 
2.2.4.5. Human angiogenesis antibody array 
For the parallel determination of relative levels of angiogenesis-related proteins, 1 ml 
of conditioned medium from control- or CD95-membrane stimulated GBM cells was 
used as input for the human angiogenesis antibody array kit. The experiment was 
performed according to manufacturer’s instructions. Briefly, the samples are mixed 
with a cocktail of biotinylated detection antibodies and subsequently incubated with 
an array membrane spotted in duplicate with capture antibodies for 55 angiogenesis-
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related proteins. Captured proteins are visualized with chemilumniscence by exposure 
to Amerham Hyperfilm films in a Western blot developing machine.  
 
2.2.5 Molecular biology  
2.2.5.1 RNA-seq sample preparation 
For RNA-seq of subcutaneous GBM tumors, SCID beige mice bearing tumors were 
sacrificed and perfused with sterile HBSS. Tumors were taken out and small pieces of 
the tumor (ca. 8 cm3) were sampled. These were chopped into pieces <0.5 mm and 
dropped into RNAlater at 4°C until RNA isolation. mRNA was isolated from 3 
control and 3 CD95L-treated xenograft tumors using the mirVana miRNA Isolation 
Kit, following the instructions for mRNA isolation. For homogenization of the tissue, 
small downers were used.  
RNA was quantified and analysed on a Bioanalyzer High Sensitivity (HS) chip before 
including ERCC Spike-Ins at a 1:1000000 dilution. 
Synthesis of full-length cDNA was performed from 10 ng mRNA using the 
SMARTer Ultra Low Input RNA for Illumina Sequencing – HV kit according to 
manufacturer’s instructions. cDNA were produced with 13 PCR cycles and quantified 
in a Bioanalyzer HS chip. 
This was followed by library preparation with the NEBNext Ultra DNA Library Prep 
Kit for Illumina to generate ca. 300 bp libraries. Libraries were quantified by Qubit, 
ran on a Bioanalyzer HS Chip, pooled and sequenced with 100 bp paired-end setting 
on an Illumina HiSeq 2000. Sequencing runs were performed at the DKFZ 
Genomics and Proteomics core facility and allocation of samples to lanes was 
arranged in a way to target a minimum of 30 million reads per sample.  
 
2.2.6 Computational analyses  
2.2.6.1 Processing and analyses of RNA-seq data (partially performed by Sheng Zhao) 
In total, 6 samples were sequenced on Illumina Hiseq 2000. For each sample, around 
36 million 100 bp, paired-end reads were retrieved.  
Read trimming and mapping: Quality of raw reads was checked by FASTQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Before alignment, 
adapter sequences in raw reads were trimmed by Btrim64 
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(http://graphics.med.yale.edu/trim) (Kong, 2011). Trimmed reads were mapped to 
human genome (ENSEMBL Release 82) using STAR_2.4.2a (Dobin et al., 2012). 
Genome mapping results were visualized by using Integrative Genome Viewer 
(www.broadinstitute.org/igv/). 
RNA-seq data quality metrics: RNA-seq data quality metrics of each cell, including 
total reads, uniquely mapped reads and transcriptome mapped rate was calculated by 
picard-tools-1.136  (https://broadinstitute.github.io/picard/) (Figure 3.18). 
Gene Expression Matrices: Expression level of each gene was quantified in unites by 
transcript per million (TPM) using rsem-1.2.22 (Li and Dewey, 2011) with default 
parameters on bam files from STAR. 
Validation RNAseq data using ERCC spike-in controls: We assessed the quality of 
RNAseq data by comparing the results with known quantities of 92 ERCC spike-in 
RNA transcripts. Briefly, 92 ERCC spike-in RNA transcripts were added to each 
sample when preparing library. Expression levels of 92 ERCC spike-in controls in 
these 6 samples were quantified in units of TPM by RSEM.  TPM of 92 spike-in 
controls across these 6 samples were plotted against known inputs (copies per 
reaction) of each spike-in control. The levels of RNA spikes determined correlated 
strongly with the known input quantities (Figure 3.18). 
Differential expression and gene ontology analysis: Differential expression was analysed 
using the DEseq package from Bioconductor (Appendix 5.2.2) (Love et al., 2014). As 
a cutoff adjusted p<0.05 and log2 fold change > 0.5 was used. Principal component 
analysis of the samples was performed using the sample to sample comparison 
function of DEseq (Appedix 5.2.3).  Gene ontology analysis was performed using the 
DAVID function annotation tool (https://david.ncifcrf.gov/home.jsp) (Huang et al., 
2008). Heatmap was generated using log2(TPM+1) values in R (Appendix 5.2.4). 
 
2.2.7 Statistical analyses  
Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad) or R. 
Differences between two groups were evaluated by unpaired two-tailed student’s T-
test and between more than two groups by on-way ANOVA. All data are presented 
as mean ± standard deviation (SD). Statistical significance was determined by the p-
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value of the statistical test and deemed as significant * p<0.05, strongly significant 
**p<0.01 and highly significant ***p<0.001.  
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3. RESULTS 
3.1 CD95 during developmental angiogenesis in the CNS  
3.1.1. CD95 promotes angiogenesis in vitro  
CD95 has previously been reported to be expressed in endothelial cells (Sata et al., 
2000). We confirmed this by analyzing the protein expression of CD95 in human 
umbilical vein cord cells (HUVECs) by fluorescence activated cell analysis (FACS) as 
well as Western blotting of HUVEC lysates (Figure 3.1 A,B). With both approaches, 
we could detect high levels of CD95. 
As the function of CD95 in endothelial cells is controversial and it has been shown to 
be both pro-apoptotic (Ishida et al., 2003; Kaplan et al., 1999) and pro-angiogenic 
(Biancone et al., 1997; Richardson et al., 1994; Sata et al., 2000), we set out to clarify 
its role.  
 
      
Figure 3.1: HUVECs express CD95 and are resistant to CD95L-induced apoptosis.  
A. FACS analysis of HUVECs. Histogram shows unstained control (gray) and anti-CD95 
PE-Cy7 stained HUVECs (orange). B. Western blot for CD95 and GAPDH of HUVEC 
lysate. C. Percentage of TUNEL+ HUVECs stimulated for four hours on control- or 
CD95L-coated membranes (n=3) n.s.: not significant, two-tailed unpaired Student’s t-test. 
 
We first tested whether endothelial cells would undergo apoptosis upon activation of 
CD95 by CD95L treatment. CD95L stimulation was conducted using membrane-
coupled CD95L where trimerized CD95L via the foldon T4 (T4-CD95L) is bound 
by biotin/neutravidin crosslinkers to a lipid bilayer – so-called solid supported 
membranes. These CD95L membranes closely mimic CD95L concentration on cells 
(8.7 nm inter-ligand distance). Analysis of TUNEL+ HUVECs four hours after 
control-membrane or CD95L-membrane stimulation showed that in both cases only 
a small percentage of cells were TUNEL+ (Ctrl: 0.59% ± 0.12 vs. CD95L: 0.73% ± 
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0.02, p=0.45)  (Figure 3.1 C). Consistent with previous reports of endothelial-
resistance to CD95L-induced apoptosis (Richardson et al., 1994; Sata et al., 2000; 
Suhara et al., 2001), no significant difference was found when comparing control- to 
CD95L- treated cells (Figure 3.1 C), indicating that CD95L does not induce 
apoptosis in endothelial cells.  
 
To further explore the functional relevance of CD95 receptor on endothelial cells, we 
subjected HUVECs to CD95L stimulation and subsequently tested their ability to 
form capillary-like tubes in matrigel. The tube formation assay has been widely used 
in the field of angiogenesis to assess factors influencing endothelial cell adhesion, 
migration and tubule formation (Arnaoutova et al., 2009) and is therefore well-suited 
as an initial screen.  
After exposure to CD95L for four hours, HUVECs formed tubes with branches of 
significantly higher number (Ctrl: 53  ± 32 vs. CD95L: 113 ± 27, p=0.029) and length 
(Ctrl: 14598 µm ± 5571 vs. CD95L: 27488 µm ± 4270, p=0.017) compared to 
control. Consistent with this, the number of nodes and meshes increased significantly 
after CD95L treatment (nodes Ctrl: 116 ± 49 vs. CD95L: 236 ± 49 p=0.013; meshes 
Ctrl: 2 ± 1 vs. CD95L: 6 ± 2, p=0.002) (Figure 3.2 A-E). 
Next, we also assessed the impact of CD95 loss on the angiogenic potential of the 
endothelial cells. For this, we performed siRNA-mediated knockdown of CD95 in 
HUVECs (Figure 3.2 K) and subsequently analysed their ability to form tubes in 
matrigel (Figure 3.2 F). A strong decrease in the number of tube branches (siScr: 42 ± 
19 vs. siCD95: 11 ± 6, p=0.0002, n=2) as well as their length (siScr: 10425 ± 4206 vs. 
siCD95: 2666  ± 1514 µm, p<0.0001, n=2) could be observed after knockdown of 
CD95 with siRNA (siCD95) compared to scrambled control siRNA (siScr) (Figure 
3.2 G-H). Moreover, the number of nodes and meshes that were formed was 
significantly reduced after siCD95 knockdown (nodes siScr: 139 ± 121 vs. siCD95: 13 
± 7, p=0.0065; meshes siScr: 5 ± 4 vs. siCD95 0 ± 0, p=0.0017, Figure 3.2 I-J).  
The ability of CD95 activation to stimulate and its deletion to cause reduced 
endothelial tube formation in vitro thus suggests a pro-angiogenic role of CD95. 
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Figure 3.2: CD95L treatment increases and CD95 knockdown decreases angiogenesis in 
vitro.  
A. Representative images and tracings of endothelial tubes formed in matrigel of HUVECs 
incubated four hours on control- or CD95-coated membranes. B.-E. Quantification of 
endothelial tubes for number of branches (B), total branches length (C), number of nodes (D) 
and number of meshes (E). (n=3) F. Representative images and tracings of endothelial tubes 
formed in matrigel of HUVECs transfected 48 hours with scrambled (siScr) or CD95 siRNA 
(siCD95). G.-J. Quantification of endothelial tubes for number of branches (G), total branch 
length (H), number of nodes (I) and number of meshes (J). K. Western blot for CD95 and 
GAPDH of HUVEC lysates transfected 48 hours with siScr or siCD95. (n=2) Scale bar=100 
µm. Data are shown as mean±SD, *p<0.05, **p<0.01, **p<0.001 two-tailed unpaired Student’s 
t-test. 
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3.1.2 CD95 is expressed in diverse cell types in the developing brain 
To gain further knowledge on the role of CD95 in vivo in the developing brain, 
where CD95 has shown to be involved in neuronal branching before ((Zuliani et al., 
2006) and unpublished data), we first assessed its expression in different cell 
populations at embryonic day 14.5 (E14.5) and postnatal day 1 (P1) by FACS.  
 
 
Figure 3.3: CD95 is expressed in different cell types of the developing brain.  
A. FACS analysis of embryonic day 14.5 (E14.5) and postnatal day 1 (P1) brain cells labeled 
with the neuronal marker PSD95, the neural progenitor marker CD133, the endothelial 
marker CD31 and CD95. Representative FACS histograms for CD95 expression within the 
different cell populations at E14.5 (upper panel) and P1 (lower panel) (unstained control in 
grey). B-C. Median fluorescence intensity (MFI) (B) and percentage of CD95+ cells (C) for 
each cell population at E14.5 and P1 (E14.5: n=4, P1: n=4). D. FACS analysis of P1 or P6 
brain cells labeled with the astrocyte marker Glast, the oligodendroctye marker O4 and 
CD95. Representative FACS histograms for CD95. E. Percentage of CD95+ cells for each 
cells population of D (P1: n=3, P6: n=4). Data are shown as mean±SD, *p<0.05, ****p<0.0001, 
unpaired two-tailed student’s t-test. 
 
Cells from whole brains were gated by the postsynaptic density protein PSD95 for 
neurons (Porter et al., 2005), CD133 for neural progenitors (Pfenninger et al., 2007) 
and CD31 for endothelial cells and CD95 expression was measured for all three 
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populations. All cell types expressed CD95, with microglia exhibiting the highest 
level and percentage of CD95+ cells (median fluorescence intensity (MFI) E14.5: 
11585.8 ± 1758.2 & P1: 14843.5 ± 3433.9, p=0.14; % CD95+ E14.5: 76.9 % ± 4.0 & 
P1: 72.7% ± 2.3, p=0.12) (Figure 3.3 A-C). Neural progenitors also express CD95 
(MFI: E14.5: 2304.8 ± 43.3 & P1: 2280.5 ± 39.9, p=0.44; % CD95+ E14.5: 52.9% ± 
1.1 & P1: 52.2% ± 1.1, p=0.41), as described previously by Corsini et al. (Corsini et 
al., 2009) (Figure 3.3 A-C). Consistent with previous data (Zuliani et al., 2006), 
CD95 was also expressed in neurons (MFI E14.5: 1011.3 ± 185.9 & P1: 1175.3 ± 
45.9, p=0.14; % CD95+ cells E14.5: 26.3% ± 8.8 & P1: 30.8% ± 1.8, p=0.35), 
although at lower levels and percentage as neural progenitors and endothelial cells 
(Figure 3.3 A-C). Interestingly, CD95 expression increased in endothelial cells from 
developmental age E14.5 to P1 (MFI E14.5 1058 ± 285.7 & P1 2107.8 ± 362.2, 
p=0.004; % CD95+ cells E14.5: 33.8% ± 6.2 & P1 53.4% ± 6.5, p=0.005) (Figure 3.3 
A-C), possibly implicating functional properties of CD95 in endothelial cells during 
development. As the glial populations in the brain are generated at about birth, their 
CD95 expression was assessed at P1 and P6. Astrocytes and oligodendrocytes were 
identified with the markers Glast and O4, respectively. Both glial populations express 
CD95 at a low, negligible level (% CD95+ cells in Glast+ population at P1: 3.6% ± 1.8, 
at P6: 1.7% ± 0.3, p=0.08; % CD95+ cells in O4+ population at P1: 2.0% ± 0.7, at P6: 
8.8% ± 1.1, p=0.0005) (Figure 3.3 D-E).  
 
 
3.1.3 CD95 regulates vessel growth and branching in the developing cortex and 
retina 
In vivo functional analyses of CD95 during angiogenesis have mainly been performed 
with lpr and gld mice so far, which bear germline mutations in CD95 and CD95L, 
respectively, and therefore lead to ubiquitous expression of non-functional CD95 and 
CD95L (Ishida et al., 2003). As we have observed CD95 expression in multiple cell 
types of the brain, a global deletion may interfere with its function on all these cells 
and lead to secondary effects, thus masking its real effect in endothelial cells.  
To more accurately address the function of CD95 during vessel development in the 
CNS, we generated conditional knockout animals for CD95 by crossing the 
endothelial cell-specific tamoxifen-inducible Cdh5-(PAC)-CreERT2 mice (Sorensen 
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et al., 2009) with CD95fl/fl mice (Hao et al., 2004). Cre activity in the resulting 
CD95fl/fl;Cdh5-CreERT2 mice was induced in newborn pups by tamoxifen injections 
from P1-P3 and on P5 (Figure 3.4 A), according to Pitulescu & collegues that uses 
the same cre-driver for recombination in early postnatal mice  (Pitulescu et al., 2010).  
 
 
Figure 3.4: Endothelial cell-specific deletion of CD95.  
A. Experimental scheme. CD95fl/fl;Cdh5(PAC)-CreERT2 mice were used to specifically 
delete CD95 in endothelial cells. Pups were subjected to tamoxifen (TAM) from P1-P3 and 
at P5, sacrificed at P6 and vessel morphology in the cortex and retina was analysed. B. FACS 
analysis of brains of CD95fl/fl and CD95fl/fl;Cdh5-CreERT2 mice for CD95 expression (Ctrl: 
n=7 vs. KO: n=4). FACS histogram of CD95 for cells gated on CD31+ cells. C-D. 
Normalized MFI (C) and percentage of CD95+ (D) endothelial cells in brains of CD95fl/fl and 
CD95fl/fl;Cdh5-CreERT2 mice. E. Relative mRNA levels of CD95 in endothelial cells isolated 
from P6 brains of  CD95fl/fl and CD95fl/fl;Cdh5-CreERT2 mice analysed by qPCR (Ctrl: n=4 
vs. KO: n=2). Data are shown as mean±SD, *p<0.05, unpaired two-tailed student’s t-test. 
 
The knockout efficiency was subsequently tested in P6 brains by FACS analysis of 
CD95 expression on CD31+ endothelial cells. Although knockout was not complete, 
nMFI and percentage of CD95+ cells were significantly reduced in tamoxifen-induced 
CD95fl/fl;Cdh5-CreERT2 pups as compared to CD95fl/fl controls (nMFI Ctrl: 91.5 ± 
17.8 vs. KO: 65.0 ± 12.5, p=0.02; % CD95+ Ctrl: 54.4 ± 9.1 vs KO: 40.5 ± 7.6, 
p=0.03) (Figure 3.4 B-D). Furthermore, expression level of CD95 mRNA in P6 brain 
endothelial cells was assessed by qPCR that consistently showed a strong decrease in 
CD95fl/fl;Cdh5-CreERT2 pups as compared to CD95fl/fl controls (Figure 3.4 E). 
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CD95fl/fl;Cdh5-CreERT2 mice were used to assess angiogenesis in the developing 
cortex and retina at P6, an age where continuous branching and proliferation is taking 
place (Harb et al., 2012).  
For this purpose, blood vessels in the brain were stained with Isolectin B4 (IsoB4) and 
vessel morphology in the somatosensory and motor cortex was quantified. 
 
 
Figure 3.5: Endothelial-specific CD95 deletion results in vessel defects in the cortex.  
A. Representative images of CD95fl/fl and CD95fl/fl;Cdh5-CreERT2 cortices stained with 
IsoB4. B. Co-staining of IsoB4 (red) and pH3 (green). C-F Quantification of the % area 
covered by endothelial cells (C), number of branches (D), number of branching points (E) 
and number of IsoB4+/pH3+ cells (F) for CD95fl/fl and CD95fl/fl;Cdh5-CreERT2  mice (Ctrl: 
n=12 vs. KO: n=5). G. Representative images of CD95fl/fl and CD95fl/fl;Cdh5-CreERT2 
cortices stained with IsoB4 (red) and TUNEL (green). H. Quantification of TUNEL+ and 
IsoB4+ cells for CD95fl/fl and CD95fl/fl;Cdh5-CreERT2  mice (Ctrl: n= vs. KO: n=3). Scale bars 
= 100 µm. Data are shown as mean±SD. *p<0.05, unpaired two-tailed student’s t-test.  
 
Deletion of CD95 in endothelial cells in the cortex led to a significant decrease in the 
area that is covered by vessels (Ctrl: 27.0% ± 1.4 vs. KO: 24.9% ± 2.5, p=0.048), the 
number of vessel branches (Ctrl: 8768 ± 920 vs. KO: 7633 ± 1172 /mm2 vessel area, 
73 
p=0.049) as well as the number of branching points (Ctrl: 3453 ± 279 vs. KO: 3049 ± 
319/mm2 vessel area, p=0.02) (Figure 3.5 A, C-E). Furthermore, endothelial-specific 
deletion of CD95 significantly diminished the number of proliferating endothelial 
cells stained with the mitosis marker phospho-histone H3 (pH3) (Ctrl: 24 ± 4 vs. 
KO: 21 ± 2, p=0.04 Figure 3.5 B, F). Notably, the number of apoptotic endothelial 
cells marked by TUNEL staining, of which not many were found at this age, did not 
differ between CD95 deleted and control mice (Ctrl: 4 ± 2 vs. KO: 4 ± 3, p=0.99, 
Figure 3.5 G-H). 
In the retina, similar results could be obtained. Quantification of whole mount retinas 
stained with IsoB4 showed significant reduction in the area covered by blood vessels 
(Ctrl: 27.8% ± 3.4 vs. KO: 23.9% ± 3.2, p=0.0002) and in the vessel radial outgrowth 
from the optic nerve to the periphery (Ctrl: 71% ± 0.1 vs. KO: 66% ± 0.1, p=0.02) in 
CD95fl/fl;Cdh5-CreERT2 mice compared to CD95fl/fl controls (Figure 3.6 A, D-E), 
indicating impaired angiogenic front progression in the primary plexus during retinal 
vascularization. These defects were accompanied by a marked decrease in the number 
of branches (Ctrl: 2820 ± 183 vs. KO: 2627 ± 177 branches/mm2 vessel area, 
p=0.0019) and branching points (Ctrl: 1684 ± 122 vs. KO: 1567 ± 112 branching 
points/mm2 vessel area, p=0.0040, Figure 3.6 B, F-G).   
To further explore the cause of the observed reduction of vessel outgrowth and 
branching, we analysed endothelial cell proliferation and vessel regression, two crucial 
aspects during the angiogenic process. Double immunostaining with pH3 and IsoB4 
showed a significantly decreased number of proliferating endothelial cells in 
CD95fl/fl;Cdh5-CreERT2 mice compared CD95fl/fl control mice (Ctrl: 75 ± 22 vs. KO: 
57 ± 17 pH3+/IsoB4+ cells/vessel area, p=0.02, Figure 3.6 B, H). Vessel regression was 
analyzed by counting collagen IV empty sleeves of basement membrane without 
endothelial cells. Quantification of the double immunostaining of IsoB4 and Collagen 
IV (ColIV) showed no difference in the number of empty sleeves between CD95fl/fl 
control and CD95fl/fl;Cdh5-CreERT2 retinas (Ctrl: 1.0 ± 0.3 vs. KO: 1.0 ± 0.4, 
ColIV+/IsoB4- normalized to CD95-control, p=0.95, Figure 3.6 C, I), suggesting that 
the effect which CD95 has on vessel development was not due to enhanced pruning 
and retraction of previously formed vessels.  
(Retina data are produced in collaboration with Rosario Yerbes Cadenas.) 
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Figure 3.6: Endothelial-specific CD95 deletion results in vessel defects in the retina.  
A. Representative images of CD95fl/fl and CD95fl/fl;Cdh5-CreERT2 retinas stained with 
IsoB4. Scale bars = 500 µm. B. Representative images of CD95fl/fl and CD95fl/fl;Cdh5-
CreERT2 retinas stained with IsoB4 (red) and pH3 (green). Scale bars = 100 µm. C. 
Representative images of “collagen empty sleeves” as indicated by IsoB4 (red) negative and 
ColIV (green) positive stainings in CD95fl/fl and CD95fl/fl Cdh5-CreERT2 mice. White 
arrowheads point to ColIV+/IsoB4- empty sleeves. Scale bars = 100 µm. D. Quantification of 
the area covered by endothelial cells (Ctrl: n=19 vs. KO: n=32 retinas). Data are expressed as 
percentage of total retina area. E. Quantification of the vessel radial outgrowth to the 
periphery (Ctrl: n=16 vs. KO: n=28 retinas). Data are expressed as percentage of total lobe 
length. F.-G. Quantification of the nuber of branches (F) and branching points (G) (Ctrl: 
n=17 vs. KO: n=27 retinas). Data are expressed as number of branches/vessel area and number 
of branching points/vessel area, respectively. H. Quantification of proliferating (pH3+) 
endothelial cells (Ctrl: n=12 vs. KO: n=17). Data are expressed as pH3+/IsoB4+ endothelial 
cells (EC)/vessel area. I. Quantification of vessel regression in retinas of CD95fl/fl and 
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CD95fl/fl Cdh5-CreERT2 mice. (Ctrl: n= 7 vs. KO: n=15). Data expressed as number of 
ColIV+/IsoB4- empty sleeves/vessel area.  
Data are shown as mean± SD. *p<0.05, **p<0.01, ***p<0.001, n.s. not significant, unpaired 
two-tailed student’s t-test. Data are produced in collaboration with Rosario Yerbes Cadenas.  
 
Altogether, these data demonstrate that CD95 regulates developmental angiogenesis 
in the cortex and retina by promoting endothelial cell proliferation and branching, 
without affecting vessel regression. 
 
3.1.4 CD95L is primarily expressed by microglia in the developing brain  
The effect of CD95 on vessel morphology and proliferation should be a consequence 
of CD95 activation by its only known ligand - CD95L. Previous reports have shown 
that CD95L mRNA is expressed largely by glial cells in white matter and to a lesser 
extent in neurons of the adult brain (Shin et al., 2002). Where the source of CD95L 
lies in the developing brain, however, is unknown. To address this question, we again 
made use of FACS analysis of live cells to assess CD95L expression in different cell 
populations of the brain at E14.5 and P1. While PSD95+ neurons and CD133+ neural 
progenitors hardly express any CD95L (neurons MFI E14.5: 305.3 ± 46.3 & P1: 
351.5 ± 11.4, p=0.1; %CD95L+ E14.5: 0.5% ± 0.2 & P1: 1.0% ± 0.3, p=0.04; neural 
progenitors (MFI E14.5: 196.0 ± 20.6 & P1: 284.8 ± 13.7, p=0.0003; % CD95L+ 
E14.5: 1.1% ± 0.4 & P1: 4.7% ± 1.6, p=0.004) and CD31+ endothelial cells express 
low levels of CD95L (MFI E14.5: 369.3 ± 80.2 & P1: 533.0 ± 62.4, p=0.02; % 
CD95L+ E14.5: 3.0% ± 1.8 & P1: 7.0% ± 1.6, p=0.02), CD45loCD11b+ microglia 
(Goldmann et al., 2013) exhibited the highest expression of CD95L and percentage 
of CD95L+ cells (MFI E14.5: 16690.3 ± 2209.2 & P1: 16170.5 ± 3905.6, p=0.82; % 
CD95L+ E14.5: 99.7% ± 0.1 & P1: 96.2% ± 7.3, p=0.38) (Figure 3.7 A, C-D). 
Notably, neural progenitors and endothelial cells upregulate CD95L expression 
during developmental progression from E14.5 to P1, although general expression 
levels are low (Figure 3.7 C-D). As astrocytes (Glast+) and oligodendrocytes (O4+) are 
just starting to be generated around birth, we assessed their expression of CD95L at 
P1 and P6. Both populations expressed barely detectable levels of CD95L (% 
CD95L+ cells in Glast+ population at P1: 0.08% ± 0.05 vs. P6: 0.22% ± 0.10, p=0.08; 
% CD95L+ cells in O4+ population at P1: 0.05% ± 0.01 vs. P6: 0.85% ± 0.13, 
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p=0.0004, Figure 3.7 B, E), thus they can be excluded from being a source of CD95L 
in early postnatal development. 
  
 
Figure 3.7: CD95L is primarly expressed by microglia in the developing brain.  
A. FACS analysis of CD95L expression in E14.5 and P1 brains gated for neurons (PSD95+), 
neural progenitors (CD133+), endothelial cells (CD31+) and microglia (CD45loCD11b+). 
Representative FACS plots for CD95L of the different cell populations at P1 (unstained 
control in grey). B. FACS analysis of CD95L expression in P1 and P6 brains gated on 
astrocytes (Glast+) and oligodendrocytes (O4+). Representative FACS plots are shown 
(unstained control in grey). C-D. Normalized median fluorescence intensity (B) and 
percentage (C) of CD95L+ cells for each cell population (E14.5: n=4 , P1: n= 4). E. 
Percentage of CD95L+ cells for astrocytes and oligodendrocytes (P1: n=3, P6: n=4). Data are 
shown as mean±SD, *p<0.05, **p<0.01, ***p<0.001, unpaired two-tailed student’s t-test. 
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The high level of CD95L in microglia prompted us to hypothesize that microglia-
derived CD95L might act in a paracrine manner to promote endothelial cell growth 
and proliferation. Thus, we further focused on the effect of microglial-derived 
CD95L in cortex and retina angiogenesis.  
 
3.1.5 Microglia-derived CD95L regulates vessel morphology in the cortex  
In order to test the effect of microglial-derived CD95L we generated microglia-
specific knockout mice for CD95L. This was achieved by crossing LysM-Cre mice 
(Clausen et al., 1999) with CD95Lfl/fl mice (Karray et al., 2004) to obtain 
CD95Lfl/fl;LysM-Cre mice (Figure 3.9 A). The LysM-Cre driver specifically 
recombines in monocytes, including microglia, but also in peripheral circulating 
monocytes (Clausen et al., 1999; Goldmann et al., 2013). To find out the 
recombination rate of the LysM-Cre driver in microglia, we made use of the LysM-
Cre YFP mice that express YFP upon recombination and counted YFP+ Iba+ 
microglia. The number of double positive cells amounted to 31.5%, indicating that 
almost a third of microglia would recombine in the LysM-Cre line (Figure 3.8 A, B).  
 
  
Figure  3.8: Microglial-recombination with the LysM-Cre line.  
A. LysM-Cre YFP mice were killed at P6 and brains were stained with Iba1 and YFP to 
assess recombination efficiency in microglia. (B) Quantification of % of YFP+/Iba1+ double 
positive cells in the cortex (n=4).   
 
 
Next, we confirmed deletion of CD95L in microglia by FACS analysis which showed 
significantly reduced levels of CD95L in CD45loCD11b+ microglia of 
CD95Lfl/fl;LysM-Cre P1 pup brains compared to CD95Lfl/fl controls (normalized 
MFI Ctrl: 113.1 ± 13.4 vs. KO: 85.9 ± 20.8, p=0.02, Figure 3.9 B-C). 
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Figure 3.9: Deletion of CD95L in microglia.  
A. LysM-Cre mice are crossed with CD95Lfl/fl mice to delete CD95L in microglia. B-C. 
FACS analysis of brains of CD95Lfl/fl and CD95Lfl/fl;LysM-Cre mice was performed for 
CD95L (Ctrl: n=7 vs. KO: n=6). FACS plot of CD95L gated on CD45lo CD11b+ cells (B) 
and graph showing CD95L expression by normalized MFI (C). D. Representative images of 
CD95Lfl/fl and CD95fl/fl;LysM-Cre cortices stained with IsoB4 and Iba1. Arrows show Iba1+ 
microglia are located closely to vessels. Scale bars = 100 µm, inlet = 50 µm. E-F. 
Quantification of microglia by FACS analysis for CD11b+ cells (Ctrl: n=9 vs. KO: n=8) (E) 
or immunohistochemical staining for Iba1 (Ctrl: n=5 vs. KO: n=4) (F) in brains of CD95Lfl/fl 
and CD95Lfl/fl;LysM-Cre mice. Data are shown as mean±SD, *p<0.05, n.s.=not significant, 
unpaired two-tailed student’s t-test. 
 
As CD95L may play a role in the recruitment of microglia to the brain during 
development, which would affect the outcome of CD95L deletion on vessel 
morphology, we wanted to rule out this possibility. Therefore, we further compared 
the number of microglia in the brain of CD95Lfl/fl;LysM-Cre knockout mice to 
CD95Lfl/fl control mice by FACS (Ctrl: 5.6% ± 0.5 vs. KO: 5.9% ± 0.7, p=0.54) and 
by Iba1+ immunostaining at P1 (Ctrl: 70 ± 14 vs. KO: 72 ± 12, p=0.71) (Figure 3.9 
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D-F). This showed comparable microglia numbers between control and knockout 
mice. Notably, Iba1+ microglia are closely located to IsoB4 stained vessels (Figure 3.9 
D), similar to previous reports of spatial association of tissue macrophages and 
sprouting vessels in early embryonic hindbrain and retina (Checchin et al., 2006; 
Fantin et al., 2013).   
 
 
Fig. 3.10: Microglial-deletion of CD95L impairs cortical vessel development.  
A. Representative images of CD95Lfl/fl and CD95fl/fl;LysM-Cre cortices stained with IsoB4 
and pH3 at P1 and P6. Scale bar = 100 µm. B-E. Quantification of vessel area (Ctrl: n=13 vs. 
KO n=12) at P1, and P6 (Ctrl: n=14 vs. KO: n=7) (B), vessel proliferation P1 (Ctrl: n=10 vs. 
KO: n=9) and P6 (Ctrl: n=12 vs. KO: n=6) (C), number of branches (D) and number of 
branching points (E) (Ctrl: n=13 vs. KO n=12) at P1, and P6 (Ctrl: n=14 vs. KO: n=7). Data 
are shown as mean±SD, *p<0.05, unpaired two-tailed student’s t-test. 
 
To answer the question of whether paracrine signaling through microglial-CD95L 
would regulate vessel morphology, we quantified cortical vessels at P1 as well as P6 by 
staining for IsoB4. This revealed a significant reduction of area covered by vessels in 
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CD95Lfl/fl;LysM-Cre pups compared to CD95Lfl/fl controls (P1 Ctrl: 25.0% ± 4.1 vs. 
KO: 21.8% ± 3.3, p=0.04; P6 Ctrl: 26.1% ± 1.9 vs. KO: 23.3% ± 2.7, p=0.01, Figure 
3.10 A-B). Co-staining of IsoB4 and pH3 further showed a decrease in vessel 
proliferation in CD95Lfl/fl;LysM-Cre pups compared to CD95Lfl/fl controls (P1 Ctrl: 
22 ± 7 vs. KO: 16 ± 6 pH3+IsoB4+/mm2 vessel area, p=0.04; P6 Ctrl: 17 ± 5 vs. KO: 
12 ± 4 pH3+IsoB4+/mm2 vessel area, p=0.04, Figure 3.10 A, C). The number of vessel 
branches and branching points was also assessed at P1 and P6. However, although 
there was a slight trend towards decreased branches and branching points in 
CD95Lfl/fl;LysM-Cre pups, statistical significance was only reached for branching 
points at P1 (branches: P1 Ctrl: 5432 ± 884/mm2 vessel area vs. KO: 5194 ± 582/mm2 
vessel area, p=0.43; P6 Ctrl: 6547 ± 787/mm2 vessel area vs. KO: 6057 ± 598/mm2 
vessel area, p=0.16; branching points: P1 Ctrl: 2503 ± 286/mm2 vessel area vs. KO: 
2245 ± 147/mm2 vessel area, p=0.01; P6 Ctrl: 2775 ± 215/mm2 vessel area vs. KO: 
2600 ± 276/mm2 vessel area, p=0.14; Figure 3.10 D-E). 
 
We further took a look at IsoB4 stained retina whole-mounts and analysed vessel 
area, outgrowth, branching and proliferation. For all parameters no significant 
difference was observed between CD95Lfl/fl;LysM-Cre pups and CD95Lfl/fl controls 
(Figure 3.11 A-D). (These data were produced in collaboration with Nathalie Tisch.) 
 
 
Figure 3.11: Microglia-specific deletion of CD95L does not affect retina angiogenesis.  
A-D. Quantification of vessel area (A), vessel outgrowth (B) (Ctrl: n=5 vs. KO: n=9)., vessel 
proliferation (Ctrl: n=4 vs. KO: n=3).  (C) and vessel regression (D) (Ctrl: n=5 vs. KO: n=9). 
of CD95Lfl/fl and CD95fl/fl;LysM-Cre wholemount retina stained with IsoB4 or IsoB4 and 
pH3. n.s=not significant, unpaired two-tailed student’s t-test. Data produced in collaboration 
with Nathalie Tisch. 
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These results suggest that indeed microglia-derived CD95L is able to regulate overall 
vessel density as well as proliferation in the cortex, but does not give a definitive 
answer on its effect on vessel branching. Due to the incomplete recombination of the 
LysM-Cre line, CD95L expression may still be present in brain and retina, resulting 
in the absence of an observable effect.  
 
3.1.6 Microglial-derived CD95L regulates neuronal branching in the cortex  
Previous work in the lab has revealed that CD95 receptor activation on cortical and 
hippocampal neurons can promote neuronal branching during development, whereas 
CD95 deletion leads to the opposite effect (unpublished data). Consistent with this, it 
has been shown by Desbarats et al. that CD95 is involved in neurite outgrowth of 
dorsal root ganglion neurons (Desbarats et al., 2003).  
Therefore, we wondered whether CD95 receptor in neurons may also be activated by 
microglia-derived CD95L, which presents the major source of CD95L in the 
developing brain as shown in (Figure 3.7 A, C-D). This would be in line with the 
theory of the neurovascular link where neurons and vessels are co-regulated by the 
same set of molecules and develop congruently with similar molecular and anatomical 
properties (Eichmann and Thomas, 2013; Segura et al., 2009). 
To investigate the role of microglia-derived CD95L in cortical neuronal branching, 
we analysed neuron morphology of layer II/III neurons in CD95Lfl/fl;LysM-Cre pups 
at the age of P3, where CD95 expression was shown to be most intense (consistent 
with previous experiments on CD95’s role in neuronal branching by Cecilia Zuliani 
and Hannes Hudalla). Single neurons were visualized using Golgi staining and 
branching morphology was quantified. This revealed an impairment in the neuronal 
branching of CD95Lfl/fl;LysM-Cre pups that was evident through a significant 
reduction in total branching length (Ctrl: 242.9 µm ± 76.8 vs. KO: 142.4 µm ± 43.0. 
p<0.0001), longest dendrite length (Ctrl: 97.4 µm ± 23.3 vs. KO: 67.0 µm ± 16.7, 
p<0.0001) and number of branching points (Ctrl: 8 ± 4 vs. KO: 5 ± 2, p<0.0001) 
compared to CD95Lfl/fl controls (Figure 3.12 A-D). The number of primary dendrites 
was unchanged (Ctrl: 2 ± 1 vs. KO: 2 ± 1, p=0.09) (Figure 3.12 E), similar to previous 
data of CD95 receptor knockout (unpublished data by Cecilia Zuliani). 
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Figure 3.12: Microglial-deletion of CD95L impairs cortical neuron branching.  
A. Representative images depicting Golgi-stained neurons in CD95Lfl/fl and CD95fl/fl;LysM-
Cre cortices at P3. Scale bar = 50 µm. B-E. Quantification of longest dendrite length (B), 
total branches length (C), number of branching points (D) and number of primary dendrites 
(E) in CD95Lfl/fl (n=69) and CD95fl/fl;LysM-Cre neurons (n=100) from at least 7 different 
pups. Data are shown as mean±SD. ****p<0.0001, n.s=not significant, unpaired two-tailed 
student’s t-test.  
 
These data together with data from section 3.15 demonstrate that microglia can co-
regulate neuron and vessel morphogenesis and that this is mediated by CD95/CD95L 
interaction.  
 
3.1.7 CD95 interacts with Src-family kinases and p85 in endothelial cells  
It has been previously shown that non-apoptotic functions of CD95 can be mediated 
by recruitment of SH2-containing proteins to the tyrosine residue Y283 lying within 
the YXXL motif of the mouse CD95 death domain (Sancho-Martinez and Martin-
Villalba, 2009). Members of the Src-family kinase (SFK) can phosphorylate this 
residue allowing recruitment of different SH2-containing proteins that in turn lead to 
activation of diverse effectors such as PI3K, NFκB, Erk etc. (Martin-Villalba et al., 
2013). CD95 therefore behaves similarly to a receptor tyrosine kinase.  
During VEGF-mediated angiogenesis, PI3K and Erk activation are crucial to 
mediate endothelial cell proliferation, migration and growth (Gerber et al., 1998; 
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Somanath et al., 2006; Srinivasan et al., 2009), thus we hypothesized that CD95 may 
act in a similar manner as VEGF and use its tyrosine kinase receptor properties to 
activate PI3K and Erk.  
We therefore examined a possible interaction of the SH2 kinases of the src family  
(SFK) as well as PI3K with CD95. First, antibody-mediated pulldown of CD95 from 
HUVEC lysates revealed binding of the regulatory subunit of PI3K, p85, to CD95 
(Figure 3.12 A), although immunopreciptiation with an isotype control antibody also 
led to unspecific binding. In order to confirm this interaction of CD95 with p85 in 
endothelial cells, we further performed peptide pulldown assays with HUVEC lysates. 
For this purpose, we designed biotinylated, 15 amino acids long peptides that 
correspond to the YXXL motif of the human CD95 death domain. These contain 
either a scrambled sequence (Scr), an alanine mutant amino acid that substitutes Y291 
of the human CD95 (A), a wildtype Y291 (Y), or a phosphorylated form of Y291 
(pY) (Figure 3.12 B). While in the pulldown fraction of the pY peptide we could 
strongly detect p85, pulldown with the alanine mutant as well as the non-
phosphorylated Y peptide resulted in much less enrichment of p85 and in the negative 
control binding was barely detectable (Figure 3.12 C). Furthermore, we also checked 
for binding of SFK to the peptides which showed a similar enrichment, with the 
highest binding found with the pY peptide. These data show that SFK and p85 can 
bind to the phosphorylated tyrosine of the death domain, and to a much lesser extent 
to the unphosphorylated one, which indicates that recruitment of SFK/p85 to CD95 
is direct and requires prior phosphorylation presumably through binding of CD95L 
and CD95 receptor clustering. Consistent with this, there is a strong decrease of SKF 
and p85 signal in the flowthrough fraction of the pY pulldown (Figure 3.12 C). 
Together, these data indicate that the CD95 death domain is able to recruit SFK and 
p85 in endothelial cells. 
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Figure 3.13: CD95 death domain associates with SFK and p85 in endothelial cells.  
A. Immunopreciptation (IP) of HUVEC lysates with isotype control antibody or anti-CD95 
antibody (Apo-1), and whole lysates. Shown are Western blots of IP fractions for p85 and 
CD95. B. Scheme of peptides used for peptide pulldown assay. C. Lysates of HUVEC cells 
were subjected to peptide pulldown with a CD95 death domain scrambled (Scr), alanin-
mutant (A), wildtype tyrosine (Y) or phosphorylated tyrosin (pY) peptide. Peptide-bound 
fraction, whole lysate as well as flowthrough fraction (FT) were blottet for SFK and p85.  
 
 
3.1.8 CD95L induces vessel growth through Akt and Erk activation  
To further elucidate the signaling downstream of PI3K activation, we examined the 
downstream effectors of PI3K upon CD95 stimulation in HUVECs as well as a brain 
microvascular endothelial cell line bEnd.3. The canonical downstream target of PI3K 
is Akt which becomes phosphorylated either at Ser-473 or Thr-308, whereby Ser-473 
phosphorylation leads to full activation of Akt (Hers et al., 2011). Upon treatment 
with trimerized T4-CD95L, Ser-473 phosphorylation of Akt, but not Thr-308 (not 
shown), was induced in HUVECs and bEnd.3 as shown by Western blot with the 
strongest activation 5 min after CD95L treatment (Figure 3.14 A-B). 
Furthermore, Erk signaling can be activated downstream of SFK which also has also 
been shown for CD95 in other systems (Barnhart et al., 2004; McKay and Morrison, 
2007; Wojtowicz et al., 2004). Thus, we also analysed phosphorylation of Erk1/2 
(p44/42 MAPK). Erk1/2 also became phosphorylated after CD95L treatment, and 
exhibited the strongest phosphorylation at 20 min after treatment (Figure 3.14 A-B). 
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Figure 3.14: CD95L activates Akt and Erk in endothelial cells.  
A. HUVECs were treated with 40 ng/ml CD95L for different time points and lysates were 
subjected to Western blot for Ser473 phosphorylated Akt (P-Akt (Ser473)), total Akt (T-
Akt), phosphorylated Erk (P-Erk) and total Erk (T-Erk). B-C. Quantification of  p-Akt (B) 
and p-Erk (C). C. bEnd.3 were treated with 40 ng/ml CD95L for different time points and 
lysates were subjected to Western blot for Ser473 phosphorylated Akt (P-Akt (Ser473)), total 
Akt (T-Akt), phosphorylated Erk (P-Erk) and total Erk (T-Erk). D-E. Quantification of  p-
Akt (D) and p-Erk (E). 
 
 
Thus, Akt and Erk are two possible downstream effectors of PI3K activation that are 
responsible for the growth and proliferation of endothelial cells seen in the previous 
experiments.  
To confirm that CD95 activates Akt and Erk to induce vessel growth on a functional 
level, we inhibited Akt signaling with a PI3K inhibitor LY294002 and Erk signaling 
with the Erk1/2 inhibitor PD98059 and assessed proliferation of HUVEC and 
bEnd.3 cells upon CD95L stimulation. Both LY294002 and PD98059 are effective at 
inhibiting Akt or Erk1/2 phosphorylation, respectively, already at low micromolar 
concentrations (Figure 3.15 A). 20 µM was chosen as it showed high effectiveness 
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with lower toxicity. CD95L stimulation resulted in increased Ki67 positivity in both 
HUVECs as well as bEnd.3 cells, which was significantly decreased upon additional 
inhibition of PI3K or Erk1/2 (Figure 3.15 B-E), indicating that endothelial cell 
proliferation upon CD95L treatment is dependent on PI3K/Akt and Erk1/2 
signaling. Of note, Erk1/2 inhibition in HUVECs already leads to decreased 
proliferation by itself, possibly due to its toxicity in this primary cell line. (Figure 3.15 
E). 
 
 
Figure 3.15: Inhibition of Akt and Erk abrogates CD95L-induced endothelial cell 
proliferation.  
A. Western blot for p-Akt (Ser473), T-Akt, pErk1/2 and T-Erk of bEnd.3 cells treated with 
the PI3K inhibitor LY294002 and the Erk1/2 inhibitor PD98059 at different concentrations. 
B-C. Immunofluorescence staining for DAPI and Ki67 in bEND.3 (B) or HUVEC (C) cells 
treated with for 1h DMSO, 20 µM LY294002, 20 µM PD98059 in combination with PBS 
or 40 ng/ml CD95L. D. Quantification of Ki67+ positive cells for B-C. Data are shown as 
mean±SD. *p<0.05, **p<0.01, ***p<0.001, statistical significance tested by ANOVA.  
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3.2 Investigation of CD95 function in glioblastoma angiogenesis 
During development, angiogenesis occurs in a highly regulated manner to vascularize 
and support metabolic requirements of the tissue. These processes are exploited 
during tumor development, where angiogenesis is reactivated to support tumor cell 
growth and their nutrient demand (Weis and Cheresh, 2011). In fact, tumors are not 
able to grow above a certain size, if the “angiogenic switch” is not activated (Folkman, 
1971). 
One of the hallmarks of the most aggressive types of tumor in the brain, glioblastoma, 
is microvascular proliferation and angiogenesis (Dunn et al., 2012). Thus, we 
investigated the role of CD95 also during the process of glioblastoma angiogenesis.  
 
3.2.1 Endothelial-specific deletion of CD95 does not significantly affect glioblastoma 
angiogenesis 
In order to assess whether CD95 would also have an effect in glioblastoma 
angiogenesis, we again made use of the CD95fl/fl;Cdh5-CreERT2 mice and combined 
endothelial-specific CD95 deletion with an orthotopic tumor model. Deletion of 
CD95 was induced at adult age by tamoxifen injection for 5 days. After a break of 7 
days during which tamoxifen could be cleared, SMA560 cells – a mouse syngeneic 
model of glioblastoma – were injected intracranially into the brain of CD95fl/fl;Cdh5-
CreERT2 or CD95fl/fl control mice. Tumor as well as vessel growth were analysed two 
weeks after tumor cell implantation, when mice started to exhibit neurological 
symptoms due to tumor expansion (Figure 3.16 A). Tumor growth in CD95fl/fl;Cdh5-
CreERT2 mice did not significantly differ from CD95fl/fl, although a trend toward a 
decrease could be observed (Ctrl: 41.1 ± 24.2 mm3 vs. KO: 25.3 ± 9.0 mm3, p=0.08, 
Figure 3.16 C). The same was observed for vessel density, as assesed by percentage 
area calculations of CD31-positive staining within the tumor. Despite a tendency 
toward decreased vessel area, no significant change was observed in tumor vessels after 
deletion of CD95 in endothelial cells (Ctrl: 10.1 ± 2.9 %; KO: 7.8 ± 2.3 %, p=0.1, 
Figure 3.16 B-C).  
(Data were generated together with Oguzhan Kaya.) 
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Figure 3.16: Endothelial-specific deletion of CD95 does not significantly affect GBM 
growth and angiogenesis.  
A. Scheme of experimental design. Endothelial-cell specific deletion of CD95 was combined 
with a syngeneic model of glioblastoma – SMA560. Mice were first induced with tamoxifen 
for 5 days after which a break of 7 days was made. 10000 SMA560 were then intracranially 
injected into the mice and sacrificed 2 weeks later for tissue analysis. B. Representative images 
of tumor vessels in CD95fl/fl and CD95fl/fl;Cdh5-CreERT2 mice stained with anti-CD31. Scale 
bars: 100 µm. C. Quantification of tumor volume by stereologic analysis and percentage vessel 
area (Ctrl: n=8, KO: n=8).  
Data are shown as mean±SD. Unpaired two-tailed student’s t-test. (Data was generated 
together with Oguzhan Kaya.) 
 
 
3.2.2 CD95 activation increases angiogenesis in a model of glioblastoma 
To further study the effect CD95 activation may have on glioblastoma angiogenesis, 
we utilized a patient-derived xenografts (PDX) model and assessed whether CD95 
activation by CD95L would increase tumor angiogenesis. PDX models have been 
increasingly accepted as the more relevant mouse model in preclinical cancer research 
as compared to syngeneic cell line models due to their higher applicability to the 
clinical situation.  
Glioblastoma cells were isolated from a patient tumor (GBM39) and cultured in vitro 
under stem cell conditions before subcutaneous transplantation into immune-
compromised SCID beige mice that lack T and B cells and have selective impairment 
in NK-cell functions. Eight weeks post transplantation, when small nodules first 
became visible, the mice were treated with either control- or CD95L-coated lipid 
beads by intravenous injection in order to assess the effect CD95 activation on tumor 
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vessels (Figure 3.17 A). Tumor growth was followed up and two weeks after 
treatment, the mice were sacrificed. When comparing the tumor size of CD95L- and 
control-treated mice, no significant difference was observed, although a trend toward 
increased tumor size was detected (Ctrl: 1281 ± 569 mm3 vs. CD95L: 1991 ± 873 
mm3, p=0.07, Figure 3.17 B-C).  
 
            
Figure 3.17: CD95L stimulation increases tumor angiogenesis.  
A. Experimental scheme. Patient-derived glioblastoma cells were subcutaneously transplanted 
into SCID beige mice. Mice with established tumors were i.v. injected with Ctrl or CD95L-
coated lipid bilayer beads. B. Development of tumor volume over time. C. Comparison of 
tumor size between control and CD95L-treated tumors at time of sacrifice (Ctrl: n=8 vs. 
CD95L: n=8). D. Representative images of CD31 stained tumors treated with control or 
CD95L.  Scale bar = 100 µm. E. Quantification of vessel area (Ctrl: n=5 vs. CD95L: n=4).  
Data are shown as mean±SD. *p<0.05, unpaired two-tailed student’s t-test.  
 
Further, tumor vessels were quantified by immunohistochemical staining for CD31, 
which showed a significant increase in the percentage of tumor area covered by vessels 
in the CD95L-treated group compared to control-treated tumors (Ctrl: 2.6% ± 0.8 vs. 
CD95L: 5.7% ± 2.0, p=0.04) (Figure 3.17 D-E). This suggests that CD95L strongly 
promotes tumor vessel growth, either directly by acting on CD95 in endothelial cells 
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or indirectly by acting on CD95 in tumor cells that also express high levels of CD95 
(Kleber et al., 2008).  
             
3.2.2 Transcriptomic analysis reveals CD95L-induced upregulation of pro-
angiogenic factors  
To further explore the changes on GBM tumor upon CD95L treatment, we 
conducted RNA-sequencing experiments to assess transcriptomic differences. PolyA 
selected mRNA of three control-treated and three CD95L-treated tumors were 
isolated and libraries were prepared and sequenced. The quality of the RNA-
sequencing experiment was controlled by spike-in RNAs of known concentrations, 
which strongly correlated with their reads detected (Figure 3.18 D). Moreover, the 
percentage of uniquely mapped reads was very high (~85%) which is indicative of low 
replicate reads (Figure 3.18 A) (These analyses were conducted by Sheng Zhao.)  
Principal component analysis and hierarchical clustering of gene expression profiles of 
the single samples revealed a clear separation according to condition, except for the 
sample CD95L_3 which did not cluster to the appropriate group, possibly indicating 
non-responsiveness to CD95L or a technical error (Figure 3.18 B-C). 
Next, we conducted differential expression analysis to investigate specific genes 
changing upon CD95L treatment. This revealed a total of 1119 genes to be 
differentially expressed between the two groups, among which 961 genes were 
upregulated and 150 were downregulated (cutoff: p<0.05, log2 fold change>0.5). To 
assess the functional relevance of the differentially expressed gene sets, we performed 
gene ontology functional enrichment analysis using the database for annotation, 
visualization and integrated discovery (DAVID) (Huang et al., 2008). This showed 
among the upregulated genes an overrepresentation of genes in several biological 
process categories involved in vessel development such as “angiogenesis”, “blood vessel 
development”, “blood vessel morphogenesis” as well as in related categories such as 
“response to hypoxia” and “extracellular matrix organisation” (Figure 3.19 A). Within 
the gene ontology category “blood vessel development”, various known, crucial drivers 
of angiogenesis were found, including VEGF, IL8, DLL4 etc. (Figure 3.19 B).  
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Figure 3.18: Quality control of RNA-seq of Ctrl- and CD95L-treated tumors. A. Percentage 
of reads uniquely mapped to the human genome (hg19). B. Principal component analysis of 
all six samples. C. Sample to sample heatmap. D. Correlation of reads detected and known 
concentration of spike-in RNAs. (Data from A. and D. are created by Sheng Zhao.) 
 
Due to the fact that whole tumors were sequenced here without distinguishing 
between different cell types, it remains unclear whether CD95L induced the release of 
pro-angiogenic factors in tumor cells, endothelial cells, or other cell types. However, 
due to the majority of the cells within the tumor being GBM cells, it is mostly likely 
that CD95L binds CD95 on GBM cells to drive the production of pro-angiogenic 
factors.  
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Figure 3.19: Functional annotation of differentially expressed genes in Ctrl- vs. CD95L-
treated tumors. A. Selected gene ontologies and the statistical significance (shown as -log10 
of Benjamini p-value) of the enrichment. B. Heatmap showing upregulated genes in CD95L-
treated compared to control-treated tumors belonging to the gene ontology category blood 
vessel development. Color code represents z-score in a linear scale.  
 
3.2.3 CD95L induces production of pro-angiogenic factors by GBM cells 
In order to test whether indeed GBM cells are responsible for the increased vessel 
growth seen after CD95L treatment, we stimulated two human-derived GBM lines 
GBM39 and GBM48 in vitro on CD95L-membranes for 4 hours and collected 
conditioned media of the GBM cells 24 hours later (Figure 3.20 A).  
The composition of the conditioned medium was subsequently analysed in regard to 
angiogenesis-related proteins using an angiogenesis antibody array (R&D Systems). 
This was composed of 55 antibodies for angiogenesis-related proteins spotted on a 
nitrocellulose membrane, thereby enabling simultaneous detection of various factors 
involved in angiogenesis. As expected, the conditioned media of both Ctrl- and 
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CD95L-stimulated GBM39 and GBM48 cells contained large, but equal amounts of 
EGF and bFGF, both of which were present in the GBM medium used for culturing 
GBM cells.  
 
 
Figure 3.20: Conditioned medium of CD95L-treated GBM cells contains pro-angiogenic 
factors.  
A. Experimental scheme. GBM cells were stimulated on CD95L membrane for 4 h and 
conditioned medium was collected 24 h later for angiogenesis protein array. B-C. 
Angiogenesis protein array blots for conditioned medium of GBM39 (B) and GBM48 (C) 
stimulated with control or CD95L membrane. Selected upregulated proteins are marked by 
red boxes. D-E. Mean pixel intensity plots for significantly upregulated proteins (fold 
change>2, p-value<0.05) for GBM39 (D) and GBM48 (E) conditioned medium.  
 
Consistent with our hypothesis, the conditioned media of CD95L-treated cells 
contained much higher concentrations of various pro-angiogenic factors. These 
changes were cell-line-specific, with some factors only enriched upon stimulation in 
GBM39 cells and others in GBM48 cells (fold change>2, p-value<0.05) (Figure 3.20 
B-E). VEGF-A, the most prominent pro-angiogenic factor, and the 
matrixmetalloprotease MMP8, were upregulated in both cell lines. 
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Table 3.1: Clinical data of patients from whom GBM cells were derived.  
 
 
Figure 3.21: Conditioned medium of CD95L-treated GBM cells increases tube formation in 
endothelial cells 
A. Experimental scheme. GBM cells were stimulated on CD95L membrane for 4 h, 
conditioned medium was collected 24 h later and given onto HUVEC cells in matrigel for 
tube formation assay. B, F, J. Representative images of endothelial tube formation with 
conditioned medium of control- or CD95L-treated GBM cells derived from three different 
patients. (n=3 for each patient) C-E, G-I, K-M. Quantification of B, F, J for number of 
branches, length and number of nodes. Unpaired two-tailed student’s t-test.  
 
To further test the functional effect of conditioned medium on angiogenesis, we 
added the GBM conditioned medium to HUVECs in matrigel and analysed their 
tube formation capacity (Figure 3.21 A). Conditioned medium from CD95L-treated 
Name Gender  Age Diagnosis Treatment 
GBM39 female 66 Glioblastoma Operation, concomitant radio- 
and chemotherapy 
GBM47 male  18 Glioblastoma Operation, concomitant radio- 
and chemotherapy 
GBM48 Unknown Unknown Glioblastoma unknown 
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GBM cells resulted in a marked increase in the tube formation capacity of endothelial 
cells as compared to control-treated GBM cells, as evident through the number of 
tubes formed (GBM39: Ctrl: 119 ± 24 vs. CD95L: 196 ± 34, p=0.004; GBM47: Ctrl: 
144 ± 32 vs. CD95L: 283 ± 42, p=0.01; GBM48: Ctrl: 194 ± 0 vs. CD95L: 349 ±18, 
p=0.007), their branching length (GBM39: Ctrl: 3010 ± 538  vs. CD95L: 4489 ± 
702, p=0.006; GBM47: Ctrl: 3280 ± 617 vs. CD95L: 5775 ± 460, p=0.01; GBM48: 
Ctrl: 4635 ± 98 vs. CD95L: 6344 ± 435, p=0.003) and the number of nodes 
(GBM39: Ctrl: 376 ± 176 vs. CD95L: 756 ± 128, p=0.005; GBM47: Ctrl: 388 ± 175 
vs. CD95L: 1757 ± 639, p=0.02; GBM48: Ctrl: 743 ± 302 vs. CD95L: 2486 ± 775, 
p=0.05) (Figure 3.21 B-M). This could not only been shown in the two primary cell 
lines GBM39 and GBM48 previously used to identify pro-angiogenic factors, but 
also in an additional primary cell line GBM47 (Table 3.1). In summary, this suggests 
that the pro-angiogenic factors contained in CD95L-treated tumor cell conditioned 
media indeed are functional and able to induce angiogenesis in vitro.  
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4. DISCUSSION 
During development, a single cell is able through division and differentiation to make 
up a whole organism consisting of billions of cells. How a complex organ such as the 
brain is produced during this process is only slowly being comprehended in detail. 
Here, we uncovered a novel way of how cellular interactions during CNS 
development can contribute to the correct formation of cells within the brain and 
retina and demonstrate that the nervous and vascular systems are tightly connected 
during development.  
The nervous and vascular systems follow similar growth patterns during development 
and are concomitantly regulated by a similar set of molecules. CD95 is a receptor that 
is expressed in both systems and has previously shown to promote neurite outgrowth 
and branching (Desbarats et al., 2003; Zuliani et al., 2006). We now demonstrate that 
CD95 is engaged in developmental angiogenesis in the cortex and retina, thus 
confirming our hypothesis that CD95 can act as an angioneurin during development.  
Furthermore, we identify microglia, commonly known as the resident immune cells of 
the brain, as the main source of CD95L that interacts with its receptor CD95 on 
endothelial cells and neurons to induce their growth and branching. Thus, our data 
support an important novel role of microglia in the neurovascular development 
(Figure 4.1). 
 
Figure 4.1: Microglial-derived CD95L promotes neurovascular development. A. Early 
postnatal development of vessels in the retina and neurons and vessels in the cortex are 
supported by microglial-derived CD95L that activates CD95 on neurons and endothelial 
cells. B. CD95 activation leads to recruitment of SFK and p85 to the CD95 death domain, 
resulting in activation of Erk and Akt signaling to promote endothelial cell proliferation, 
migration and branching.  
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Once development is completed, only little angiogenesis occurs. However, in tumors, 
the processes of development are often hijacked and exploited to drive tumor growth. 
Thus, we further examined the role of CD95 in glioblastoma angiogenesis. 
Unexpectedly, CD95 deletion in endothelial cells does not significantly affect vessel 
density in glioblastoma. This could be due to the nature of the highly proliferating 
syngeneic model used that might be independent of vessel supply. However, we found 
that CD95L stimulation of glioblastoma tumors indirectly promotes tumor vessel 
growth. As glioblastoma cells also express CD95, downstream signaling is elicited by 
CD95L stimulation in tumor cells that results in the production of pro-angiogenic 
factors. These are released by tumor cells into the their microenvironment in order to 
promote vessel growth (Figure 4.2). 
 
 
Figure 4.2: Glioblastoma cells secrete pro-angiogenic factors upon CD95L stimulation. A. 
CD95L possibly from the tumor microenvironment, e.g. from GBM cells themselves, 
infiltrating immune cells or endothelial cells activates CD95L on GBM cells resulting in the 
production of pro-angiogenic factors such as VEGF, MMPs etc. that promote endothelial 
cell growth and tumor angiogenesis.  
 
By studying CD95 in development and disease we could show that it is both involved 
in angiogenesis of the developing CNS as well as in glioblastoma tumors.  
 
4.1 CD95 in developmental angiogenesis of the CNS 
By using in vitro models of angiogenesis and endothelial-cell specific deletion of 
CD95 in vivo we find that CD95 promotes endothelial cell proliferation and vessel 
branching during postnatal CNS development in the cortex and retina. When 
depleted of CD95, both vessels in culture as well as in vivo consistently display 
decreased branching and proliferation. In the retina, we further observed that the 
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increased branching is not due to a lack of pruning, but rather a direct effect on vessel 
growth. Consistent with this, no decrease in apoptotic endothelial cells is observed 
upon CD95 deletion. 
Unlike in the retina, where angiogenesis starts postnatally and where the surface just 
becomes covered by vessels in the first 7 days after birth, the cortex is initially 
vascularized at E12.5 already. At the postnatal age of P6, when our analyses are 
conducted, the majority of the cortex vasculature is already existent, although 
endothelial cell proliferation and vessel branching is still taking place (Harb et al., 
2012). The fact that CD95 seems to regulate both early and late angiogenesis in the 
retina and cortex hints at its versatile role. However, it would also be interesting to 
confirm CD95’s role in early cortical angiogenesis at embryonic stages or in the early 
mouse hindbrain, another commonly used model for CNS angiogenesis due to the 
stereotypical ingrowth of vessels (Ruhrberg and Bautch, 2013). An early induction of 
CD95 deletion either using a Cdh5-cre line or tamoxifen administration to the 
pregnant mice would also give insights into the global phenotype of endothelial-cell 
CD95 deletion in embryonic development and its effect on embryonic survival. The 
drawback of the Cdh5-cre line however would be the unspecific targeting of 
hematopoietic cells (Alva et al., 2006) and tamoxifen induction in pregnant mice may 
cause toxic effects involving abortion or fetal death (Hayashi and McMahon, 2002; 
Higashi et al., 2009).  
With the tamoxifen protocol applied for the mouse pups in this study, it was not 
possible to reach a 100% deletion of CD95. Based on the CD95 FACS data, a 
deletion of around 15% was reached. Thus, the effect sizes seen are not very 
pronounced with a decrease of vessel area of ca. 2-3% and of branching of ca. 5-10% 
after CD95 deletion. These numbers however are comparable with other molecules 
involved in developmental angiogenesis, such as another angioneurin Slit1/2 (Rama et 
al., 2015). 
 
A number of proteins are implicated in developmental angiogenesis. Among those, 
VEGF-A and its main receptor VEGFR2 are the best studied. VEGF-A regulates 
various steps of developmental angiogenesis and exhibits a severe phenotype when 
deleted (Raab et al., 2004). CD95L thus is one of many players in angiogenesis and 
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may have overlapping functions with other growth factors. In fact, it has previously 
been demonstrated that HUVECs express an increased level of VEGF-A when 
stimulated by CD95L (Marx et al., 1999). It however also remains to be discovered 
whether the CD95L pathway can crosstalk with the VEGF-A pathway.  
 
4.2 Controversial role of CD95 in angiogenesis 
CD95 has not been described to promote angiogenic processes in development 
previously. Rather the opposite has been reported in that CD95 acts as a death 
receptor to induce apoptosis in endothelial cells upon CD95L exposure, in different 
pathological settings as well as during development, mainly in the retina (Barreiro et 
al., 2003; Davies et al., 2003; Ishida et al., 2003; Kaplan et al., 1999). These findings 
however stand in sharp contrast to studies that suggest endothelial-cell resistance to 
CD95-induced apoptosis (Aoudjit and Vuori, 2001; Bannerman et al., 2001; Limaye 
et al., 2005; Richardson et al., 1994; Sata et al., 2000; Suhara et al., 2001). Especially 
in situations of acute inflammation, the endothelium is protected against apoptotic 
signals from cytotoxic immune cells such as CD95L or TNFɑ (Al-Lamki et al., 
2008), and rather exhibit increased growth (Biancone et al., 1997), indicating that 
CD95 signaling may confer endothelial cell survival. 
The discrepancy may be a result of the different mouse models used. While previous 
studies were mainly conducted with the lpr or gld mice or systemic treatment that 
affect CD95 or CD95L expression globally in every cell, the model used in this study 
specifically targets deletion of CD95 in endothelial cells, thus pinning the observed 
effects down to the cell type of interest. Systemic effects of global deletions have 
masked CD95’s function in other studies before. While it was thought that CD95 has 
a direct detrimental function on injured tissues of the CNS through induction of 
apoptosis (Broughton et al., 2009; Demjen et al., 2004), it was actually found that 
after spinal cord injury CD95 and its ligand participate in the recruitment of innate 
inflammatory mediators that are ultimately responsible for increased cell death 
(Letellier et al., 2010). Thus, cell-specific models may give more precise insights into 
the function of a protein. In both our in vitro as well as in vivo analyses no significant 
alterations to apoptosis rate were observed after modulating CD95. 
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In addition to CD95, other DD-containing receptors were also shown to be involved 
in angiogenesis. For instance, another member of the TNF receptor superfamily 
TNFR1 mediates TNFɑ-mediated tip cell induction and angiogenic sprouting 
(Sainson et al., 2008). Moreover, the  DD-containing netrin receptor UNC5B is 
present in endothelial tip cells and modulates vascular morphogenesis through 
filopodial repulsion (Llambi et al., 2001; Lu et al., 2004). The presence of a DD 
therefore does not preclude from non-death functions of a receptor.  
 
4.3 CD95 signaling elicits angiogenesis  
CD95 is generally known as a cell death receptor. However, increasingly more studies 
underpin its functions in promoting cell survival, both in homeostasis as well as in 
disease (Brint et al., 2013). CD95’s DD is known to be able to recruit alternative 
players beside cell death-inducing caspases to signal for proliferation, migration and 
growth (Sancho-Martinez and Martin-Villalba, 2009). As a cell surface receptor with 
adaptor-dependent intracellular kinase activity, CD95 is able to share the same 
signaling machinery with other receptor tyrosine kinases. The ability of the 
intracellular domain of CD95 to bind SH2-domain proteins (Sancho-Martinez and 
Martin-Villalba, 2009) therefore provides a signaling hub for proliferation, migration 
and branching. 
Here, we find that CD95 engages Src family kinases and the PI3K regulatory subunit 
p85 specifically at the ITAM/ITIM-like domain with the YXXL motif in its DD and 
induces downstream phosphorylation of Erk and Akt in endothelial cells. In absence 
of Erk and Akt signaling through pharmacological inhibition, the proliferative effect 
of CD95 on endothelial cells is abrogated in vitro.  
Thus, CD95 signaling inputs directly into major established pathways controlling 
vessel fate. PI3K and its main downstream target Akt play important roles in 
endothelial cell proliferation and migration (Gerber et al., 1998; Jiang et al., 2000; 
Somanath et al., 2006). Akt can phosphorylate the cell cycle inhibitor p21Cip1 in 
endothelial cells, resulting in release of the replication protein PCNA and subsequent 
induction of endothelial cell proliferation (Rossig et al., 2001). Moreover, activation 
of the PI3K pathway via VEGFR2 has been shown before to trigger Rac/Rho as well 
as Grb2 and subsequently Cdc42, resulting in actin reorganization, filopodia 
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formation and cell migration in endothelial cells (Lamalice et al., 2004; Le Boeuf et 
al., 2004; Ruiz de Almodovar et al., 2009). In addition, CD95 may also support 
endothelial cell migration through activation of MMPs via a PI3K/Akt/GSK3β axis 
previously shown for glioblastoma cells (Kleber et al., 2008). Interestingly, CD95L 
can also mediate eNOS expression through Akt phosphorylation in order to regulate 
vascular tone and proliferation (Takemura et al., 2004). 
Erk signaling overlaps in some aspects with the functions of PI3K signaling and can 
also induce endothelial cell proliferation as well as migration (Srinivasan et al., 2009). 
Deletion of Erk1/2 in endothelial cells results in embryonic lethality at E10.5 which is 
caused by decreased endothelial proliferation and migration as well as perturbed actin 
organization due to reduced levels of Paxilin and FAK (Srinivasan et al., 2009). 
Similar to VEGF-A, CD95 may induce Erk activity through Src and c-Raf activation 
(Hood et al., 2003).  
The exact final effectors downstream of Erk and Akt that are ultimately responsible 
for the branching and proliferation phenotype elicited by CD95 activation remain to 
be elucidated.  
Both the PI3K/Akt and Erk pathways can be activated downstream of SFKs (Lowell, 
2011; McKay and Morrison, 2007; Rui et al., 1AD). SFKs are known to promote 
endothelial cell differentiation (Klint et al., 1999), survival (Wong et al., 1999), 
proliferation and angiogenesis (Eliceiri et al., 1999) and have been shown to be 
required for endothelial cell survival (Eliceiri et al., 1999) . The different members of 
SFKs such as Src, Yes and Fyn often have redundant functions and many have been 
shown to be involved in angiogenic processes. Major growth factors including VEGF-
A and EGF signal through Src (Eliceiri et al., 1999; Thakker et al., 1999) to promote 
angiognesis.  
To further validate whether PI3K and Erk are both activated by SFKs, SFK 
inhibition using the SFK inhibitor PP2 together with analysis of Akt and Erk 
phosphorylation upon CD95L stimulation can be conducted.   
As neither Erk1/2 inhibition with PD98059 nor PI3K inhibition with LY294002 
blocked proliferation of endothelial cells in vitro completely, CD95 may be mediating 
proliferation through multiple pathways. Concurrent inhibition of both PI3K and 
Er1/2 could provide insight into whether this is the case. 
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An open question remains which form of CD95L – the soluble or membrane bound – 
induces endothelial cell growth. In our in vitro tube formation experiments, we used 
trimerized CD95L bound to lipid membranes that resemble the membrane-bound 
form. This form of CD95L has been described to induce apoptosis, for instance in 
neurons, whereas the soluble form of CD95L antagonizes apoptosis (Gregory et al., 
2011; Matsumoto et al., 2015; O' Reilly et al., 2009). However, the Western blot 
analyses also showed phosphorylation of downstream AKT and ERK upon 
stimulation of endothelial cells by soluble trimerized CD95L. Thus, it seems that 
endothelial cells are resistant to both membrane-bound as well as soluble forms of 
CD95L-induced apoptosis. This is likely also due to the elevated expression of the 
caspase-8 inhibitor c-FLIP (Suhara 2001).  Which form(s) of CD95L is expressed by 
microglia in vivo, the main source of CD95L in the CNS, remains elusive. As 
microglia express matrixmetalloproteases during development that are required for 
CD95L cleavage from the membrane (Kierdorf et al., 2013), both forms of the ligand 
could potentially be present.  
 
4.4 The angiogenic process: where does CD95 regulation fit? 
Here, we report that CD95 is required for proper branching of vessels and 
proliferation of endothelial cells. How does this fit into the angiogenic process of 
tip/stalk cell selection, tip cell sprouting, stalk cell proliferation, guidance, anastomosis 
and vessel maturation?  
As CD95 activates the Akt and Erk pathway, it potentially plays an important role in 
several steps. CD95 may be crucially involved in the first phase of angiogenesis 
through activation of MMPs via the PI3K/AKT/GSK3β pathway that has been 
previously described for glioblastoma cells (Kleber et al., 2008) MMP-mediated 
breakdown of the extracellular matrix is crucial for endothelial tip cells to begin the 
sprouting process (Potente et al., 2011). While the tip cells are sprouting, stalk cells 
proliferate to form the vessel lumen and CD95 seems to contribute to this process as 
well. At the same time, Erk and PI3K-induced cytoskeletal changes via FAK or 
Cdc42 respectively can lead to guidance-induced migration as well as increased 
branching.  
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In summary, we suggest that CD95 is involved in several steps of the angiogenic 
process, mainly promoting migration and proliferation of endothelial cells, two crucial 
processes during angiogenesis required for proper vessel formation.  
 
4.5 CD95 in neuronal regulation  
Beside CD95’s role in vessel development, we further show that microglial-derived 
CD95L can affect dendrite branching of cortical neurons. Previous studies already 
described the involvement of CD95 in neurite branching of peripheral neurons as well 
as hippocampal neurons (Desbarats et al., 2003; Zuliani et al., 2006). Moreover, 
unpublished data from our laboratory show that neuron-specific deletion of CD95 by 
in utero electroporation results in decreased dendrite branching of layer II/III callosal 
projection neurons.  However, the source of CD95L was not clear so far. By deleting 
CD95L specifically in microglia, the cell type in the brain that produces the largest 
amount of CD95L, we could see a similar decrease on callosal projection neuron 
branching, thus demonstrating that CD95L produced from microglia has the largest 
effect on neuron development.  
Similar to endothelial cells, CD95 promotes dendritic branching via SFK and PI3K 
(unpublished data). Knockdown or pharmacological inhibition of SFK and PI3K 
abrogate CD95L-mediated neuronal branching. Further, unpublished data from our 
laboratory show that inhibition of PI3K in neurons abolishes CD95-dependent 
phosphorylation of GSK3β, a target effector of PI3K signaling important for the 
establishment and maintenance of neuronal polarity and neurite length (Jiang et al., 
2005; Yoshimura et al., 2005). Moreover, GSK3β phosphorylation and therefore 
inactivation leads to dephosphorylation of Tau that promotes assembly and 
stabilization of microtubules important for regulation of neuronal morphology 
(Zuliani et al., 2006). As a regulator of GSK3β, CD95 thus can act as a determinant 
of neuronal polarity as well as promoter of branching.  
A parallel pathway that has been described for CD95 in neurons is the recruitment of 
the adaptor protein ezrin and subsequent activation of Rac1, resulting in neurite 
growth in cortical neurons (Ruan et al., 2008).  
Here, we merely describe CD95’s role in dendritic branching. However, previous 
studies have also indicated CD95 in axonal branching of hippocampal neurons 
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(Zuliani et al., 2006). Thus, CD95 does neither seem to be a dedicated or a bimodal 
regulator but instead is involved in both axonal as well as dendritic branching, possibly 
at different developmental stages.  
 
4.6 The connection of neural and vascular system and CD95 
Previous studies have identified a number of growth factors and guidance molecules 
that are involved in the establishment of the neurovascular network (Segura et al., 
2009). Similar to these molecules, we show that CD95/CD95L signaling promotes 
both neuronal branching and vessel growth to support congruent development of 
these two systems. In both neurons and endothelial cells, development is promoted by 
SFK and PI3K signalling via the CD95 death domain. We propose that by utilizing 
its tyrosine phosphorylation, CD95 acts as a growth factor receptor stimulating 
branching in neurons and proliferation in vessels.  
An interesting question remains whether aberrant vessel growth in the 
CD95fl/fl;Cdh5-(PAC)-CreERT2 would affect neuron growth and function and 
conversely, whether neuronal branching defects associated with CD95 deletion would 
perturb vessel growth. Further studies are required to answer these questions related 
to the functional dependency of neurons and vessels.  
As we have shown in the FACS experiments for CD95, neurons and endothelial cells 
are not the only populations expressing it. CD133+ neural stem cells also exhibit high 
expression of CD95, thus it is likely that CD95 might also have a role in embryonic 
neural stem cell survival and differentiation, similar to the adult situation (Corsini and 
Martin-Villalba, 2010). 
 
4.7 Novel functions of microglia 
Extensive reciprocal interaction exist between different cell types of the CNS during 
development. We identify an important neuron/vessel/glia-interaction that is essential 
for proper neurovascular development. Traditionally, microglia have been mainly 
attributed the role of phagocyting apoptotic neurons (Bessis et al., 2007; 
Schlegelmilch et al., 2011). However, a plethora of studies have eluted to other 
functions of microglia beyond this. Microglia have been shown to have a variety of 
functions during brain development, including neuronal survival, vascularization, cell 
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differentiation as well as axon pathfinding and synaptogenesis (Aarum et al., 2003; 
Arnold and Betsholtz, 2013; Jonakait et al., 2000; Pont-Lezica et al., 2014; Ueno et 
al., 2013; Zhan et al., 2014). Interestingly, microglia can also promote neurite 
outgrowth and development in co-culture or conditioned media experiments, partially 
by releasing thrombospondin (Chamak et al., 1994; Pont-Lezica et al., 2014; Zhang 
and Fedoroff, 1996). In the brain and retina, microglia associate closely to vascular 
junctions in order to “bridge” vascular sprouts and depletion of microglia from the 
developing brain or retina reduces vessel density and branching (Checchin et al., 
2006; Fantin et al., 2013; Rymo et al., 2011). The molecules responsible for 
microglia’s ability to shape the neural and vascular system, however, have not been 
well studied so far. Our study provides evidence that CD95L is one of the players 
expressed by microglia that mediates both processes.  
The CD95Lf/fl; LysMcre model used in this study to assess the effect of CD95L 
deletion on the neurovascular system, did not reach a 100% deletion of CD95L. This 
is partially due to the fact that the LysM promoter is expressed in ca. 30% of 
microglia. An underestimation of the effect of microglia-derived CD95L can 
therefore not be completely excluded, especially in regard to the observed tendency 
towards decreased vessel branching in CD95L deleted mice. The fact that a 
functional impairment in vessels and neurons was still observerd indicates that 
microglia-derived CD95L has a strong effect on both systems. An alternative to the 
LysM driver for the expression of cre-recombinase would be a Cx3cr1 driver which is 
expressed in nearly 100% of microglia (Goldmann et al., 2013) and can therefore lead 
to a higher level of deletion of the floxed gene. This line might also be helpful in 
detecting CD95L-dependent angiogenesis in the retina which was not possible using 
the LysM-cre line. LysM is also expressed in peripheral monocytes and macrophages 
and whether lack of CD95L in this cell types could affect the CNS development is 
unclear. With the blood-brain-barrier established at E13.5-E14.5 (Schneider 2015), 
it is however unlikely that peripheral cells enter the CNS without any perturbations in 
order to alter CNS development.  
Moreover, as our FACS analysis showed, not only microglia express CD95L but also 
endothelial cells, although to a much lower extend. This is consistent with studies 
from literature, where CD95L was found to be expressed by human brain 
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microvascular endothelial cells (Bajou et al., 2008). Therefore, autocrine signaling in 
endothelial cells via self-produced CD95L cannot be ruled out and may also 
contribute to CD95-mediated vessel growth. To address this question, CD95Lfl/fl; 
Cdh5-(PAC)-CreERT2 mice could be utilized.  
One of the preferential localizations of microglia in the developing brain is areas of 
neuronal cell death which are associated with debris clearance (Cuadros et al., 1993; 
Peri and Nüsslein-Volhard, 2008). However, once clearance is completed, microglia 
might participate in reshaping surviving neurons, and concomittantly engaging the 
development of vessels to ensure their oxygen and nutrient support. Together, our 
study adds to the existing functions of microglia during development and establishes a 
link for neurovascular development by microglia through CD95L.  
 
4.8 Implications on brain function and behavior 
With CD95/CD95L deletion leading to impairments in neuronal and vessel 
branching that are crucial for the brain’s function, it would be interesting to assess 
whether this would have a long-term functional effect on the brain.  
Notably, early studies from the 90s using MRL lpr mice have already uncovered that 
loss of CD95 can induce a series of neurological symptoms. In these mice, global 
CD95 deficiency induced a number of behavioral and cognitive deficits at the age of 
7-11 weeks that were assessed by standardized tests. The deficits included reduction 
in spontaneous activity, impaired exploration of the open field, increased anxiousness 
and disturbed emotionality (Sakić et al., 1992; 1994; Szechtman et al., 1997). 
This phenotypes were attributed to a strong reduction of dendritic branching and loss 
of up to 20% of spines in pyramidal neurons in the parietal cortex and CA1 
hippocampus at 5-14 weeks, induced by autoimmunity-associated CNS inflammation 
(Sakić et al., 1998). During development, however, when inflammation is not 
apparent yet in lpr mice, neuronal branching is still affected by CD95 deletion in 
hippocampal neurons (Zuliani et al., 2006), indicating that inflammation is not the 
main cause of the neuronal impairments. Thus, a lack of CD95 may directly influence 
behavioral and cognitive functions of the brain.  
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4.9 CD95 and glioblastoma angiogenesis 
In different pathologies, angiogenesis plays an important role. Especially in cancer, 
angiogenesis is the major process by which new blood vessels are built to nourish 
tumor cell growth (Folkman, 1971). GBM is a type of cancer of the brain that is 
highly heterogenous, highly migratory and highly angiogenic.  
As tumor vessels exhibit CD95 expression (Bhattacharya et al., 2016) we expected 
that CD95 also has a role during tumor angiogenesis. However, deletion of CD95 in 
endothelial cells did not affect the growth of tumor vessels in GBM in a syngeneic 
intracranial transplantation model. This may either be due to technical reasons 
whereby non-complete deletion of CD95 led to the preferred growth of WT 
endothelial cells in the tumor, or due to the fact that the syngeneic model represents a 
fast-growing tumor model that may not necessarily rely on tumor angiogenesis.  
Surprisingly, treatment of subcutaneous tumor-bearing mice with the CD95L led to 
an increased vessel growth as well as a tendency of increased tumor growth. As GBM 
cells themselves are known to express CD95 and its activation has previously been 
shown to be vital for GBM migration and invasiveness as well as survival (Hadji et al., 
2014; Kleber et al., 2008), we suspected an effect of CD95L on GBM cells that led to 
the increased angiogenesis. Indeed, GBM cells increased their expression of pro-
angiogenic factors such as VEGF-A, IL-8 and DLL4 upon CD95L stimulation. 
Moreover, GBM culture conditioned medium also contain increased pro-angiogenic 
factors after CD95L treatment and the conditioned medium has a functional effect on 
endothelial cells as evident through increased tube formation in matrigel. Thus, it 
seems like that GBM cells do not only require CD95 for growth and migration, but 
also utilize it for tumor angiogenesis. In fact, it has been previously shown that CD95 
activation in glioma cells can lead to production of chemokines such as MCP-1, IL-8 
and IL-6 (Choi et al., 2001; 2002). Interestingly, GBM cells themselves as well as 
glioma-associated microglia produce CD95L (Badie et al., 2001; Kleber et al., 2008) 
that can potentially drive tumor angiogenesis in situ through activation of CD95 on 
tumor cells.  
It remains elusive how CD95 activation on GBM cells results in expression of pro-
angiogenic factors. However, VEGF-A expression for instance can be directly 
activated downstream of Erk signaling (Berra et al., 2000; Choi et al., 2001), a 
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pathway that is also activated by CD95 in tumor cells (Barnhart et al., 2004). Further 
experiments involving inhibition of the Erk pathway and its effect on pro-angiogenic 
factor release from CD95L stimulated GBM cells will provide answers to this 
question.  
 
With CD95 involved in GBM migration, growth and angiogenesis, targeting CD95 
signaling as a therapeutic intervention for GBM is an attractive avenue. APG101, a 
fusion protein of the extracellular domain of CD95 and the FC domain of IgG, has 
already been designed to block CD95L as a decoy receptor. In a phase II clinical trial, 
APG101 treatment has increased the percentage of patients reaching six months of 
progression-free survival in combination with radiotherapy (Bendszus et al., 2012).  
CD95L was recently described to be expressed on the endothelium of different tumor 
entities with the function of inducing apoptosis of tumor invading cytotoxic T-cells, 
thus allowing immune evasion. The expression of CD95L on tumor endothelium was 
further found to be upregulated by tumor cell secreted IL-10, PGE2 and VEGF-A 
(Motz et al., 2014). Thus, blocking CD95L with a CD95-Fc such as the APG101 
may act on different levels of tumor growth and serve as a multifunctional approach.  
 
4.10 Conclusive remarks 
In summary, the data from this study support an important role of microglia in 
neurovascular development and reveal an important function of the CD95/CD95L 
system in angiogenesis both during development and cancer. These results implicate 
that the CD95/CD95L system may be targeted to modulate neurovascular plasticity 
in the brain or angiogenesis in brain tumors.  
 
 
 
 
 
 
  
 
 
 
109 
5. APPENDIX 
5.1 Fiji scripts 
5.1.1 Macro for vessel area analysis  
 
// choose folder with images to analyse 
showMessage("Si, bitte wähle einen Ordner, dessen Inhalt bearbeitet 
werden soll."); 
dir = getDirectory("Choose a Directory "); 
list = getFileList(dir); 
 
// choose folder for analysed images 
showMessage("Si, bitte wähle einen Ordner, in den die bearbeiteten 
Bilder gespeichert werden sollen."); 
folder = getDirectory("Choose a Directory"); 
 
// loop for each picture of the folder  
// reset ROI manager after each loop run 
for (i=0; i<list.length; i++) { 
 roiManager("Reset");  
 showProgress(i, list.length); 
    open(dir+list[i]); 
  
 title= getTitle(); 
 image= folder+title; 
  
 //set scale for image, taken with 20x ojective SP5  
run("Set Scale...", "distance=1.3213 known=1 pixel=1 unit=um 
global"); 
  
 //background substraction and filter 
 run("Subtract Background...", "rolling=10 sliding"); 
 run("Gaussian Blur...", "sigma=2"); 
  
 // Color Thresholder 2.0.0-rc-28/1.49q 
 min=newArray(3); 
 max=newArray(3); 
 filter=newArray(3); 
 a=getTitle(); 
 run("HSB Stack"); 
 run("Convert Stack to Images"); 
 selectWindow("Hue"); 
 rename("0"); 
 selectWindow("Saturation"); 
 rename("1"); 
 selectWindow("Brightness"); 
 rename("2"); 
 min[0]=0; 
 max[0]=255; 
 filter[0]="pass"; 
 min[1]=0; 
 max[1]=255; 
 filter[1]="pass"; 
 min[2]=38; 
 max[2]=255; 
 filter[2]="pass"; 
 for (j=0;j<3;j++){ 
    selectWindow(""+j); 
    setThreshold(min[j], max[j]); 
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    run("Convert to Mask"); 
    if (filter[j]=="stop")  run("Invert"); 
  } 
 imageCalculator("AND create", "0","1"); 
 imageCalculator("AND create", "Result of 0","2"); 
 for (j=0;j<3;j++){ 
    selectWindow(""+j); 
    close(); 
  } 
 selectWindow("Result of 0"); 
 close(); 
 selectWindow("Result of Result of 0"); 
 rename(a); 
 // Colour Thresholding end 
  
 //save thresholded picture 
 saveAs ("Tiff", image+ " Threshold Mean"); 
  
  
//measure area of all vessels, excluding particles smaller than 
400px 
run("Analyze Particles...", "size=400-Infinity show=Outlines 
display summarize add"); 
  
 //save image with outlines of analysed particles 
saveAs("PNG", image + "-outline.png"); 
  
  
 close(); 
  
 selectWindow(title+" Threshold Mean.tif"); 
 close(); 
  
 } 
 
 
5.1.2 Macro for cortical vessel branching analysis 
 
// choose folder with images to analyse, should be thresholded image 
from the area analysis 
showMessage("Si, bitte wähle einen Ordner, dessen Inhalt bearbeitet 
werden soll."); 
dir = getDirectory("Choose a Directory "); 
list = getFileList(dir); 
 
// choose folder for analysed images 
showMessage("Si, bitte wähle einen Ordner, in den die bearbeiteten 
Bilder gespeichert werden sollen."); 
folder = getDirectory("Choose a Directory"); 
 
 
// loop for each picture of the folder  
// reset ROI manager after each loop run 
for (i=0; i<list.length; i++) { 
 roiManager("Reset");  
 showProgress(i, list.length); 
     open(dir+list[i]); 
  
 title= getTitle(); 
 image= folder+title; 
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 //set scale for image, taken with 20x ojective SP5  
run("Set Scale...", "distance=1.3213 known=1 pixel=1 unit=um 
global"); 
  
 //measure branches (number, branches)  
 run("Skeletonize"); 
run("Analyze Skeleton (2D/3D)", "prune=none calculate show 
display"); 
  
//save table with info on number of branches and branching 
points 
 selectWindow("Results"); 
 saveAs("Measurements", image+ "_results.xls");  
 close(); 
  
//save table with info on branch lengths 
 selectWindow("Branch information"); 
 saveAs("Measurements", image+ "_branch_length.xls");  
 close(); 
  
//save image of skeletonized vessels 
 selectWindow(title); 
 saveAs("Tiff", image+"_skeleton.tif"); 
 close(); 
  
 } 
 
 
5.2 R scripts: 
5.2.1 Interpolation of intracranial tumor volume  
This script was created by Frederik Ziebell. 
 
library(ggplot2) 
 
# measured areas of the slides 
y <- c(2,3,6,8,4,3) 
 
# distances between slides 
# Note: there need to be exactly n-1 distances to be specified 
between the n slides 
# dist[i] is the distance between slide i and slide i+1 
dist=c(7,10,8,6,3) 
 
x <- cumsum(append(dist,0,0)) 
d <- data.frame(x, y) 
sfun <- splinefun(d,method="fmm") 
area <- integrate(sfun,min(x),max(x)) 
 
ggplot(d,aes(x,y)) +  
  geom_point() +  
  stat_function(fun=sfun) +  
  ggtitle(paste("Volume = ",format(area[1]))) + 
  xlab("Distance from start of volume") + 
  ylab("Area") 
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5.2.2 Differential expression analysis of RNA-Seq 
Parts of the script were generated by Almut Lütge 
##libraries 
library("DESeq2") 
library("biomaRt") 
library("vsn") 
library("RColorBrewer") 
library("gplots") 
library("ggplot2") 
library("clusterProfiler") 
library("pathview") 
 
# DEseq2 package used for differential expression analysis 
###define DE functions 
##1. 
#function to load raw count data and analyse by DESeq2 to find 
differetially expressed genes 
mydeseq <- function(counttable, condition){ 
   
  coldata <- data.frame(row.names = colnames(counttable), condition = 
condition ) 
  countDS <- DESeqDataSetFromMatrix(countData = counttable, colData = 
coldata, design = ~condition) 
   
  dds <- DESeq(countDS) 
  res <- results(dds) 
   
  resordered <- res[order(res$padj),] 
  dtab <- as.data.frame(resordered) 
  desall <- list(deseqtable = dtab, deseq = dds, resordered = 
resordered) 
  return(desall) 
}   
 
 
##2. 
#function to add further informations using BiomaRt 
mybiomart <- function(deseqtable){ 
  ensembl <- useMart("ensembl", dataset = "hsapiens_gene_ensembl") 
  selfilters <- c("ensembl_gene_id") 
  attr <- c("ensembl_gene_id", "external_gene_name", "entrezgene", 
"chromosome_name", "gene_biotype") 
  #further interesting attributes: "go_id", "name_1006", 
"definition_1006" 
  val <- c(rownames(deseqtable)) 
  BMtable <- getBM(attributes = attr, filters = selfilters, values = 
val, mart=ensembl) 
  return(BMtable) 
} 
 
 
#function to merge all informations in one table 
myresulttable <- function(deseqtable, BMtable, resfile){ 
  restable <- merge(deseqtable, BMtable, by.x = "row.names", by.y = 
"ensembl_gene_id") 
  write.table(restable, file = paste(resfile, "tsv", sep = "."), sep= 
"\t", eol = "\r", row.names = F) 
  return(restable) 
} 
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#comparison DOPC vs CD95L 
 
counttable <- read.table(file = 
paste("/Users/schen/Documents/Data/Human tumor sequencing 
project/GBM39_RNAseq_CD95L_beads_vs_DOPC_01_06_2013_Si/Raw_counts/raw
_count_renamed.txt", sep=""), header=T)  
 
condition <- c(rep("DOPC", 3), rep("CD95L",3)) 
 
resfile <- paste("DOPC_vs_CD95L", sep ="") 
desall <- mydeseq(counttable, condition) 
 
BMtable <- mybiomart(desall$deseqtable) 
resulttable <- myresulttable(desall$deseqtable, BMtable, resfile) 
 
 
 
5.2.3 Principal component analysis and sample-to-sample heatmap of RNA-Seq  
counttable <- read.table(file = 
paste("/Users/schen/Documents/Data/Human tumor sequencing 
project/GBM39_RNAseq_CD95L_beads_vs_DOPC_01_06_2013_Si/Raw_counts/raw
_count_renamed.txt", sep=""), header=T)  
condition <- c(rep("DOPC", 3), rep("CD95L",3)) 
 
coldata <- data.frame(row.names = colnames(counttable), condition = 
condition) 
countDS <- DESeqDataSetFromMatrix(countData = counttable, colData = 
coldata, design = ~condition) 
 
dds <- DESeq(countDS) 
 
# two types of transformation of the data for normalization 
rld <- rlogTransformation(dds) 
vsd <- varianceStabilizingTransformation(dds) 
 
# generate png and pdf of PCA with rld transformed data 
png("PCA_CD95L_rld.png") 
pdf("PCA_CD95L_rld.pdf") 
rldpca <- plotPCA(rld, intgroup=c("condition"), returnData=TRUE) 
percentVar <- round(100 * attr(rldpca, "percentVar")) 
ggplot(rldpca, aes(PC1, PC2, color=condition)) + 
  geom_point(size=4) + 
  xlab(paste0("PC1: ",percentVar[1],"% variance")) + 
  ylab(paste0("PC2: ",percentVar[2],"% variance")) + 
  scale_shape_manual(values=c(4,3,25,10,19,17,8)) 
dev.off() 
 
# generate png and pdf of PCA with rld transformed data 
png("PCA_CD95L_vsd.png") 
pdf("PCA_CD95L_vsd.pdf") 
vsdpca <- plotPCA(vsd, intgroup=c("condition"), returnData=TRUE) 
percentVar <- round(100 * attr(vsdpca, "percentVar")) 
ggplot(vsdpca, aes(PC1, PC2, color=condition)) + 
  geom_point(size=4) + 
  xlab(paste0("PC1: ",percentVar[1],"% variance")) + 
  ylab(paste0("PC2: ",percentVar[2],"% variance")) + 
  scale_shape_manual(values=c(4,3,25,10,19,17,8))  
dev.off() 
 
# generate sample-to-sample heatmap with rld transformed data 
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rldmat <- as.matrix(dist(t(assay(rld)))) 
 
# define colors 
hmcol <- colorRampPalette(brewer.pal(9,"YlGnBu"))(100) 
 
png("StoS_heatmap_CD95L_rld.png", w=1500, h=1500, pointsize=20) 
heatmap.2(rldmat, trace = "none", col = rev(hmcol), margin = 
c(17,17), main = "rlog") 
dev.off() 
 
pdf("StoS_heatmap_CD95L_rld.pdf") 
heatmap.2(rldmat_2, trace = "none", col = rev(hmcol), margin = 
c(18,18)) 
dev.off() 
 
 
5.2.4 Heatmap generation of differentially expressed genes 
#load data, GO categories of DE genes and tpm values  
BVD <- read.table(file = paste("/Users/schen/Documents/Data/Human 
tumor sequencing 
project/GBM39_RNAseq_CD95L_beads_vs_DOPC_01_06_2013_Si/R_analysis/GO_
blood vessel development_genes_ensembl.txt", sep=""), header=F) 
BVD_vector <- as.vector(BVD) 
tpm <- read.table(file = paste("/Users/schen/Documents/Data/Human 
tumor sequencing 
project/GBM39_RNAseq_CD95L_beads_vs_DOPC_01_06_2013_Si/TPM/All_genes.
TPM_renamed.txt", sep=""), header=T) 
 
#transform tpm values to log2(tpm+1) 
log2_1_tpm <- log2(tpm[,1:6]+1) 
 
#select genes that are in GO blood vessel development 
log2_1_tpm_BVD <- subset(log2_1_tpm, rownames(log2_1_tpm) %in% 
c("ENSG00000128917",                                                       
"ENSG00000112715",                                                           
"ENSG00000100292",                                                                
"ENSG00000214274",                                                                 
"ENSG00000070495",                                                                 
"ENSG00000204291", 
"ENSG00000008710", 
"ENSG00000198959", 
"ENSG00000163235", 
"ENSG00000119630", 
"ENSG00000182492", 
"ENSG00000099250", 
"ENSG00000121966", 
"ENSG00000158195", 
"ENSG00000091879", 
"ENSG00000167772", 
                                                                 
"ENSG00000157483", 
"ENSG00000187045", 
"ENSG00000169429", 
"ENSG00000078401", 
"ENSG00000116016"))  
 
#translate ensemble ID to gene symbol 
rownames(log2_1_tpm_BVD) <- c("DLL4", 
                              "VEGFA", 
                              "HMOX1", 
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                              "ANG", 
                              "JMJD6", 
                              "COL15A1", 
                              "PKD1", 
                              "TGM2", 
                              "TGFA", 
                              "PGF", 
                              "BGN", 
                              "NRP1", 
                              "CXCR4", 
                              "WASF2", 
                              "ANGPT2", 
                              "ANGPTL4", 
                              "MYO1E", 
                              "TMPRSS6", 
                              "IL8", 
                              "EDN1", 
                              "EPAS1") 
 
#define colors 
hmcol <- colorRampPalette(brewer.pal(9,"Oranges"))(100) 
 
 
#generate heatmap  
png("Heatmap_blood_vesseL_dev.png", w=2000, h=2000, pointsize=20) 
heatmap.2(as.matrix(log2_1_tpm_BVD), dendrogram = "column", trace = 
"none", col = hmcol, margin = c(20,20), cexRow=2, cexCol=1.8, 
srtCol=45, scale="row", key=T, keysize=1) 
dev.off() 
 
pdf("Heatmap_blood_vesseL_dev.pdf") 
heatmap.2(as.matrix(log2_1_tpm_BVD), dendrogram = "column", trace = 
"none", col = hmcol, margin = c(15,15), cexRow=1, cexCol=0.8, 
srtCol=45, scale="row", key=T, keysize=1) 
dev.off() 
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